Method for producing chimeric antigen receptor-expressing cells
By removing T regulatory cells and tumor cells from immune effector cells and optimizing expansion conditions, the method enhances CAR expression and efficacy in treating hematological cancers.
Patent Information
- Application Number
- JP2024140764
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-03-13
- Filing Date
- 2024-08-22
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods for producing immune effector cells, such as T cells and NK cells, engineered to express chimeric antigen receptors (CARs) are limited by the presence of T regulatory cells (Tregs) and tumor cells, which can hinder effective CAR expression and function.
A method to produce T regulatory depleted immune effector cells by removing CD25+ T cells and tumor cells, followed by expressing CARs in these cells using nucleic acids and vectors, and optimizing expansion conditions to enhance potency.
The method results in a population of immune effector cells with reduced Tregs and tumor cells, achieving enhanced CAR expression and improved efficacy in treating hematological cancers by increasing cell proliferation, cytokine production, and target cell killing.
Smart Images

Figure 2024167266000001_ABST
Abstract
Description
[Technical Field]
[0001] This application claims priority to U.S. Application No. 62 / 097,375, filed December 29, 2014, and U.S. Application No. 62 / 133,137, filed March 13, 2015, the contents of which are incorporated herein by reference in their entireties.
[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy was created on December 18, 2015, has the file name N2067-7067WO_SL.txt, and is 246,147 bytes in size.
[0003] FIELD OF THE INVENTION The present invention relates generally to methods for producing immune effector cells (e.g., T cells, NK cells) engineered to express chimeric antigen receptors (CARs) and compositions comprising same. [Background technology]
[0004] Background of the Invention Adoptive cell transfer (ACT) treatment with autologous T cells, particularly chimeric antigen receptor (CAR)-transduced T cells, has shown promise in several hematological cancer trials. Summary of the Invention
[0005] Summary of the Invention The present invention relates to methods for producing immune effector cells (e.g., T cells, NK cells) that can be engineered to express a CAR and compositions comprising same.
[0006] Accordingly, in one aspect, the invention relates to a method of producing immune effector cells (e.g., T cells, NK cells) that can be engineered to express a CAR, comprising providing a population of immune effector cells (e.g., T cells) and removing T regulatory cells, e.g., CD25+ T cells, from the population, thereby providing a population of T regulatory depleted cells, e.g., CD25+ depleted cells, that are suitable for CAR expression.
[0007] In some embodiments, the population of T regulatory depleted cells comprises fewer than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells.
[0008] In some embodiments, the population of immune effector cells are cells from a subject with cancer, e.g., a CD25-expressing cancer, such as chronic lymphocytic leukemia (CLL). In some embodiments, the population of T regulatory depleted cells is less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1% CD25. + cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% tumor cells.
[0009] In some embodiments, the population of immune effector cells is autologous to the subject receiving the cells for treatment. In some embodiments, the population of immune effector cells is allogeneic to the subject receiving the cells for treatment.
[0010] In some embodiments, T regulatory cells, e.g., CD25+ T cells, are removed from the population using an anti-CD25 antibody or fragment thereof, or a CD25-binding ligand, e.g., IL-2. In some embodiments, the anti-CD25 antibody or fragment thereof, or CD25-binding ligand, is conjugated to a substrate, e.g., a bead, or is otherwise coated on a substrate, e.g., a bead. In some embodiments, the anti-CD25 antibody or fragment thereof is conjugated to a substrate described herein. In some embodiments, T regulatory cells, e.g., CD25+ T cells, are removed from the population using an anti-CD25 antibody molecule or fragment thereof.
[0011] In some embodiments, T regulatory cells, e.g., CD25+ T cells, are derived from Miltenyi TM In one embodiment, the cells to CD25 depletion agent ratio is 1e7 cells to 20 μL, or 1e7 cells to 15 μL, or 1e7 cells to 10 μL, or 1e7 cells to 5 μL, or 1e7 cells to 2.5 μL, or 1e7 cells to 1.25 μL.
[0012] In one embodiment, the population of T regulatory depleted cells, e.g., CD25+ depleted cells, is suitable for expression of a CAR described herein, e.g., a CD19 CAR described herein. In one embodiment, the population of immune effector cells is obtained from a subject with a hematological cancer, e.g., a leukemia, e.g., chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), or a lymphoma, e.g., mantle cell lymphoma (MCL) or Hodgkin's lymphoma (HL). In one embodiment, the population of T regulatory depleted cells comprises less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1% of leukemia cells, e.g., CLL cells, ALL cells, or lymphoma cells, e.g., MCL cells or HL cells. In one embodiment, the population of immune effector cells is obtained from a subject with CLL and has a population of T regulatory depleted cells, e.g., CD25+ depleted cells, that comprise less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of leukemia cells, e.g., CLL cells, and is suitable for expression of a CD19 CAR described herein. In one embodiment, the population of T regulatory depleted cells comprises less than 15%, 10%, 5%, 4%, 3%, 2%, 1% of CD25+ cells and less than 15%, 10%, 5%, 4%, 3%, 2%, 1% of tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells. In some embodiments, the population of T regulatory depleted cells comprises less than 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells.
[0013] In some embodiments, the population of immune effector cells is T cells isolated from peripheral blood lymphocytes. In some embodiments, the population of T cells can be obtained by red blood cell lysis and / or monocyte depletion. In some embodiments, the population of T cells is isolated from peripheral lymphocytes, for example, using the methods described herein.
[0014] In some embodiments, the population of immune effector cells can be obtained from a blood sample from a subject, e.g., obtained by apheresis. In some embodiments, cells collected by apheresis are washed to remove the plasma fraction, and optionally, the cells are placed in an appropriate buffer or medium for subsequent processing steps. In some embodiments, the cells are washed with a buffer, e.g., phosphate-buffered saline (PBS). In some embodiments, the cells are washed with a wash solution lacking one or more divalent cations, such as calcium and magnesium, e.g., lacking both calcium and magnesium. In some embodiments, the cells are washed with a buffer substantially free of divalent cations.
[0015] In some embodiments, the method further includes removing cells from the population that express a tumor antigen, e.g., a tumor antigen that does not contain CD25, e.g., CD19, CD30, CD38, CD123, CD20, CD14, or CD11b, thereby providing a population of T regulatory-depleted, e.g., CD25+-depleted and tumor antigen-depleted cells suitable for expression of a CAR, e.g., a CAR described herein. In some embodiments, tumor antigen-expressing cells are removed simultaneously with T regulatory, e.g., CD25+, cells. For example, an anti-CD25 antibody or fragment thereof and an anti-tumor antigen antibody or fragment thereof can be bound to the same substrate, e.g., beads, that can be used to remove the cells, or the anti-CD25 antibody or fragment thereof or the anti-tumor antigen antibody or fragment thereof can be bound to separate beads, the mixture of which can be used to remove the cells. In other embodiments, removal of T regulatory cells, e.g., CD25+ cells, and removal of tumor antigen-expressing cells are sequential, e.g., can occur in either order.
[0016] In some embodiments, the method further comprises depleting the cells from a population that expresses a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein, e.g., one or more (e.g., two or three) PD1+ cells, LAG3+ cells, and TIM3+ cells, thereby providing a population of T regulatory-depleted, e.g., CD25+-depleted cells and checkpoint inhibitor-depleted cells, e.g., PD1+, LAG3+, and / or TIM3+-depleted cells. In some embodiments, PD1+ cells and LAG3+ cells are depleted; PD1+ cells and TIM3+ cells are depleted; or LAG3+ and TIM3+ cells are depleted. In some embodiments, checkpoint inhibitor-expressing cells are depleted simultaneously with T regulatory, e.g., CD25+ cells. For example, an anti-CD25 antibody, or fragment thereof, and an anti-checkpoint inhibitor antibody, or fragment thereof, can be coupled to the same beads that can be used to remove the cells, or the anti-CD25 antibody, or fragment thereof, and the anti-checkpoint inhibitor antibody, or fragment thereof, can be coupled to separate beads whose mixture can be used to remove the cells. In other embodiments, the depletion of T regulatory cells, e.g., CD25+ cells, and the depletion of checkpoint inhibitor-expressing cells are sequential, e.g., can occur in either order.
[0017] In some embodiments, the population of cells to be removed are not regulatory T cells or tumor cells, but are cells that otherwise negatively affect the expression and / or function of CART cells, such as cells that express CD14, CD11b, CD33, CD15, or other markers expressed by potentially immunosuppressive cells. In some embodiments, it is contemplated that such cells are removed simultaneously with the regulatory T cells and / or tumor cells, or after the depletion, or in other orders.
[0018] In some embodiments, the method further comprises removing cells from the CD14-expressing population, thereby providing a population of T regulatory depletion, e.g., CD25+ depleted cells and CD14+ depleted cells. In some embodiments, CD14+ cells are removed simultaneously with T regulatory, e.g., CD25+ cells. For example, an anti-CD25 antibody or fragment thereof and an anti-CD14 antibody or fragment thereof can be bound to the same bead that can be used to remove cells; or an anti-CD25 antibody or fragment thereof and an anti-CD14 antibody or fragment thereof can be bound to separate beads that can be used to remove cells. In other embodiments, the removal of T regulatory cells, e.g., CD25+ cells, and the removal of CD14+ cells are sequential, e.g., can occur in either order. In some embodiments, CD14+ cells are removed using a CD14 antibody molecule or fragment thereof.
[0019] In some embodiments, the population of immune effector cells provided is selected based on expression of one or more markers (e.g., 2, 3, 4, 5, 6, 7 or more markers), e.g., CD3, CD28, CD4, CD8, CD27, CD127, CD45RA and CD45RO, e.g., the provided population of immune effector cells (e.g., T cells) are CD3+ and / or CD28+.
[0020] In some embodiments, the method further comprises obtaining a population of immune effector cells, e.g., T cells, enriched for expression of one or more markers (e.g., 2, 3, 4, 5, 6, 7 or more markers), e.g., CD3, CD28, CD4, CD8, CD27, CD127, CD45RA and CD45RO. In some embodiments, the population of immune effector cells is enriched for CD3+ and / or CD28+ cells. For example, isolated T cells are obtained by incubation with anti-CD3 / anti-CD28 conjugated beads. In some embodiments, the method further comprises selecting cells from a population of T regulatory-depleted cells, e.g., CD25+-depleted cells, that express one or more markers (e.g., 2, 3, 4, 5 or more markers), e.g., CD3, CD28, CD4, CD8, CD45RA and CD45RO.
[0021] In one embodiment, the method includes activating a population of T regulatory depleted cells, e.g., CD25+ depleted cells, e.g., by a method described herein.
[0022] In some embodiments, the method further includes transducing cells from the population of T regulatory-depleted cells, e.g., the population of CD25+-depleted cells, with a vector comprising a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein. In some embodiments, the vector is selected from the group consisting of DNA, RNA, a plasmid, a lentiviral vector, an adenoviral vector, or a retroviral vector. In some embodiments, the cells from the population of T regulatory-depleted cells, e.g., the population of CD25+-depleted cells, are transduced with the vector at one time, e.g., within one day after obtaining the population of immune effector cells from a blood sample from the subject, e.g., obtained by apheresis.
[0023] In some embodiments, the method further includes producing a population of RNA-engineered cells that transiently express an exogenous RNA from the population of T regulatory-depleted cells, e.g., the population of CD25+-depleted cells. The method includes introducing in vitro transcribed RNA or synthetic RNA into cells from the population, wherein the RNA comprises a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein.
[0024] In some embodiments, cells transduced with a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein, are expanded, e.g., by a method described herein. In some embodiments, the cells are expanded in culture for a period of several hours (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 18, 21 hours) to about 14 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days). In some embodiments, the cells are expanded for a period of 3 to 9 days. In some embodiments, the cells are expanded for a period of 4 to 9 days. In some embodiments, the cells are expanded for 8 days or less, e.g., 7, 6, 5, 4, or 3 days. In some embodiments, cells, e.g., CD19 CAR cells described herein, are expanded in culture for 3 or 4 days, and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same culture conditions. In some embodiments, cells, e.g., CD19 CAR cells described herein, are expanded in culture for 5 days, and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same culture conditions. Potency can be defined, for example, by various T cell functions, such as proliferation, target cell killing, cytokine production, activation, migration, or a combination thereof. In some embodiments, cells expanded for 3 or 4 days, e.g., CD19 CAR cells described herein, exhibit at least a 1-fold, 2-fold, 3-fold, or 4-fold increase in cell doublings upon antigen stimulation compared to the same cells expanded in culture for 9 days under the same culture conditions. In some embodiments, cells expanded for 5 days, e.g., CD19 CAR cells described herein, exhibit at least a 1-fold, 2-fold, 3-fold, or 4-fold increase in cell doublings upon antigen stimulation compared to the same cells expanded in culture for 9 days under the same culture conditions. In one embodiment, cells, e.g., cells expressing a CD19 CAR described herein, are expanded in culture for 3 or 4 days, and the resulting cells exhibit increased pro-inflammatory cytokine production, e.g., IFN-γ and / or GM-CSF levels, compared to the same cells expanded in culture for 9 days under the same culture conditions.In some embodiments, cells, e.g., cells expressing a CD19 CAR described herein, are expanded in culture for 5 days, and the resulting cells exhibit increased proinflammatory cytokine production, e.g., IFN-γ and / or GM-CSF levels, compared to the same cells expanded in culture for 9 days under the same culture conditions. In some embodiments, cells expanded for 3 or 4 days, e.g., CD19 CAR cells described herein, exhibit at least a 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more increase in proinflammatory cytokine production, e.g., IFN-γ and / or GM-CSF levels, in pg / ml, compared to the same cells expanded in culture for 9 days under the same culture conditions. In some embodiments, cells expanded for 5 days, e.g., CD19 CAR cells described herein, exhibit at least a 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more increase in proinflammatory cytokine production, e.g., IFN-γ and / or GM-CSF levels, in pg / ml, compared to the same cells expanded in culture for 9 days under the same culture conditions. In some embodiments, cells expanded for 3, 4, or 5 days, e.g., CD19 CAR cells described herein, exhibit at least the same pg / ml cytokine production, e.g., IL-2, IFN-gamma, GM-CSF, TNF-alpha, IL-1b, IL4, IL5, IL6, IL8, or IL10 levels, or at least a 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more increase, compared to the same cells expanded in culture for 9 days under the same culture conditions.
[0025] In some embodiments, beads (e.g., CD3 / 28 stimulatory beads) are removed from cells by mechanical disruption. In some embodiments, mechanical disruption involves passing (e.g., repeatedly passing) cells through a pipette tip, e.g., a narrow-bore pipette tip. In some embodiments, cells are passed through one or more (e.g., 2, 3, 4, or 5 or more) tubes, e.g., narrow-bore tubes. In some embodiments, the tubes are part of a closed cell culture system. In some embodiments, the inner diameter of the pipette tip or tube is less than about 1 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.5 mm, 0.4 mm, 0.3 mm, or 0.2 mm, and optionally, the diameter is greater than 0.1 mm, 0.2 mm, 0.3 mm, or 0.4 mm.
[0026] In some embodiments, cells expanded for 3, 4, or 5 days, e.g., CAR cells described herein, e.g., CD19 CAR cells described herein, have an increased proportion of Tem cells, Tcm cells, or both Tem and Tcm cells, as compared to the same cells expanded in culture for 9 days under the same culture conditions. In some embodiments, cells expanded for 3, 4, or 5 days, e.g., CAR cells described herein, e.g., CD19 CAR cells described herein, have an increased proportion of Tem cells, Teff cells, or both Tem and Teff cells, as compared to the same cells expanded in culture for 9 days under the same culture conditions. In some embodiments, the population of cells expanded for 3, 4, or 5 days, e.g., CD19 CAR cells described herein, has a percentage of T naive-like cells (among T naive-like, Teff, and Tcm cells) of at least about 20%, 25%, 30%, 35%, 40%, 45%, or 50%, optionally up to about 40% or 50%. In some embodiments, a population of cells, e.g., CD19 CAR cells described herein, expanded for 3, 4, or 5 days has a percentage of Tem cells (among T naive-like, Teff, and Tcm cells) of at least about 10%, 15%, or 20%, and optionally up to about 15% or 20%. In some embodiments, a population of cells, e.g., CD19 CAR cells described herein, expanded for 3, 4, or 5 days has a percentage of (T naive-like + Tem) cells (among T naive-like, Teff, and Tcm cells) of at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70%, and optionally up to about 50% or 70%.
[0027] In one embodiment, cells expanded for 3, 4, or 5 days, e.g., CD19 CAR cells described herein, are 0.5 x 10 6 When administered at a dose of 1 x 10 cells, the same cells expanded for 9 days in culture under the same culture conditions in the NALM6 assay in Figure 31A were 6 , 1.5×10 6 , 2 × 10 6 , 2.5×10 6 , 3×10 6 , 4×106 or 5×10 6 In some embodiments, activity is measured at 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks.
[0028] In some embodiments, the cells are expanded by cell culture in the presence of an agent that stimulates a CD3 / TCR complex-associated signal and a ligand that stimulates a costimulatory molecule on the surface of the cells, e.g., as described herein. In some embodiments, the agent is a bead conjugated with an anti-CD3 antibody or fragment thereof and / or an anti-CD28 antibody or fragment thereof.
[0029] In one embodiment, the cells are expanded in an appropriate medium (e.g., a medium described herein) containing one or more (e.g., two, three, four, or five or more) factors for proliferation and / or viability, optionally including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-γ, IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, IL-21, TGFβ, and TNF-α, or any other additives for cell growth.
[0030] In one embodiment, the cells are expanded in an appropriate medium (e.g., a medium described herein) containing one or more (e.g., two, three, four, or five or more) interleukins that result in at least a 200-fold (e.g., 200-fold, 250-fold, 300-fold, 350-fold) increase in cells over a 14-day expansion period, as measured by a method described herein, such as, for example, flow cytometry. In one embodiment, the cells are expanded in the presence of IL-15 and / or IL-7 (e.g., IL-15 and IL-7).
[0031] In some embodiments, the cells are cryopreserved after a suitable expansion period. In some embodiments, the cells are cryopreserved according to methods described herein. In some embodiments, the expanded cells are cryopreserved in an appropriate medium, e.g., a lysis-insensitive medium, e.g., as described herein.
[0032] In some embodiments, the method further comprises contacting the population of immune effector cells with a nucleic acid encoding a telomerase subunit, e.g., hTERT. In some embodiments, the nucleic acid is DNA or RNA.
[0033] In another aspect, the invention pertains to a reaction mixture comprising a population of T regulatory depleted cells comprising less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells. In one embodiment, the reaction mixture comprises a population of T regulatory depleted cells comprising less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25-expressing tumor cells, e.g., CLL cells. In some embodiments, the population of cells comprises less than 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 15%, 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells. In some embodiments, the population of cells comprises less than 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells.
[0034] In some embodiments, the reaction mixture comprises a population of T regulatory-depleted cells that comprises less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% checkpoint inhibitor-expressing cells, e.g., PD1+ cells, LAG3+ cells, or TIM3+ cells. The reaction mixture may further comprise a buffer or other reagent, e.g., a PBS-containing solution.
[0035] In some embodiments, the reaction mixture comprises a population of T regulatory depleted cells comprising less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD14+ cells. The reaction mixture may further comprise a buffer or other reagent, e.g., a PBS-containing solution.
[0036] In some embodiments, the reaction mixture can further include an agent that activates and / or expands the cells of the population, e.g., an agent that stimulates CD3 / TCR complex-associated signals and / or a ligand that stimulates costimulatory molecules on the surface of the cells, e.g., as described herein. In some embodiments, the agent is a bead conjugated to an anti-CD3 antibody or fragment thereof and / or an anti-CD28 antibody or fragment thereof.
[0037] In some embodiments, the reaction mixture further comprises one or more (e.g., 2, 3, 4, or 5) factors for proliferation and / or viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-γ, IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, IL-21, TGFβ, and TNF-α, or any other additive for cell growth. In some embodiments, the reaction mixture further comprises IL-15 and / or IL-7.
[0038] In one embodiment, the population of cells in the reaction mixture comprises a nucleic acid molecule, e.g., a nucleic acid molecule described herein, that comprises a CAR-encoding sequence, e.g., a CD19 CAR-encoding sequence, e.g., as described herein.
[0039] In one embodiment, the population of cells in the reaction mixture comprises a vector comprising a nucleic acid sequence encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein. In one embodiment, the vector is a vector described herein, e.g., a vector selected from the group consisting of DNA, RNA, a plasmid, a lentiviral vector, an adenoviral vector, or a retroviral vector.
[0040] In some embodiments, the reaction mixture further comprises a cryoprotectant or stabilizer, such as, for example, saccharides, oligosaccharides, polysaccharides and polyols (e.g., trehalose, mannitol, sorbitol, lactose, sucrose, glucose and dextran), salts and crown ethers. In some embodiments, the cryoprotectant is dextran.
[0041]
[0013] In another aspect, the invention relates to a method of producing a population of immune effector cells (e.g., T cells, NK cells) engineered to express a CAR, comprising providing a population of immune effector cells (e.g., T cells), wherein a plurality of the immune effector cells comprise a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein, and expanding the population of cells in the presence of one or more (e.g., 2, 3, 4, or 5) interleukins that result in at least a 200-fold (e.g., 200-fold, 250-fold, 300-fold, 350-fold) increase in cells over a 14-day expansion period, as measured by a method described herein, such as flow cytometry. In one embodiment, the population of cells is expanded in the presence of IL-15 and / or IL-7, e.g., IL-15 and IL-7.
[0042] In some embodiments, the cells are expanded in culture for a period of several hours (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 18, 21 hours) to about 14 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days). In some embodiments, the cells are expanded for a period of 4 to 9 days. In some embodiments, the cells are expanded for 8 days or less, e.g., 7, 6, or 5 days. In some embodiments, cells are expanded in culture for 5 days, and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same culture conditions. Potency can be defined, for example, by various T cell functions, such as proliferation, target cell killing, cytokine production, activation, migration, or a combination thereof. In some embodiments, cells expanded for 5 days, e.g., CD19 CAR cells described herein, exhibit at least a 1-fold, 2-fold, 3-fold, or 4-fold increase in cell doublings upon antigen stimulation compared to the same cells expanded for 9 days in culture under the same culture conditions. In some embodiments, cells, e.g., cells expressing a CD19 CAR described herein, are expanded for 5 days in culture, and the resulting cells exhibit elevated proinflammatory cytokine production, e.g., IFN-γ and / or GM-CSF levels, compared to the same cells expanded for 9 days in culture under the same culture conditions. In some embodiments, cells expanded for 5 days, e.g., CD19 CAR cells described herein, exhibit at least a 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in proinflammatory cytokine production in pg / ml, e.g., IFN-γ and / or GM-CSF levels, compared to the same cells expanded for 9 days in culture under the same culture conditions.
[0043] In some embodiments, the cells are expanded by cell culture in the presence of an agent that stimulates a CD3 / TCR complex-associated signal and a ligand that stimulates a costimulatory molecule on the surface of the cells, e.g., as described herein. In some embodiments, the agent is a bead conjugated with an anti-CD3 antibody or fragment thereof and / or an anti-CD28 antibody or fragment thereof.
[0044] In some embodiments, the population of immune effector cells provided is a population of T regulatory depleted cells that comprises less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells. In some embodiments, the population of immune effector cells provided is a population of T regulatory depleted cells that comprises less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25-expressing tumor cells, e.g., CLL cells. In some embodiments, the population of cells provided comprises less than 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 15%, 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells. In some embodiments, the population of cells provided comprises less than 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells.
[0045] In some embodiments, the population of immune effector cells provided is a population of T regulatory depleted cells that comprises less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% checkpoint inhibitor-expressing cells, e.g., PD1+ cells, LAG3+ cells, or TIM3+ cells.
[0046] In some embodiments, the population of immune effector cells provided is a population of T regulatory depleted cells that comprises less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD14+ cells.
[0047] In some embodiments, the method further comprises removing T regulatory cells, e.g., CD25+ T cells, from the population prior to expansion, thereby providing T regulatory depleted cells, e.g., CD25+ depleted cells, to be expanded. In some embodiments, the T regulatory cells, e.g., CD25+ cells, are removed by the methods described herein.
[0048] In some embodiments, the method further comprises removing T regulatory cells, e.g., CD14+ cells, from the population prior to expansion, thereby providing a population of CD14+ depleted cells for expansion. In some embodiments, the T regulatory cells, e.g., CD14+ cells, are removed by the methods described herein.
[0049] In some embodiments, the method further comprises contacting the population of immune effector cells with a nucleic acid encoding a telomerase subunit, e.g., hTERT. In some embodiments, the nucleic acid is DNA or RNA.
[0050] In another aspect, the invention pertains to a reaction mixture comprising a population of immune effector cells, wherein a plurality of the population of cells in the reaction mixture comprises a nucleic acid molecule, e.g., a nucleic acid molecule described herein, comprising a CAR-encoding sequence, e.g., a CD19 CAR-encoding sequence, e.g., as described herein, and IL-7 and / or IL-15.
[0051] In one embodiment, the population of cells in the reaction mixture comprises a vector comprising a nucleic acid sequence encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein. In one embodiment, the vector is a vector described herein, e.g., a vector selected from the group consisting of DNA, RNA, a plasmid, a lentiviral vector, an adenoviral vector, or a retroviral vector.
[0052] In some embodiments, the reaction mixture can further include an agent that activates and / or expands the cells of the population, e.g., an agent that stimulates CD3 / TCR complex-associated signals and / or a ligand that stimulates costimulatory molecules on the surface of the cells, e.g., as described herein. In some embodiments, the agent is a bead conjugated to an anti-CD3 antibody or fragment thereof and / or an anti-CD28 antibody or fragment thereof.
[0053] In another aspect, the invention pertains to a method of producing a population of immune effector cells (e.g., T cells, NK cells) engineered to express a CAR, comprising providing a population of immune effector cells (e.g., T cells), wherein a plurality of the immune effector cells comprise a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein, and expanding the population of cells in culture for 5 days, wherein the resulting cells are more potent, as measured by the level of cell proliferation upon antigen stimulation, compared to the same cells expanded in culture for 9 days under the same culture conditions.
[0054] In some embodiments, cells expanded for 5 days exhibit at least a 1-fold, 2-fold, 3-fold, or 4-fold increase in cell doublings upon antigen stimulation compared to the same cells expanded for 9 days in culture under the same culture conditions. In some embodiments, cells, e.g., cells expressing a CD19 CAR described herein, are expanded for 5 days in culture, and the resulting cells exhibit higher proinflammatory cytokine production, e.g., IFN-γ and / or GM-CSF levels, compared to the same cells expanded for 9 days in culture under the same culture conditions. In some embodiments, cells expanded for 5 days exhibit at least a 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more increase in proinflammatory cytokine production, e.g., IFN-γ and / or GM-CSF levels, in pg / ml compared to the same cells expanded for 9 days in culture under the same culture conditions.
[0055] In another aspect, the invention pertains to a method, comprising administering to a subject a population of immune effector cells produced by a method described herein and engineered to express a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein.
[0056] In some embodiments, the method provides anti-tumor immunity in a subject with cancer, e.g., a hematological cancer, such as CLL. In some embodiments, the method is a method of treating a subject with cancer, e.g., a hematological cancer described herein, such as leukemia (e.g., CLL, ALL) or lymphoma (e.g., MCL, HL). In some embodiments, the population of cells is autologous to the subject to whom the population is administered. In some embodiments, the population of cells is allogeneic to the subject to whom the population is administered. In some embodiments, the subject is human.
[0057] In some embodiments, the disease associated with a tumor antigen, e.g., a tumor antigen described herein, e.g., CD19, is selected from a proliferative disease, such as a cancer or malignant tumor, or a precancerous condition, such as myelodysplasia, myelodysplastic syndrome, or preleukemia, or is a non-cancer-related indication associated with expression of a tumor antigen described herein. In some embodiments, the disease is a cancer described herein, e.g., a cancer described herein as being associated with a target described herein. In some embodiments, the hematological cancer is leukemia. In some embodiments, the cancer is one or more acute leukemias, including but not limited to B-cell acute lymphoid leukemia ("BALL"), T-cell acute lymphoid leukemia ("TALL"), acute lymphoid leukemia (ALL); one or more chronic leukemias, including but not limited to chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL); B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma. , myelodysplasia and myelodysplastic syndromes, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia, and "preleukemia," a collection of various hematological conditions united by ineffective production (or dysplasia) of bone marrow blood cells, and additional blood cancers or hematological conditions, including, but not limited to, diseases associated with expression of a tumor antigen described herein, including, but not limited to, atypical and / or non-classical cancers, malignancies, precancerous conditions, or proliferative disorders that express a tumor antigen described herein; and any combination thereof. In other embodiments, the disease associated with a tumor antigen described herein is a solid tumor, e.g., a solid tumor described herein, e.g., prostate, colorectal, pancreatic, cervical, gastric, ovarian, head, or lung cancer.
[0058] In one embodiment, a population of immune effector cells transduced with a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein, is expanded, e.g., by a method described herein. In one embodiment, the cells are expanded for 8 days or less, e.g., 7, 6, 5, 4, or 3 days. In one embodiment, cells, e.g., CD19 CAR cells described herein, are expanded in culture for 5 days, and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same culture conditions. In one embodiment, 10 per kg of subject body weight is used. 4 ~10 6 Immune effector cells are administered to the subject. In some embodiments, the subject receives an initial administration of a population of immune effector cells (e.g., 10 per kg of the subject's body weight). 4 ~10 6 Immune effector cells, e.g., 10 per kg of subject's body weight 4 ~10 5 a first administration of immune effector cells), a plurality of which comprises a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein, and then administering to the subject a population of one or more (e.g., 2, 3, 4, or 5) immune effector cells (e.g., 10 per kg body weight of the one or more subjects) 4 ~10 6 Immune effector cells, e.g., 10 per kg of subject's body weight 4 ~10 5 In one embodiment, the subject receives a total of about 10 immune effector cells per kg of the subject's body weight over the course of at least three doses of the population of immune effector cells, the plurality of which comprises a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein. In one embodiment, one or more subsequent doses are administered within 15 days, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 days after the previous dose, e.g., within 4, 3, 2 days after the previous dose. In one embodiment, the subject receives a total of about 10 immune effector cells per kg of the subject's body weight over the course of at least three doses of the population of immune effector cells. 6 For example, a subject may receive 1 x 10 immune effector cells. 5 initial dose of immune effector cells, 3 × 10 5Second dose of immune effector cells and 6 x 10 5 A third dose of immune effector cells is administered, for example, with each dose administered within 4 days, 3 days, 2 days after the previous dose.
[0059] In one aspect, the invention pertains to a population of autoimmune effector cells, a plurality of which are transduced or transduced with a vector comprising a nucleic acid molecule encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein, wherein the population of cells comprises less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CLL cells. In one embodiment, the population of cells comprises less than 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 15%, 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells. In some embodiments, the population of cells comprises less than 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells.
[0060]
[00010] In another aspect, the invention relates to a method of producing a population of immune effector cells (e.g., T cells, NK cells). In one embodiment, the method includes providing a population of immune effector cells (e.g., T cells or NK cells) and contacting the population of immune effector cells with a nucleic acid encoding a CAR and a nucleic acid encoding a telomerase subunit, e.g., hTERT, under conditions that allow for CAR and telomerase expression.
[0061] In some embodiments, the nucleic acid encoding the telomerase subunit is RNA. In other embodiments, the nucleic acid encoding the telomerase subunit is DNA. In some embodiments, the nucleic acid encoding the telomerase subunit comprises a promoter capable of driving expression of the telomerase subunit.
[0062] In a related aspect, the invention features a method of producing a population of immune effector cells (e.g., T cells, NK cells), comprising providing a population of immune effector cells (e.g., T cells) and contacting the population of immune effector cells with a nucleic acid encoding a CAR and an RNA encoding a telomerase subunit, e.g., hTERT, under conditions that allow for CAR and telomerase expression.
[0063] In some embodiments, the nucleic acid encoding the CAR and the RNA encoding the telomerase subunit are part of the same nucleic acid molecule. In some embodiments, the nucleic acid encoding the CAR and the RNA encoding the telomerase subunit are part of separate nucleic acid molecules.
[0064] In some embodiments, the method comprises substantially simultaneously contacting a population of immune effector cells with a nucleic acid encoding a CAR and an RNA encoding a telomerase subunit. In some embodiments, the method comprises contacting the population of immune effector cells with a nucleic acid encoding a CAR before contacting the population of immune effector cells with an RNA encoding a telomerase subunit. In some embodiments, the method comprises contacting the population of immune effector cells with a nucleic acid encoding a CAR after contacting the population of immune effector cells with an RNA encoding a telomerase subunit.
[0065] In some embodiments, the RNA encoding the telomerase subunit is mRNA. In some embodiments, the RNA encoding the telomerase subunit comprises a poly(A) tail. In some embodiments, the RNA encoding the telomerase subunit comprises a 5' cap structure.
[0066] In some embodiments, the method comprises transfecting immune effector cells with RNA encoding a telomerase subunit. In some embodiments, the method comprises transducing immune effector cells with RNA encoding a telomerase subunit. In some embodiments, the method comprises electroporating immune effector cells with RNA encoding a telomerase subunit under conditions that allow CAR and telomerase expression.
[0067] In another aspect, the invention pertains to a method of producing a population of immune effector cells (e.g., T cells, NK cells), the method comprising: providing a population of immune effector cells (e.g., T cells or NK cells) that express a CAR and / or comprise a nucleic acid encoding a CAR; and contacting the population of immune effector cells with a nucleic acid encoding a telomerase subunit, e.g., hTERT, under conditions that allow for hTERT expression.
[0068] In another aspect, the invention pertains to a method of producing a population of immune effector cells (e.g., T cells, NK cells), the method comprising providing a population of immune effector cells (e.g., T cells or NK cells) that express a nucleic acid encoding a telomerase subunit, e.g., hTERT, and contacting the population of immune effector cells with a nucleic acid encoding a CAR under conditions that allow for CAR expression.
[0069] In one aspect, the present invention provides an immune effector cell (e.g., a T cell or an NK cell) comprising a nucleic acid encoding a CAR, e.g., a CAR described herein; and a nucleic acid encoding an exogenous telomerase subunit, e.g., hTERT. In one embodiment, the nucleic acid encoding the exogenous telomerase subunit is RNA, e.g., mRNA.
[0070] In one aspect, the present invention provides an immune effector cell (e.g., a T cell or an NK cell) comprising a CAR, e.g., a CAR described herein; and an exogenous telomerase subunit, e.g., hTERT. In some embodiments, the cell does not contain DNA, e.g., exogenous DNA, e.g., a vector, encoding the exogenous telomerase subunit. For example, the cell can be contacted with mRNA encoding the exogenous telomerase subunit.
[0071] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references (e.g., sequence database reference numbers) described herein are incorporated by reference in their entirety. For example, all GenBank, Unigene, and Entrez sequences listed herein, e.g., in any table herein, are incorporated by reference. Unless otherwise specified, the sequence accession numbers specified herein, including any table herein, refer to database entries current as of December 29, 2014. When multiple sequence accession numbers are cited for a gene or protein, all sequence variants are encompassed.
[0072] Furthermore, the materials, methods, and examples are illustrative only and not intended to be limiting. Titles, subtitles, or numbered or lettered elements, e.g., (a), (b), (i), etc., are provided solely for ease of reading. The use of titles or numbered or lettered elements herein does not require the steps or elements to be performed in alphabetical order or that the steps or elements are necessarily distinct from one another. Other features, objects, and advantages of the present invention will be apparent from the specification and drawings, and from the claims. [Brief explanation of the drawings]
[0073] [Figure 1-1]Figure 1A shows the differential effects of γc cytokines and IL-18 on CAR-T cell accumulation. Figure 1A is a schematic diagram of the C4-27z CAR vector. Figure 1B shows two representative FACS histogram plots of CAR expression in CD4+ and CD8+ T cells 48 hours after lentiviral transduction. Figure 1C is a graph showing the overall accumulation of CAR-T cells in response to various cytokine exposures. T cells were transduced and exposed to various exogenous cytokines at a final concentration of 10 ng / mL starting the following day (day 0). The number of CAR-T cells was calculated based on the T cell count and CAR expression percentage. Curves are representative of six donors. *P<0.05, ***P<0.001. NC, no cytokine. Figure 1D is a graph showing CAR expression by T cells 15 days after lentiviral transduction. The bar graph shows CAR expression levels (±SEM, n = 6) on the surface of CD3+, CD4+, and CD8+ T cells, normalized to CAR expression in the NC group as 1. *P < 0.05 vs. the IL-2 group; NS, no statistical difference. Figure 1E is a histogram showing T cell proliferation in response to various cytokines. Seven days after lentiviral transduction, T cells from the NC group were labeled with CFSE (2.5 μM) and exposed to various cytokines. Seven days later, T cells were analyzed for CFSE dilution by flow cytometry. Figure 1F is a graph showing T cell viability 15 days after lentiviral transduction. T cells from the various cytokine groups were stained with Annexin V and 7-AAD, and the ratio of viable cells was analyzed (negative for both Annexin V and 7-AAD). *P < 0.05, **P < 0.01 vs. the IL-2 group (n = 6). Figures 1G and 1H show Bcl-xL expression by CAR-T cells. Fifteen days after lentiviral transduction, CAR-T cells were evaluated for Bcl-2 protein expression by flow cytometry. Figure 1G shows a representative FACS histogram plot of Bcl-xL expression in various cytokine groups. Figure 1H shows a graph depicting Bcl-xL expression (±SEM) in CD4+ and CD8+ CAR-T cells from six donors. *P<0.01 vs. IL-2 group. [Figure 1-2]Figure 1A shows the differential effects of γc cytokines and IL-18 on CAR-T cell accumulation. Figure 1A is a schematic diagram of the C4-27z CAR vector. Figure 1B shows two representative FACS histogram plots of CAR expression in CD4+ and CD8+ T cells 48 hours after lentiviral transduction. Figure 1C is a graph showing the overall accumulation of CAR-T cells in response to various cytokine exposures. T cells were transduced and exposed to various exogenous cytokines at a final concentration of 10 ng / mL starting the following day (day 0). The number of CAR-T cells was calculated based on the T cell count and CAR expression percentage. Curves are representative of six donors. *P<0.05, ***P<0.001. NC, no cytokine. Figure 1D is a graph showing CAR expression by T cells 15 days after lentiviral transduction. The bar graph shows CAR expression levels (±SEM, n = 6) on the surface of CD3+, CD4+, and CD8+ T cells, normalized to CAR expression in the NC group as 1. *P < 0.05 vs. the IL-2 group; NS, no statistical difference. Figure 1E is a histogram showing T cell proliferation in response to various cytokines. Seven days after lentiviral transduction, T cells from the NC group were labeled with CFSE (2.5 μM) and exposed to various cytokines. Seven days later, T cells were analyzed for CFSE dilution by flow cytometry. Figure 1F is a graph showing T cell viability 15 days after lentiviral transduction. T cells from the various cytokine groups were stained with Annexin V and 7-AAD, and the ratio of viable cells was analyzed (negative for both Annexin V and 7-AAD). *P < 0.05, **P < 0.01 vs. the IL-2 group (n = 6). Figures 1G and 1H show Bcl-xL expression by CAR-T cells. Fifteen days after lentiviral transduction, CAR-T cells were evaluated for Bcl-2 protein expression by flow cytometry. Figure 1G shows a representative FACS histogram plot of Bcl-xL expression in various cytokine groups. Figure 1H shows a graph depicting Bcl-xL expression (±SEM) in CD4+ and CD8+ CAR-T cells from six donors. *P<0.01 vs. IL-2 group. [Figure 1-3]Figure 1A shows the differential effects of γc cytokines and IL-18 on CAR-T cell accumulation. Figure 1A is a schematic diagram of the C4-27z CAR vector. Figure 1B shows two representative FACS histogram plots of CAR expression in CD4+ and CD8+ T cells 48 hours after lentiviral transduction. Figure 1C is a graph showing the overall accumulation of CAR-T cells in response to various cytokine exposures. T cells were transduced and exposed to various exogenous cytokines at a final concentration of 10 ng / mL starting the following day (day 0). The number of CAR-T cells was calculated based on the T cell count and CAR expression percentage. Curves are representative of six donors. *P<0.05, ***P<0.001. NC, no cytokine. Figure 1D is a graph showing CAR expression by T cells 15 days after lentiviral transduction. The bar graph shows CAR expression levels (±SEM, n = 6) on the surface of CD3+, CD4+, and CD8+ T cells, normalized to CAR expression in the NC group as 1. *P < 0.05 vs. the IL-2 group; NS, no statistical difference. Figure 1E is a histogram showing T cell proliferation in response to various cytokines. Seven days after lentiviral transduction, T cells from the NC group were labeled with CFSE (2.5 μM) and exposed to various cytokines. Seven days later, T cells were analyzed for CFSE dilution by flow cytometry. Figure 1F is a graph showing T cell viability 15 days after lentiviral transduction. T cells from the various cytokine groups were stained with Annexin V and 7-AAD, and the ratio of viable cells was analyzed (negative for both Annexin V and 7-AAD). *P < 0.05, **P < 0.01 vs. the IL-2 group (n = 6). Figures 1G and 1H show Bcl-xL expression by CAR-T cells. Fifteen days after lentiviral transduction, CAR-T cells were evaluated for Bcl-2 protein expression by flow cytometry. Figure 1G shows a representative FACS histogram plot of Bcl-xL expression in various cytokine groups. Figure 1H shows a graph depicting Bcl-xL expression (±SEM) in CD4+ and CD8+ CAR-T cells from six donors. *P<0.01 vs. IL-2 group. [Figure 1-4]Figure 1A shows the differential effects of γc cytokines and IL-18 on CAR-T cell accumulation. Figure 1A is a schematic diagram of the C4-27z CAR vector. Figure 1B shows two representative FACS histogram plots of CAR expression in CD4+ and CD8+ T cells 48 hours after lentiviral transduction. Figure 1C is a graph showing the overall accumulation of CAR-T cells in response to various cytokine exposures. T cells were transduced and exposed to various exogenous cytokines at a final concentration of 10 ng / mL starting the following day (day 0). The number of CAR-T cells was calculated based on the T cell count and CAR expression percentage. Curves are representative of six donors. *P<0.05, ***P<0.001. NC, no cytokine. Figure 1D is a graph showing CAR expression by T cells 15 days after lentiviral transduction. The bar graph shows CAR expression levels (±SEM, n = 6) on the surface of CD3+, CD4+, and CD8+ T cells, normalized to CAR expression in the NC group as 1. *P < 0.05 vs. the IL-2 group; NS, no statistical difference. Figure 1E is a histogram showing T cell proliferation in response to various cytokines. Seven days after lentiviral transduction, T cells from the NC group were labeled with CFSE (2.5 μM) and exposed to various cytokines. Seven days later, T cells were analyzed for CFSE dilution by flow cytometry. Figure 1F is a graph showing T cell viability 15 days after lentiviral transduction. T cells from the various cytokine groups were stained with Annexin V and 7-AAD, and the ratio of viable cells was analyzed (negative for both Annexin V and 7-AAD). *P < 0.05, **P < 0.01 vs. the IL-2 group (n = 6). Figures 1G and 1H show Bcl-xL expression by CAR-T cells. Fifteen days after lentiviral transduction, CAR-T cells were evaluated for Bcl-2 protein expression by flow cytometry. Figure 1G shows a representative FACS histogram plot of Bcl-xL expression in various cytokine groups. Figure 1H shows a graph depicting Bcl-xL expression (±SEM) in CD4+ and CD8+ CAR-T cells from six donors. *P<0.01 vs. IL-2 group.
[0074] [Figure 2-1]We show the memory T cell subsets of CAR-T cells. Figure 2A is a representative FACS plot showing the gating strategy for T cell subset analysis. T cells were divided into four subsets based on CD45RA and CD62L expression, and then the expression of CCR7, CD27, CD28, and CD95 was further evaluated in all subsets. CD95 expression was significantly upregulated by lentiviral transduction. Figure 2B shows CD95 expression in the CD45RA+CD62L+ subT cell population before transduction and in CAR-T cells 15 days after transduction. Figures 2C and 2D are graphs showing the increase in the proportion of memory stem T cells (Tscm) in CD4+ (Figure 2C) and CD8+ T cells (Figure 2D) after lentiviral transduction. Tscm is defined as the CD45RA+CD62L+CD95+CCR7+ T cell subset. Figure 2E is a graph showing the correlation between the amount of naive T (Tn, defined as the CD45RA+CD62L+CD95- population) before T cell transduction and the proportion of Tscm in CAR-T cells after transduction (n=6). The left bar represents the percentage of Tn in CD4+ and CD8+ T cells before transduction, and the right bar represents the percentage of Tscm in CD4+ and CD8+ CAR-T cells. *P<0.05, **P<0.01. Figures 2F, 2G, and 2H are graphs showing the distribution of CD4+ and CD8+ CAR-T cell subsets. T subsets in CD4+ and CD8+ CAR-T cells are defined based on CD95, CD45RA, and CD62L expression. The proportion of Tscm is similar across cytokine groups; *P<0.05, **P<0.01 vs. IL-2 group (n=6). (F) Self-renewal and differentiation of various subsets of CAR-T cells. FACS-sorted CAR+Tscm, Tcm, Tem, and Tempra cells were cultured and exposed to IL-2 (10 ng / mL) for 3 days, then analyzed for phenotype based on CD45RA and CD62L expression (n=3). Figure 2I is a histogram plot showing the proliferation of various subsets of CAR-T cells in response to IL-2. FACS-sorted CAR+Tscm, Tcm, Tem, and Tempra cells were photolabeled with CFSE (2.5 μM) and then cultured and exposed to IL-2 (10 ng / mL) for 3 days. After 3 days, T cells were analyzed for CFSE dilution. [Figure 2-2]We show the memory T cell subsets of CAR-T cells. Figure 2A is a representative FACS plot showing the gating strategy for T cell subset analysis. T cells were divided into four subsets based on CD45RA and CD62L expression, and then the expression of CCR7, CD27, CD28, and CD95 was further evaluated in all subsets. CD95 expression was significantly upregulated by lentiviral transduction. Figure 2B shows CD95 expression in the CD45RA+CD62L+ subT cell population before transduction and in CAR-T cells 15 days after transduction. Figures 2C and 2D are graphs showing the increase in the proportion of memory stem T cells (Tscm) in CD4+ (Figure 2C) and CD8+ T cells (Figure 2D) after lentiviral transduction. Tscm is defined as the CD45RA+CD62L+CD95+CCR7+ T cell subset. Figure 2E is a graph showing the correlation between the amount of naive T (Tn, defined as the CD45RA+CD62L+CD95- population) before T cell transduction and the proportion of Tscm in CAR-T cells after transduction (n=6). The left bar represents the percentage of Tn in CD4+ and CD8+ T cells before transduction, and the right bar represents the percentage of Tscm in CD4+ and CD8+ CAR-T cells. *P<0.05, **P<0.01. Figures 2F, 2G, and 2H are graphs showing the distribution of CD4+ and CD8+ CAR-T cell subsets. T subsets in CD4+ and CD8+ CAR-T cells are defined based on CD95, CD45RA, and CD62L expression. The proportion of Tscm is similar across cytokine groups; *P<0.05, **P<0.01 vs. IL-2 group (n=6). (F) Self-renewal and differentiation of various subsets of CAR-T cells. FACS-sorted CAR+Tscm, Tcm, Tem, and Tempra cells were cultured and exposed to IL-2 (10 ng / mL) for 3 days, then analyzed for phenotype based on CD45RA and CD62L expression (n=3). Figure 2I is a histogram plot showing the proliferation of various subsets of CAR-T cells in response to IL-2. FACS-sorted CAR+Tscm, Tcm, Tem, and Tempra cells were photolabeled with CFSE (2.5 μM) and then cultured and exposed to IL-2 (10 ng / mL) for 3 days. After 3 days, T cells were analyzed for CFSE dilution. [Figure 2-3]We show the memory T cell subsets of CAR-T cells. Figure 2A is a representative FACS plot showing the gating strategy for T cell subset analysis. T cells were divided into four subsets based on CD45RA and CD62L expression, and then the expression of CCR7, CD27, CD28, and CD95 was further evaluated in all subsets. CD95 expression was significantly upregulated by lentiviral transduction. Figure 2B shows CD95 expression in the CD45RA+CD62L+ subT cell population before transduction and in CAR-T cells 15 days after transduction. Figures 2C and 2D are graphs showing the increase in the proportion of memory stem T cells (Tscm) in CD4+ (Figure 2C) and CD8+ T cells (Figure 2D) after lentiviral transduction. Tscm is defined as the CD45RA+CD62L+CD95+CCR7+ T cell subset. Figure 2E is a graph showing the correlation between the amount of naive T (Tn, defined as the CD45RA+CD62L+CD95- population) before T cell transduction and the proportion of Tscm in CAR-T cells after transduction (n=6). The left bar represents the percentage of Tn in CD4+ and CD8+ T cells before transduction, and the right bar represents the percentage of Tscm in CD4+ and CD8+ CAR-T cells. *P<0.05, **P<0.01. Figures 2F, 2G, and 2H are graphs showing the distribution of CD4+ and CD8+ CAR-T cell subsets. T subsets in CD4+ and CD8+ CAR-T cells are defined based on CD95, CD45RA, and CD62L expression. The proportion of Tscm is similar across cytokine groups; *P<0.05, **P<0.01 vs. IL-2 group (n=6). (F) Self-renewal and differentiation of various subsets of CAR-T cells. FACS-sorted CAR+Tscm, Tcm, Tem, and Tempra cells were cultured and exposed to IL-2 (10 ng / mL) for 3 days, then analyzed for phenotype based on CD45RA and CD62L expression (n=3). Figure 2I is a histogram plot showing the proliferation of various subsets of CAR-T cells in response to IL-2. FACS-sorted CAR+Tscm, Tcm, Tem, and Tempra cells were photolabeled with CFSE (2.5 μM) and then cultured and exposed to IL-2 (10 ng / mL) for 3 days. After 3 days, T cells were analyzed for CFSE dilution. [Figure 2-4]We show the memory T cell subsets of CAR-T cells. Figure 2A is a representative FACS plot showing the gating strategy for T cell subset analysis. T cells were divided into four subsets based on CD45RA and CD62L expression, and then the expression of CCR7, CD27, CD28, and CD95 was further evaluated in all subsets. CD95 expression was significantly upregulated by lentiviral transduction. Figure 2B shows CD95 expression in the CD45RA+CD62L+ subT cell population before transduction and in CAR-T cells 15 days after transduction. Figures 2C and 2D are graphs showing the increase in the proportion of memory stem T cells (Tscm) in CD4+ (Figure 2C) and CD8+ T cells (Figure 2D) after lentiviral transduction. Tscm is defined as the CD45RA+CD62L+CD95+CCR7+ T cell subset. Figure 2E is a graph showing the correlation between the amount of naive T (Tn, defined as the CD45RA+CD62L+CD95- population) before T cell transduction and the proportion of Tscm in CAR-T cells after transduction (n=6). The left bar represents the percentage of Tn in CD4+ and CD8+ T cells before transduction, and the right bar represents the percentage of Tscm in CD4+ and CD8+ CAR-T cells. *P<0.05, **P<0.01. Figures 2F, 2G, and 2H are graphs showing the distribution of CD4+ and CD8+ CAR-T cell subsets. T subsets in CD4+ and CD8+ CAR-T cells are defined based on CD95, CD45RA, and CD62L expression. The proportion of Tscm is similar across cytokine groups; *P<0.05, **P<0.01 vs. IL-2 group (n=6). (F) Self-renewal and differentiation of various subsets of CAR-T cells. FACS-sorted CAR+Tscm, Tcm, Tem, and Tempra cells were cultured and exposed to IL-2 (10 ng / mL) for 3 days, then analyzed for phenotype based on CD45RA and CD62L expression (n=3). Figure 2I is a histogram plot showing the proliferation of various subsets of CAR-T cells in response to IL-2. FACS-sorted CAR+Tscm, Tcm, Tem, and Tempra cells were photolabeled with CFSE (2.5 μM) and then cultured and exposed to IL-2 (10 ng / mL) for 3 days. After 3 days, T cells were analyzed for CFSE dilution. [Figure 2-5]We show the memory T cell subsets of CAR-T cells. Figure 2A is a representative FACS plot showing the gating strategy for T cell subset analysis. T cells were divided into four subsets based on CD45RA and CD62L expression, and then the expression of CCR7, CD27, CD28, and CD95 was further evaluated in all subsets. CD95 expression was significantly upregulated by lentiviral transduction. Figure 2B shows CD95 expression in the CD45RA+CD62L+ subT cell population before transduction and in CAR-T cells 15 days after transduction. Figures 2C and 2D are graphs showing the increase in the proportion of memory stem T cells (Tscm) in CD4+ (Figure 2C) and CD8+ T cells (Figure 2D) after lentiviral transduction. Tscm is defined as the CD45RA+CD62L+CD95+CCR7+ T cell subset. Figure 2E is a graph showing the correlation between the amount of naive T (Tn, defined as the CD45RA+CD62L+CD95- population) before T cell transduction and the proportion of Tscm in CAR-T cells after transduction (n=6). The left bar represents the percentage of Tn in CD4+ and CD8+ T cells before transduction, and the right bar represents the percentage of Tscm in CD4+ and CD8+ CAR-T cells. *P<0.05, **P<0.01. Figures 2F, 2G, and 2H are graphs showing the distribution of CD4+ and CD8+ CAR-T cell subsets. T subsets in CD4+ and CD8+ CAR-T cells are defined based on CD95, CD45RA, and CD62L expression. The proportion of Tscm is similar across cytokine groups; *P<0.05, **P<0.01 vs. IL-2 group (n=6). (F) Self-renewal and differentiation of various subsets of CAR-T cells. FACS-sorted CAR+Tscm, Tcm, Tem, and Tempra cells were cultured and exposed to IL-2 (10 ng / mL) for 3 days, then analyzed for phenotype based on CD45RA and CD62L expression (n=3). Figure 2I is a histogram plot showing the proliferation of various subsets of CAR-T cells in response to IL-2. FACS-sorted CAR+Tscm, Tcm, Tem, and Tempra cells were photolabeled with CFSE (2.5 μM) and then cultured and exposed to IL-2 (10 ng / mL) for 3 days. After 3 days, T cells were analyzed for CFSE dilution.
[0075] [Figure 3] Figure 3A shows the correlation between CD45RA expression and CFSE intensity. Figure 3A shows that CD45RA expression is inversely correlated with CFSE intensity. Figure 3B shows that for the entire cytokine group (IL-2, IL-7, IL-15, IL-18, and IL-21), CD45RA+ T cells showed much lower CFSE levels than CD45RA dim and negative T cells, indicating that CD45RA+ T cells had stronger proliferative activity than CD45RA- T cells.
[0076] [Figure 4-1] The phenotype of CAR-T cells obtained by exposure to various cytokines is shown. Figure 4A is a representative FACS dot plot showing the expression of CD45RA, CD62L, CCR7, CD27, and CD28 in CAR- and CAR+ T cells exposed to IL-2 14 days after lentiviral transduction. Figure 4B is a series of graphs showing quantification of CD45RA, CD62L, CCR7, CD27, CD28, and IL-7Rα expression on the surface of CAR-T cells in the indicated cytokine groups. Histograms represent the mean ± SEM of expression levels from six independent donors. *P<0.05, **P<0.01 vs. the IL-2 group. [Figure 4-2] The phenotype of CAR-T cells obtained by exposure to various cytokines is shown. Figure 4A is a representative FACS dot plot showing the expression of CD45RA, CD62L, CCR7, CD27, and CD28 in CAR- and CAR+ T cells exposed to IL-2 14 days after lentiviral transduction. Figure 4B is a series of graphs showing quantification of CD45RA, CD62L, CCR7, CD27, CD28, and IL-7Rα expression on the surface of CAR-T cells in the indicated cytokine groups. Histograms represent the mean ± SEM of expression levels from six independent donors. *P<0.05, **P<0.01 vs. the IL-2 group.
[0077] [Figure 5-1]Functional analysis of CAR-T cells exposed to various cytokines is shown. Figure 5A is a representative FACS plot showing staining of intracellular IFN-γ, TNF-α, and IL-2 in CAR-T cells. Figures 5B, 5C, and 5D are quantitative plots showing the percentage of cytokine-producing CAR-T cells in various cytokine groups (n=6) for the production of IFN-γ (Figure 5B), TNF-α (Figure 5C), and IL-2 (Figure 5D). Lentiviral-transduced T cells were exposed to the indicated cytokines for 14 days, then cocultured with SKOV3 cells for 5 hours and harvested for flow cytometry analysis. Figure 5E is a series of pie charts depicting the proportion of cells producing various numbers of cytokines (IFN-γ, TNF-α, and IL-2) after SKOV3 stimulation. *P<0.05. Figure 5F is a representative FACS plot showing the expression of perforin and granzyme B (GranzB) in CAR-T cells. Figures 5G and 5H are quantitative plots showing the percentage of perforin (Figure 5G) and granzyme B expression (Figure 5H) in CAR-T cells in various cytokine groups (n = 6). Lentiviral-transduced T cells were exposed to the indicated cytokines for 14 days, then cocultured with SKOV3 cells for 5 hours and harvested for flow cytometry analysis. Figure 5I is a graph showing the antigen-specific cytotoxic activity of CAR-T cells. After 14 days of exposure to the indicated cytokines, CAR-T cells were cocultured with SKOV3 cells at the indicated E / T ratio for 18 hours, and then their cytolytic potential was assessed using a luciferase-based assay. Untransduced T cells (UNT) served as a negative effector control. Data shown are the mean ± SEM of six independent cytolytic assays. [Figure 5-2]Functional analysis of CAR-T cells exposed to various cytokines is shown. Figure 5A is a representative FACS plot showing staining of intracellular IFN-γ, TNF-α, and IL-2 in CAR-T cells. Figures 5B, 5C, and 5D are quantitative plots showing the percentage of cytokine-producing CAR-T cells in various cytokine groups (n=6) for the production of IFN-γ (Figure 5B), TNF-α (Figure 5C), and IL-2 (Figure 5D). Lentiviral-transduced T cells were exposed to the indicated cytokines for 14 days, then cocultured with SKOV3 cells for 5 hours and harvested for flow cytometry analysis. Figure 5E is a series of pie charts depicting the proportion of cells producing various numbers of cytokines (IFN-γ, TNF-α, and IL-2) after SKOV3 stimulation. *P<0.05. Figure 5F is a representative FACS plot showing the expression of perforin and granzyme B (GranzB) in CAR-T cells. Figures 5G and 5H are quantitative plots showing the percentage of perforin (Figure 5G) and granzyme B expression (Figure 5H) in CAR-T cells in various cytokine groups (n = 6). Lentiviral-transduced T cells were exposed to the indicated cytokines for 14 days, then cocultured with SKOV3 cells for 5 hours and harvested for flow cytometry analysis. Figure 5I is a graph showing the antigen-specific cytotoxic activity of CAR-T cells. After 14 days of exposure to the indicated cytokines, CAR-T cells were cocultured with SKOV3 cells at the indicated E / T ratio for 18 hours, and then their cytolytic potential was assessed using a luciferase-based assay. Untransduced T cells (UNT) served as a negative effector control. Data shown are the mean ± SEM of six independent cytolytic assays. [Figure 5-3]Functional analysis of CAR-T cells exposed to various cytokines is shown. Figure 5A is a representative FACS plot showing staining of intracellular IFN-γ, TNF-α, and IL-2 in CAR-T cells. Figures 5B, 5C, and 5D are quantitative plots showing the percentage of cytokine-producing CAR-T cells in various cytokine groups (n=6) for the production of IFN-γ (Figure 5B), TNF-α (Figure 5C), and IL-2 (Figure 5D). Lentiviral-transduced T cells were exposed to the indicated cytokines for 14 days, then cocultured with SKOV3 cells for 5 hours and harvested for flow cytometry analysis. Figure 5E is a series of pie charts depicting the proportion of cells producing various numbers of cytokines (IFN-γ, TNF-α, and IL-2) after SKOV3 stimulation. *P<0.05. Figure 5F is a representative FACS plot showing the expression of perforin and granzyme B (GranzB) in CAR-T cells. Figures 5G and 5H are quantitative plots showing the percentage of perforin (Figure 5G) and granzyme B expression (Figure 5H) in CAR-T cells in various cytokine groups (n = 6). Lentiviral-transduced T cells were exposed to the indicated cytokines for 14 days, then cocultured with SKOV3 cells for 5 hours and harvested for flow cytometry analysis. Figure 5I is a graph showing the antigen-specific cytotoxic activity of CAR-T cells. After 14 days of exposure to the indicated cytokines, CAR-T cells were cocultured with SKOV3 cells at the indicated E / T ratio for 18 hours, and then their cytolytic potential was assessed using a luciferase-based assay. Untransduced T cells (UNT) served as a negative effector control. Data shown are the mean ± SEM of six independent cytolytic assays. [Figure 5-4]Functional analysis of CAR-T cells exposed to various cytokines is shown. Figure 5A is a representative FACS plot showing staining of intracellular IFN-γ, TNF-α, and IL-2 in CAR-T cells. Figures 5B, 5C, and 5D are quantitative plots showing the percentage of cytokine-producing CAR-T cells in various cytokine groups (n=6) for the production of IFN-γ (Figure 5B), TNF-α (Figure 5C), and IL-2 (Figure 5D). Lentiviral-transduced T cells were exposed to the indicated cytokines for 14 days, then cocultured with SKOV3 cells for 5 hours and harvested for flow cytometry analysis. Figure 5E is a series of pie charts depicting the proportion of cells producing various numbers of cytokines (IFN-γ, TNF-α, and IL-2) after SKOV3 stimulation. *P<0.05. Figure 5F is a representative FACS plot showing the expression of perforin and granzyme B (GranzB) in CAR-T cells. Figures 5G and 5H are quantitative plots showing the percentage of perforin (Figure 5G) and granzyme B expression (Figure 5H) in CAR-T cells in various cytokine groups (n = 6). Lentiviral-transduced T cells were exposed to the indicated cytokines for 14 days, then cocultured with SKOV3 cells for 5 hours and harvested for flow cytometry analysis. Figure 5I is a graph showing the antigen-specific cytotoxic activity of CAR-T cells. After 14 days of exposure to the indicated cytokines, CAR-T cells were cocultured with SKOV3 cells at the indicated E / T ratio for 18 hours, and then their cytolytic potential was assessed using a luciferase-based assay. Untransduced T cells (UNT) served as a negative effector control. Data shown are the mean ± SEM of six independent cytolytic assays.
[0078] [Figure 6] Figures 5A-5I show the phenotype and function of the CAR-T cells described above. Figures 6A and 6B show that, compared with CD62L-CAR-T cells (Tem and Temra), CD62L+CAR-T cells (Tscm and Tcm) exhibited lower cytokine production activity (Figures 6A and 6B) and weaker cytolytic activity (Figure 6C).
[0079] [Figure 7-1] Figure 7A shows two graphs depicting the overall accumulation and viability of CAR-T cells upon antigen challenge. Figure 7A shows two graphs depicting the overall accumulation and viability of CAR-T cells upon exposure to antigen and the indicated cytokines. IL-2-exposed T cells were harvested on day 15 and then cocultured with SKOV3 cells at a 5:1 E / T ratio and the indicated cytokines (10 ng / mL) for 7 days, with SKOV3 cells replenished on days 1 and 14 (same protocol as Figures 7C, 7D, and 7E). Fold expression is mean ± SEM. T cells were stained with Annexin V and 7-AAD and then analyzed for the percentage of viable cells on the same day. *P<0.05 vs. IL-2 group. Figure 7B shows two graphs depicting the overall accumulation and viability of CAR-T cells upon antigen challenge and exposure to the indicated cytokines. T cells exposed to the indicated cytokines were harvested on day 15 and then cocultured with SKOV3 cells at a 5:1 E / T ratio. CAR-T cell expression is calculated and T cell viability is assessed on day 7. Figure 7C is a graph showing CAR expression by T cells after 7 days of co-culture with SKOV3 and the indicated cytokines. *P<0.05 vs. IL-2. Figure 7D is two graphs showing quantification of CD27 and CD28 expression in CAR-T cells after 7 days of co-culture with SKOV3 and the indicated cytokines. *P<0.05 vs. IL-2. Figure 7E is two graphs showing the distribution of memory T subsets of CD4+ and CD8+ CAR-T cells in the various cytokine groups. NS, not statistically different. [Figure 7-2]Figure 7A shows two graphs depicting the overall accumulation and viability of CAR-T cells upon antigen challenge. Figure 7A shows two graphs depicting the overall accumulation and viability of CAR-T cells upon exposure to antigen and the indicated cytokines. IL-2-exposed T cells were harvested on day 15 and then cocultured with SKOV3 cells at a 5:1 E / T ratio and the indicated cytokines (10 ng / mL) for 7 days, with SKOV3 cells replenished on days 1 and 14 (same protocol as Figures 7C, 7D, and 7E). Fold expression is mean ± SEM. T cells were stained with Annexin V and 7-AAD and then analyzed for the percentage of viable cells on the same day. *P<0.05 vs. IL-2 group. Figure 7B shows two graphs depicting the overall accumulation and viability of CAR-T cells upon antigen challenge and exposure to the indicated cytokines. T cells exposed to the indicated cytokines were harvested on day 15 and then cocultured with SKOV3 cells at a 5:1 E / T ratio. CAR-T cell expression is calculated and T cell viability is assessed on day 7. Figure 7C is a graph showing CAR expression by T cells after 7 days of co-culture with SKOV3 and the indicated cytokines. *P<0.05 vs. IL-2. Figure 7D is two graphs showing quantification of CD27 and CD28 expression in CAR-T cells after 7 days of co-culture with SKOV3 and the indicated cytokines. *P<0.05 vs. IL-2. Figure 7E is two graphs showing the distribution of memory T subsets of CD4+ and CD8+ CAR-T cells in the various cytokine groups. NS, not statistically different. [Figure 7-3]Figure 7A shows two graphs depicting the overall accumulation and viability of CAR-T cells upon antigen challenge. Figure 7A shows two graphs depicting the overall accumulation and viability of CAR-T cells upon exposure to antigen and the indicated cytokines. IL-2-exposed T cells were harvested on day 15 and then cocultured with SKOV3 cells at a 5:1 E / T ratio and the indicated cytokines (10 ng / mL) for 7 days, with SKOV3 cells replenished on days 1 and 14 (same protocol as Figures 7C, 7D, and 7E). Fold expression is mean ± SEM. T cells were stained with Annexin V and 7-AAD and then analyzed for the percentage of viable cells on the same day. *P<0.05 vs. IL-2 group. Figure 7B shows two graphs depicting the overall accumulation and viability of CAR-T cells upon antigen challenge and exposure to the indicated cytokines. T cells exposed to the indicated cytokines were harvested on day 15 and then cocultured with SKOV3 cells at a 5:1 E / T ratio. CAR-T cell expression is calculated and T cell viability is assessed on day 7. Figure 7C is a graph showing CAR expression by T cells after 7 days of co-culture with SKOV3 and the indicated cytokines. *P<0.05 vs. IL-2. Figure 7D is two graphs showing quantification of CD27 and CD28 expression in CAR-T cells after 7 days of co-culture with SKOV3 and the indicated cytokines. *P<0.05 vs. IL-2. Figure 7E is two graphs showing the distribution of memory T subsets of CD4+ and CD8+ CAR-T cells in the various cytokine groups. NS, not statistically different.
[0080] [Figure 8-1]Figure 8A shows the antitumor activity of various CAR-T cells previously exposed to cytokines. Figure 8B shows tumor growth curves of mice treated with various cytokine-exposed C4-27z CAR-T cells, anti-CD19-27z CAR-T cells, and non-transduced T cells. Data are shown as mean ± SEM. Arrows indicate the time of T cell infusion. Figure 8C shows bioluminescence images of fLuc+SKOV3 tumors in NSG mice immediately before (day 38), 2 weeks (day 53), and 5 weeks (day 74) after the first intravenous injection of CAR-T cells. Figure 8D shows a graph quantification of the number of circulating human CD4+ and CD8+ T cells in mouse peripheral blood 15 days after the first dose of CAR-T cell infusion. Figure 8E shows a graph quantification of CAR expression on circulating human CD4+ and CD8+ T cells in mouse blood. Figure 8F is a graph showing the distribution of T cell subsets of circulating human T cells in mouse blood based on CD45RA and CD62L staining, and Figure 8G is a graph showing quantification of CD27 and CD28 expression of circulating human CD4+ and CD8+ T cells in mouse blood. [Figure 8-2]Figure 8A shows the antitumor activity of various CAR-T cells previously exposed to cytokines. Figure 8B shows tumor growth curves of mice treated with various cytokine-exposed C4-27z CAR-T cells, anti-CD19-27z CAR-T cells, and non-transduced T cells. Data are shown as mean ± SEM. Arrows indicate the time of T cell infusion. Figure 8C shows bioluminescence images of fLuc+SKOV3 tumors in NSG mice immediately before (day 38), 2 weeks (day 53), and 5 weeks (day 74) after the first intravenous injection of CAR-T cells. Figure 8D shows a graph quantification of the number of circulating human CD4+ and CD8+ T cells in mouse peripheral blood 15 days after the first dose of CAR-T cell infusion. Figure 8E shows a graph quantification of CAR expression on circulating human CD4+ and CD8+ T cells in mouse blood. Figure 8F is a graph showing the distribution of T cell subsets of circulating human T cells in mouse blood based on CD45RA and CD62L staining, and Figure 8G is a graph showing quantification of CD27 and CD28 expression of circulating human CD4+ and CD8+ T cells in mouse blood. [Figure 8-3]Figure 8A shows the antitumor activity of various CAR-T cells previously exposed to cytokines. Figure 8B shows tumor growth curves of mice treated with various cytokine-exposed C4-27z CAR-T cells, anti-CD19-27z CAR-T cells, and non-transduced T cells. Data are shown as mean ± SEM. Arrows indicate the time of T cell infusion. Figure 8C shows bioluminescence images of fLuc+SKOV3 tumors in NSG mice immediately before (day 38), 2 weeks (day 53), and 5 weeks (day 74) after the first intravenous injection of CAR-T cells. Figure 8D shows a graph quantification of the number of circulating human CD4+ and CD8+ T cells in mouse peripheral blood 15 days after the first dose of CAR-T cell infusion. Figure 8E shows a graph quantification of CAR expression on circulating human CD4+ and CD8+ T cells in mouse blood. Figure 8F is a graph showing the distribution of T cell subsets of circulating human T cells in mouse blood based on CD45RA and CD62L staining, and Figure 8G is a graph showing quantification of CD27 and CD28 expression of circulating human CD4+ and CD8+ T cells in mouse blood.
[0081] [Figure 9-1] Figure 9A shows a series of FACS plots showing the distribution of CD45, CD3, and CD25 expression in cells from apheresis of a CLL patient. Figure 9B shows a series of FACS plots (top) showing CD3 and CD19 populations and a histogram (bottom) showing CD14 expression in cells from apheresis, cells selected with anti-CD3 / CD28, CD25-depleted cells, and CD25-enriched cells. [Figure 9-2] Figure 9A shows a series of FACS plots showing the distribution of CD45, CD3, and CD25 expression in cells from apheresis of a CLL patient. Figure 9B shows a series of FACS plots (top) showing CD3 and CD19 populations and a histogram (bottom) showing CD14 expression in cells from apheresis, cells selected with anti-CD3 / CD28, CD25-depleted cells, and CD25-enriched cells.
[0082] [Figure 10] 2 FACs plots comparing the distribution of CD4+ and CD8+ T cell populations after CD3 / CD28 selection or CD25 depletion.
[0083] [Figure 11] Figure 11 shows a comparison of the proliferation potential between CD3 / CD28-selected cells and CD25-depleted cells. Figure 11A is a graph showing total cell number on the indicated culture days. Figure 11B is a graph showing quantified population doublings on each indicated culture day. Figure 11C shows the percentage of viable cells on the indicated culture days.
[0084] [Figure 12-1] Figure 12 shows the effect of CD25 depletion on lentiviral transduction of CAR19. Figure 12A shows a series of FACS plots showing the efficiency of CD25 depletion. Figure 12B shows a series of FACS plots showing CAR19 expression in non-transduced cells, CD3-selected cells, and CD25-depleted cells. [Figure 12-2] Figure 12 shows the effect of CD25 depletion on lentiviral transduction of CAR19. Figure 12A shows a series of FACS plots showing the efficiency of CD25 depletion. Figure 12B shows a series of FACS plots showing CAR19 expression in non-transduced cells, CD3-selected cells, and CD25-depleted cells.
[0085] [Figure 13] 1 is a series of FACS plots showing the distribution of CD3, CD19 and CD25 expression on cells from PBMCs from patients before CD25-depleted or cytokine-supplemented culture.
[0086] [Figure 14] 1 is a series of FACs plots showing the distribution of CD3 and CD19 in unmanipulated and CD25-depleted PBMCs after culture with the indicated cytokine supplements, IL-7, IL-15, or IL-7 and IL-15.
[0087] [Figure 15]Graph showing total cell numbers after 10 days of culture with the indicated cytokine supplementation.
[0088] [Figure 16] Graph showing the percentage of green fluorescent protein (GFP) signaling as a measure of lentiviral transduction levels of donor cells on the day the cells were obtained by apheresis (day 0) and one day later (day 1), two days after transduction (day 0+1); on the day the donor cells were transduced once on the day the cells were obtained by apheresis (day 0); on the day the donor cells were transduced once the day after the cells were obtained by apheresis (day 1); on the day the donor cells were transduced once two days after the cells were obtained by apheresis (day 2); and on the day the donor cells were transduced once the day after the cells were obtained by apheresis (day 3).
[0089] [Figure 17] Graphs are included showing the expansion profile in population doublings (FIG. 17A) and average size (fL) (FIG. 17B) of PBMCs stimulated with anti-CD3 and CD28 beads, either left unmanipulated (UTD) or stimulated by transduction with CD19 CAR (CD19.BBz), de-beaded, and then collected on days 5 and 9.
[0090] [Figure 18] Included are graphs showing cytotoxicity as percent lysis of PMBC-treated CD19-expressing K562 cells stimulated with anti-CD3 and CD28 beads, either left unmanipulated (UTD) or stimulated by transduction with CD19 CAR (CD19.BBz), de-beaded, and then harvested on days 5 and 9.
[0091] [Figure 19]Included are graphs showing proliferation of PBMCs stimulated with anti-CD3 and CD28 beads (3x28 beads), wild-type K562 cells, CD19-expressing K562 cells, ALL cells (Nalm6), or CLL cells (PI14). PBMCs were either left unmanipulated (UTD) or stimulated by transduction with a CD19 CAR (CD19.BBz), de-beaded, and then harvested on days 5 and 9.
[0092] [Figure 20] FIG. 1 is a schematic diagram of an exemplary operating scheme.
[0093] [Figure 21] FIG. 1 is a schematic diagram of an exemplary operating scheme.
[0094] [Figure 22] Graphs are included showing cell proliferation levels for two different engineered batches of CTL019 CAR-transduced donor cells expanded over days 0-9, patient 15 (left panel) and patient 21 (right panel).
[0095] [Figure 23] Included are graphs showing the production of pro-inflammatory cytokines, IFN-γ, GM-CSF, TNF-α, and IL-4, of two different production batches of donor cells transfected with either CTL019 CAR, i.e., patient 15 cells, or ss1-mesoCAR, i.e., patient 21 cells, and expanded 0-9 days post-apheresis.
[0096] [Figure 24] Graphs showing IFN-γ, TNF-α, IL-6, IL-8, IL-2, IL-1β, GM-CSF, and IL-4 production levels in donor cells transfected with the CTL019 CAR and expanded for 5-9 days, stimulated with anti-CAR19-idiotype antibody beads or control beads. No or low cytokine levels (<200 pg / ml) were detected with control beads.
[0097] [Figure 25] Graphs are included showing cell killing based on total lysate using luciferase assays of Nalm6 (ALL) cells from PBMCs that were either left unmanipulated (UTD) or transduced with CD19 CAR (CART19), de-beaded, and then harvested on days 5 and 9. PBMCs to Nalm6 cells (effector (E):target (T)) were cultured at various ratios. As shown, CART19 cells harvested on day 5 have good killing ability.
[0098] [Figure 26] 1 is a graph showing the long-term in vivo killing capacity of PBMCs that were left unmanipulated (UTD) or transduced with CD19 CAR (CART19), de-beaded, and then collected on days 5 and 9. PBMCs were transferred into non-obese diabetic / severe combined immunodeficient mice inoculated with Nalm6 cells.
[0099] [Figure 27-1] This indicates that bead removal at early time points does not induce cell loss. Figure 27A is a Coulter analysis showing the mean T cell volume and concentration before and after removal of αCD3 / αCD28-coated magnetic beads with a magnet on day 3. Cells were then frozen after bead removal. Figure 27B shows cell numbers assessed before and after magnetic bead removal. Concentrations were similar. Figure 27C is a layer showing the mean cell volume of the same cells before and after thawing. Cells retain their volume during the freeze-thaw process. Results are representative of at least 15 different experiments. Figure 27D shows a representative Coulter analysis of the T cell product before and after αCD3 / αCD28-coated magnetic bead removal, demonstrating the efficiency of the process. [Figure 27-2]This indicates that bead removal at early time points does not induce cell loss. Figure 27A is a Coulter analysis showing the mean T cell volume and concentration before and after removal of αCD3 / αCD28-coated magnetic beads with a magnet on day 3. Cells were then frozen after bead removal. Figure 27B shows cell numbers assessed before and after magnetic bead removal. Concentrations were similar. Figure 27C is a layer showing the mean cell volume of the same cells before and after thawing. Cells retain their volume during the freeze-thaw process. Results are representative of at least 15 different experiments. Figure 27D shows a representative Coulter analysis of the T cell product before and after αCD3 / αCD28-coated magnetic bead removal, demonstrating the efficiency of the process.
[0100] [Figure 28-1] These figures show that activated T cells transduced with a CD19-specific CAR bearing BBz signaling and recovered from T cell culture as early as day 3 post-activation have potent, antigen-specific cytotoxic activity in vitro. Figure 28A, top panel: 4-hour killing assay using K562-WT cells. Figure 28B, bottom panel: 4-hour killing assay using K562-19 cells. Figure 28B, top panel: Transduction efficiency using IL-7 / IL-15 (left) or IL-2 (right). Figure 28B, middle panel: Population doublings using IL-7 / IL-15 compared to IL-2. Figure 28B, bottom panel: Volume using IL-7 / IL-15 compared to IL-2. [Figure 28-2] These figures show that activated T cells transduced with a CD19-specific CAR bearing BBz signaling and recovered from T cell culture as early as day 3 post-activation have potent, antigen-specific cytotoxic activity in vitro. Figure 28A, top panel: 4-hour killing assay using K562-WT cells. Figure 28B, bottom panel: 4-hour killing assay using K562-19 cells. Figure 28B, top panel: Transduction efficiency using IL-7 / IL-15 (left) or IL-2 (right). Figure 28B, middle panel: Population doublings using IL-7 / IL-15 compared to IL-2. Figure 28B, bottom panel: Volume using IL-7 / IL-15 compared to IL-2.
[0101] [Figure 29-1] Day 3 and day 9 4-1BBζ CART cells produce similar patterns of cytokines in response to K562-CD19. Day 3 and day 9 CART 19 cells, precultured in IL-2- or IL-7 / 15-containing medium, were incubated with K562-CD19 (Figures 29A and 29B) or medium alone (Figure 29C) for 24 hours. "No antigen" in Figures 29A and 29B indicates that cells were stimulated with CD19-absent wild-type K562 cells. Cytokines were measured in the culture supernatant by cytokine bead array (Luminex). Figure 29C shows representative cytokine production in CART 19 T cells 24 hours after thawing. Cytokine levels are minimal. [Figure 29-2] Day 3 and day 9 4-1BBζ CART cells produce similar patterns of cytokines in response to K562-CD19. Day 3 and day 9 CART 19 cells, precultured in IL-2- or IL-7 / 15-containing medium, were incubated with K562-CD19 (Figures 29A and 29B) or medium alone (Figure 29C) for 24 hours. "No antigen" in Figures 29A and 29B indicates that cells were stimulated with CD19-absent wild-type K562 cells. Cytokines were measured in the culture supernatant by cytokine bead array (Luminex). Figure 29C shows representative cytokine production in CART 19 T cells 24 hours after thawing. Cytokine levels are minimal. [Figure 29-3]Day 3 and day 9 4-1BBζ CART cells produce similar patterns of cytokines in response to K562-CD19. Day 3 and day 9 CART 19 cells, precultured in IL-2- or IL-7 / 15-containing medium, were incubated with K562-CD19 (Figures 29A and 29B) or medium alone (Figure 29C) for 24 hours. "No antigen" in Figures 29A and 29B indicates that cells were stimulated with CD19-absent wild-type K562 cells. Cytokines were measured in the culture supernatant by cytokine bead array (Luminex). Figure 29C shows representative cytokine production in CART 19 T cells 24 hours after thawing. Cytokine levels are minimal.
[0102] [Figure 30-1] We show that a gradual transition occurs toward a more differentiated phenotype, accompanied by an increase in the proportion of Tem and Tcm cells. [Figure 30-2] We show that a gradual transition occurs toward a more differentiated phenotype, accompanied by an increase in the proportion of Tem and Tcm cells.
[0103] [Figure 31-1] Figure 31A shows the experimental setup for testing the efficacy of CART cells generated under various conditions. Figure 31B shows the efficacy of IL-2-treated CART cells in slowing Nalm6 tumor growth in mice. D3, D5, and D9 indicate CART cells harvested on days 3, 5, or 9. 3e6 and 0.5e6 indicate the number of CAR+ cells administered. The percentage of CAR+ cells is shown in Figure 31C. Figure 31D compares the efficacy of IL-2-treated and IL-7 / IL-15-treated CART cells in slowing Nalm6 tumor growth in mice. [Figure 31-2]Figure 31A shows the experimental setup for testing the efficacy of CART cells generated under various conditions. Figure 31B shows the efficacy of IL-2-treated CART cells in slowing Nalm6 tumor growth in mice. D3, D5, and D9 indicate CART cells harvested on days 3, 5, or 9. 3e6 and 0.5e6 indicate the number of CAR+ cells administered. The percentage of CAR+ cells is shown in Figure 31C. Figure 31D compares the efficacy of IL-2-treated and IL-7 / IL-15-treated CART cells in slowing Nalm6 tumor growth in mice. [Figure 31-3] Figure 31A shows the experimental setup for testing the efficacy of CART cells generated under various conditions. Figure 31B shows the efficacy of IL-2-treated CART cells in slowing Nalm6 tumor growth in mice. D3, D5, and D9 indicate CART cells harvested on days 3, 5, or 9. 3e6 and 0.5e6 indicate the number of CAR+ cells administered. The percentage of CAR+ cells is shown in Figure 31C. Figure 31D compares the efficacy of IL-2-treated and IL-7 / IL-15-treated CART cells in slowing Nalm6 tumor growth in mice.
[0104] [Figure 32] In vitro expansion of CAR+ T cells in IL-2 and IL-7 / 15-containing medium after antigen stimulation. Left panel: PBMCs from a healthy human donor were stimulated with αCD3 / αCD28-coated Dynal beads on day 0 and lentivirally transduced with 19-BBζ on day 1. These cells were expanded for 9 days in IL-2- or IL-7 / 15-supplemented medium. T cells were counted by flow cytometry using bead-based counting every other day. Right panel: Mean T cell volume (fl) was monitored during expansion. Data are representative of at least 6 independent donors.
[0105] [Figure 33]On days 3 and 9, CART19 cells cultured in IL-2- or IL-7 / 15-containing medium proliferated in response to K562-CD19, but not K562-WT or medium alone. T cells were labeled with CFSE and cocultured for 120 hours with K562-CD19, wild-type K562, or medium alone as a negative control. The number of proliferating T cells was significantly higher in response to K562-CD19 compared to wild-type K562 or medium alone and was comparable in the IL-7 / 15 and IL-2 groups. Results are representative of two different donors. DETAILED DESCRIPTION OF THE INVENTION
[0106] Detailed Description definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0107] The terms "a," "an," and "an" refer to one or more than one (i.e., at least one) of the subject article. By way of example, "a component" means one component or more than one component.
[0108] The term "about," when referring to a measurable value such as an amount, temporal duration, etc., is meant to encompass variations of ±20%, or in some instances ±10%, or in some instances ±5%, or in some instances ±1%, or in some instances ±0.1% from the specified value, provided such variations are appropriate for the practice of the disclosed methods.
[0109]
[0013] The term "chimeric antigen receptor" or alternatively "CAR" refers to a set of, generally in its simplest embodiment, two polypeptides that, in an immune effector cell, confer specificity and intracellular signaling to the cell for a target cell, generally a cancer cell. In some embodiments, a CAR comprises at least an extracellular antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain (referred to herein as an "intracellular signaling domain") that comprises a functional signaling domain derived from a stimulatory molecule and / or costimulatory molecule, as defined below. In some embodiments, the set of polypeptides are on the same polypeptide chain (e.g., comprise a chimeric fusion protein). In some embodiments, the set of polypeptides are not adjacent to one another, e.g., are on different polypeptide chains. In some embodiments, the set of polypeptides comprise a dimerization switch that can link one polypeptide to the other in the presence of a dimerization molecule, e.g., link the antigen binding domain to the intracellular signaling domain. In some embodiments, the stimulatory molecule of the CAR is a zeta chain that binds to the T cell receptor complex. In one aspect, the cytoplasmic signaling domain comprises a primary signaling domain (e.g., the primary signaling domain of CD3 zeta). In some embodiments, the cytoplasmic signaling domain further comprises one or more functional signaling domains of at least one costimulatory molecule as defined below. In some embodiments, the costimulatory molecule is a costimulatory molecule described herein, e.g., 4-1BB (i.e., CD137), CD27, ICOS, and / or CD28. In some embodiments, the CAR is a chimeric fusion protein comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising a functional signaling domain of a stimulatory molecule. In some embodiments, the CAR comprises a chimeric fusion protein comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising a functional signaling domain of a costimulatory molecule and a functional signaling domain of a stimulatory molecule.In some embodiments, the CAR comprises a chimeric fusion protein comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising two functional signaling domains of one or more costimulatory molecules and a functional signaling domain of a stimulatory molecule. In some embodiments, the CAR comprises a chimeric fusion protein comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising at least two functional signaling domains of one or more costimulatory molecules and a functional signaling domain of a stimulatory molecule. In some embodiments, the CAR comprises an optional leader sequence at the amino-terminus (N-terminus) of the CAR fusion protein. In some embodiments, the CAR further comprises a leader sequence at the N-terminus of the extracellular antigen-binding domain, where the leader sequence is optionally cleaved from the antigen-binding domain (e.g., scFv) during cellular processing and localization of the CAR to the cell membrane.
[0110] A CAR that includes an antigen-binding domain (e.g., scFv or TCR) that targets a specific tumor antigen X, such as those described herein, is also referred to as an XCAR. For example, a CAR that includes an antigen-binding domain that targets CD19 is referred to as a CD19CAR.
[0111] The term "signaling domain" refers to a functional portion of a protein that acts by transmitting information within the cell to control cellular activity via defined signaling pathways, either by producing second messengers or by functioning as an effector in response to such messengers.
[0112] As used herein, the term "antibody" refers to a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. Antibodies can be polyclonal or monoclonal, multi-chain or single-chain, or intact immunoglobulins, and can be derived from natural or recombinant sources. An antibody can be a tetramer of immunoglobulin molecules.
[0113] The term "antibody fragment" refers to at least a portion of an antibody that retains the ability to specifically interact (e.g., by binding, steric hindrance, stabilization / destabilization, spatial distribution) with an epitope of an antigen. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab'), Fv fragments, scFv antibody fragments, disulfide-bridged Fvs (sdFv), Fd fragments consisting of the VH and CH1 domains, linear antibodies, single domain antibodies (either VL or VH) such as sdAb, camelid VHH domains, multispecific antibodies formed from antibody fragments such as bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region, and isolated CDR or other epitope-binding fragments of an antibody. Antigen-binding fragments may also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs, and bis-scFvs (see, e.g., Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005). Antigen-binding fragments can also be grafted onto scaffolds based on polypeptides such as fibronectin type III (Fn3) (see U.S. Patent No. 6,703,199, which describes fibronectin polypeptide minibodies).
[0114] The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising a variable region of a light chain and at least one antibody fragment comprising a variable region of a heavy chain, wherein the light and heavy chain variable regions are contiguously linked via a synthetic linker, e.g., a short flexible polypeptide linker, and can be expressed as a single-chain polypeptide, wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless otherwise specified, an scFv as used herein can comprise the VL and VH variable regions in either order, e.g., with respect to the N- and C-termini of the polypeptide, and the scFv can comprise VL-linker-VH or VH-linker-VL.
[0115] The portion of the CAR comprising an antibody or antibody fragment thereof can exist in a variety of forms in which the antigen-binding domain is expressed as part of a continuous polypeptide chain, including, for example, single-domain antibody fragments (sdAb), single-chain antibodies (scFv), and humanized antibodies (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In some embodiments, the antigen-binding domain of the CAR comprises an antibody fragment. In further embodiments, the CAR comprises an antibody fragment comprising an scFv.
[0116] As used herein, the term "binding domain" or "antibody molecule" refers to a protein, e.g., an immunoglobulin chain or fragment thereof, that comprises at least one immunoglobulin variable domain sequence. The term "binding domain" or "antibody molecule" encompasses antibodies and antibody fragments. In certain embodiments, an antibody molecule is a multispecific antibody molecule, e.g., comprises a plurality of immunoglobulin variable domain sequences, where a first immunoglobulin variable domain sequence in the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence in the plurality has binding specificity for a second epitope. In certain embodiments, a multispecific antibody molecule is a bispecific antibody molecule. Bispecific antibodies have specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence that has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope.
[0117] The portion of the CAR of the invention comprising an antibody or antibody fragment thereof can exist in a variety of forms in which the antigen-binding domain is expressed as part of a continuous polypeptide chain, including, for example, a single-domain antibody fragment (sdAb), a single-chain antibody (scFv), a humanized antibody, or a bispecific antibody (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one aspect, the antigen-binding domain of the CAR composition of the invention comprises an antibody fragment. In a further aspect, the CAR comprises an antibody fragment comprising an scFv.
[0118] The term "antibody heavy chain" refers to the larger of the two types of polypeptide chains present in antibody molecules in their naturally occurring configurations, and which usually determines the class to which the antibody belongs.
[0119] The term "antibody light chain" refers to the smaller of the two types of polypeptide chains present in antibody molecules in their naturally occurring conformations. Kappa (κ) and lambda (λ) light chains refer to the two major antibody light chain isotypes.
[0120] As used herein, the term "complementarity-determining region" or "CDR" refers to the sequence of amino acids within an antibody variable region that confers antigen specificity and binding affinity. For example, there are typically three CDRs in each heavy chain variable region (e.g., HCDR1, HCDR2, and HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, and LCDR3). The precise amino acid sequence boundaries of a CDR can be determined using any of a number of well-known schemes, including those described in Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme); Al-Lazikani et al., (1997) JMB 273, 927-948 ("Chothia" numbering scheme), or a combination thereof. Under the Kabat numbering scheme, in some embodiments, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3), and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under the Chothia numbering scheme, in some embodiments, the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3), and the CDR amino acid residues in the VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3). In a combination of the Kabat and Chothia numbering schemes, in some embodiments, the CDRs correspond to amino acid residues that are part of a Kabat CDR, a Chothia CDR, or both.For example, in one embodiment, the CDRs correspond to amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3) in a VH, e.g., a mammalian VH, e.g., a human VH; and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) in a VL, e.g., a mammalian VL, e.g., a human VL.
[0121] The term "recombinant antibody" refers to an antibody produced using recombinant DNA technology, such as, for example, an antibody expressed in a bacteriophage or yeast expression system. The term should also be construed to mean an antibody produced by synthesis of a DNA molecule encoding the antibody, which DNA molecule expresses an antibody protein or an amino acid sequence specifying the antibody, where the DNA or amino acid sequence has been obtained using recombinant DNA or amino acid sequence technology that is available and well known in the art.
[0122] The term "antigen" or "Ag" refers to a molecule that elicits an immune response. This immune response may involve antibody production, specific immunocompetent cell activation, or both. Those skilled in the art will understand that any macromolecule, including virtually any protein or peptide, can serve as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. Those skilled in the art will understand that any DNA containing a nucleotide sequence or partial nucleotide sequence encoding a protein that elicits an immune response therefore encodes an "antigen" as that term is used herein. Furthermore, those skilled in the art will understand that an antigen need not necessarily be encoded solely by the full-length nucleotide sequence of a gene. It will be readily apparent that the present invention includes the use of partial nucleotide sequences of more than one gene, including, but not limited to, these nucleotide sequences arranged in various combinations to encode a polypeptide that elicits a desired immune response. Furthermore, those skilled in the art will understand that an antigen need not be encoded by a "gene" at all. Antigens can be synthetically produced or derived from a biological sample or can be a macromolecule other than a polypeptide. Such biological samples can include, but are not limited to, tissue samples, tumor samples, cells, or fluids along with other biological components.
[0123] The term "autologous" refers to any material derived from the same individual into which it is subsequently reintroduced.
[0124] The term "allogeneic" refers to any material derived from a different animal of the same species as the individual into whom the material is subsequently introduced. Two or more individuals are said to be allogeneic to one another when the genes at one or more loci are not identical. In some aspects, allogeneic material from individuals of the same species may not be sufficiently similar genetically to interact antigenically.
[0125] The term "xenogenic" refers to any material derived from an animal of a different species.
[0126] The term "cancer" refers to a disease characterized by the uncontrolled growth of abnormal cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. Examples of various cancers are described herein and include, but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, kidney cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, and the like. The terms "tumor" and "carcinoma" are used interchangeably herein, e.g., both terms include solid and liquid, e.g., diffuse or circulating, tumors. As used herein, the term "cancer" or "tumor" includes pre-malignant and malignant cancers and tumors.
[0127] As used herein, the term "derived from" refers to the relationship between a first and a second molecule. It generally refers to the structural similarity between the first and second molecules and does not imply or imply any processing or source limitations on the first molecule from which the second molecule is derived. For example, in the case of an intracellular signaling domain derived from a CD3 zeta molecule, the intracellular signaling domain retains sufficient CD3 zeta structure so that it has the required function, i.e., the ability to produce a signal under appropriate conditions. It does not imply or imply any limitations on the particular method of producing the intracellular signaling domain, e.g., it does not mean that one must start with the CD3 zeta sequence and remove or mutate undesired sequences to arrive at the intracellular signaling domain in order to provide the intracellular signaling domain.
[0128] The term "disease associated with expression of a tumor antigen described herein" includes, but is not limited to, a disease associated with expression of a tumor antigen described herein or a condition associated with cells expressing a tumor antigen described herein, including, for example, a proliferative disease such as a cancer or malignancy or a precancerous condition such as myelodysplasia, myelodysplastic syndrome, or preleukemia; or a non-cancer-related indication associated with cells expressing a tumor antigen described herein. In some embodiments, a cancer associated with expression of a tumor antigen described herein is a hematological cancer. In some embodiments, a cancer associated with expression of a tumor antigen described herein is a solid cancer. Further, diseases associated with expression of a tumor antigen described herein include, but are not limited to, atypical and / or non-classical cancers, malignancies, precancerous conditions, or proliferative diseases associated with expression of a tumor antigen described herein. Non-cancer-related indications associated with expression of a tumor antigen described herein include, but are not limited to, for example, autoimmune diseases (e.g., lupus), inflammatory disorders (allergies and asthma), and transplantation. In some embodiments, tumor antigen-expressing cells express or have at some time expressed mRNA encoding a tumor antigen. In some embodiments, tumor antigen-expressing cells produce tumor antigen proteins (e.g., wild-type or mutant), and the tumor antigen proteins can be expressed at normal or reduced levels. In some embodiments, tumor antigen-expressing cells express detectable levels of tumor antigen proteins at one time, and then produce substantially no detectable tumor antigen proteins thereafter.
[0129] The term "disease associated with CD19 expression" includes, but is not limited to, a disease associated with CD19 expression or a condition associated with cells that express CD19, including, for example, a proliferative disease such as a cancer or malignancy or a precancerous condition such as myelodysplasia, myelodysplastic syndrome, or a preleukemia; or a non-cancer related indication associated with cells that express CD19. In one aspect, the cancer associated with CD19 expression is a hematological cancer. In one aspect, the hematological cancer is a leukemia or lymphoma. In one aspect, cancers associated with CD19 expression include, but are not limited to, cancers and malignancies, including, but not limited to, e.g., one or more acute leukemias, including but not limited to, acute myeloid leukemia (AML), B-cell acute lymphoid leukemia (BALL), T-cell acute lymphoid leukemia (TALL), acute lymphoid leukemia (ALL); e.g., one or more chronic leukemias, including but not limited to, chronic myeloid leukemia (CML), chronic lymphoid leukemia (CLL). Additional cancers or hematological conditions associated with CD19 expression include, for example, B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndromes, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic leukemia, and leukemia. Diseases associated with CD19 expression include, but are not limited to, lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia, myeloproliferative neoplasm; histiocytic disorders (e.g., mast cell disorders or blastic plasmacytoid dendritic cell neoplasm); mast cell disorders, e.g., systemic mastocytosis or mast cell leukemia; B-cell prolymphocytic leukemia, plasma cell myeloma, and "preleukemia," a collection of various hematological conditions united by ineffective production (or dysplasia) of bone marrow blood cells. Diseases associated with CD19 expression further include, but are not limited to, atypical and / or non-classical cancers, malignancies, precancerous conditions, or diseases associated with proliferative CD19 expression.Non-cancer-related indications associated with CD19 expression include, but are not limited to, autoimmune diseases (e.g., lupus), inflammatory disorders (allergies and asthma), and transplantation. In some embodiments, tumor antigen-expressing cells express or have expressed at any time mRNA encoding a tumor antigen. In some embodiments, tumor antigen-expressing cells produce tumor antigen protein (e.g., wild-type or mutant), and the tumor antigen protein may be present at normal or reduced levels. In some embodiments, tumor antigen-expressing cells produce detectable levels of tumor antigen protein at one time, and then produce substantially no detectable tumor antigen protein. In other embodiments, the disease is CD19-negative cancer, e.g., CD19-negative recurrent cancer. In some embodiments, tumor antigen (e.g., CD19)-expressing cells express or have expressed at any time mRNA encoding a tumor antigen. In some embodiments, tumor antigen (e.g., CD19)-expressing cells produce tumor antigen protein (e.g., wild-type or mutant), and the tumor antigen protein may be present at normal or reduced levels. In some embodiments, tumor antigen (e.g., CD19)-expressing cells produce detectable levels of tumor antigen protein at one time and then produce substantially no detectable tumor antigen protein thereafter.
[0130] The term "disease associated with B cell antigen expression" includes, but is not limited to, a disease associated with expression of one or more of CD19, CD20, CD22, or ROR1, or a condition associated with cells that express, or have at any time expressed, one or more of CD19, CD20, CD22, or ROR1, including, for example, a proliferative disease such as a cancer or malignant tumor or a precancerous condition such as myelodysplasia, myelodysplastic syndrome, or preleukemia; or a non-cancer-related indication associated with cells expressing one or more of CD19, CD20, CD22, or ROR1. For the avoidance of doubt, diseases associated with B cell antigen expression include conditions associated with cells that do not currently express the B cell antigen, for example, where antigen expression has been downregulated due to, for example, treatment with a molecule that targets the B cell antigen, e.g., a B cell-targeted CAR. The term "disease associated with B cell antigen expression" includes diseases associated with CD19 expression as described herein. In some embodiments, the CAR-expressing cells are used to treat diseases associated with B cell antigens. In some embodiments, the CAR produced by the methods herein comprises an antigen-binding domain that targets a B cell antigen.
[0131] As used herein, the term "relapse" refers to the reappearance of a disease (e.g., cancer) after a period of initial responsiveness, e.g., after initial treatment (e.g., complete or partial response) with a therapeutic agent, e.g., a cancer therapeutic agent. The period of initial responsiveness can include a decrease in cancer cell levels to below a certain threshold, e.g., 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1%. Reappearance can include an increase in cancer cell levels above a certain threshold, e.g., 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1%. For example, in the context of B-ALL, reappearance can include the reappearance of blasts in the blood, bone marrow (>5%), or any extramedullary site, e.g., after a complete response. In this context, a complete response can include <5% BM blasts. More generally, in some embodiments, a response (e.g., complete response or partial response) can include the absence of detectable MRD (minimal residual disease). In some embodiments, the initial period of responsiveness lasts for at least 1, 2, 3, 4, 5, or 6 days; at least 1, 2, 3, or 4 weeks; at least 1, 2, 3, 4, 6, 8, 10, or 12 months; or at least 1, 2, 3, 4, or 5 years.
[0132] As used herein, "refractory" refers to a disease, e.g., cancer, that does not respond to treatment. In some embodiments, a refractory cancer may be resistant to treatment before or at the start of treatment. In other embodiments, a refractory cancer may become resistant during treatment. A refractory cancer may also be referred to as a resistant cancer.
[0133] The term "conservative sequence modifications" refers to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody or antibody fragment containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the antibodies or antibody fragments of the present invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within the CARs described herein can be replaced with other amino acid residues from the same side chain family, and the modified CARs can be tested using the functional assays described herein.
[0134] The term "stimulation" refers to a primary response elicited by the binding of a stimulatory molecule (e.g., a TCR / CD3 complex or a CAR) to its cognate ligand (or tumor antigen in the case of a CAR), thereby mediating a signal transduction event, including, but not limited to, signal transduction through the TCR / CD3 complex or signal transduction through the signaling domain of the appropriate NK receptor or CAR. Stimulation may alter the expression of certain molecules.
[0135] The term "stimulatory molecule" refers to a molecule expressed by an immune cell (e.g., T cell, NK cell, B cell) that provides cytoplasmic signaling sequences that regulate activation of the immune cell in a stimulatory manner for at least some aspect of the immune cell signaling pathway. In one aspect, the signal is a primary signal that is initiated, for example, by binding of the TCR / CD3 complex to a peptide-loaded MHC molecule and leads to mediation of a T cell response, including, but not limited to, proliferation, activation, differentiation, etc. Primary cytoplasmic signaling sequences (also referred to as "primary signaling domains") that act in a stimulatory manner can contain signaling motifs known as immunoreceptor tyrosine-based activation motifs, or ITAMs. Examples of ITAM-containing cytoplasmic signaling sequences that are particularly useful in the present invention include, but are not limited to, those derived from CD3 zeta, common FcR gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc epsilon R1b), CD3 gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10, and DAP12. In certain CARs of the invention, the intracellular signaling domain of any one or more CARs of the invention comprises an intracellular signaling sequence, e.g., the primary signaling sequence of CD3 zeta. In certain CARs of the invention, the primary signaling sequence of CD3 zeta is the sequence provided as SEQ ID NO: 9 (mutant CD3 zeta) or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc. In certain CARs of the invention, the primary signaling sequence of CD3 zeta is the sequence provided in SEQ ID NO: 10 (wild-type human CD3 zeta) or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc.
[0136] The term "antigen-presenting cell" or "APC" refers to a cell of the immune system, such as an accessory cell (e.g., a B cell, a dendritic cell, etc.), that displays foreign antigens complexed with major histocompatibility complexes (MHC) on its surface. T cells can recognize these complexes using the T cell receptor (TCR). APCs process antigens and present them to T cells.
[0137] As used herein, the term "intracellular signaling domain" refers to the intracellular portion of a molecule. The intracellular signaling domain can generate a signal that promotes immune effector function of a CAR-containing cell, e.g., a CART cell. For example, examples of immune effector function in a CART cell include cytolytic activity and helper activity, including cytokine secretion. In some embodiments, the intracellular signaling domain is the portion of a protein that transmits an effector function signal and directs the cell to perform a specialized function. While the entire intracellular signaling domain can be used, it is often not necessary to use the entire chain. A truncated portion of the intracellular signaling domain can be used, and such a truncated portion can be used in place of the intact chain, so long as it transmits the effector function signal. The term intracellular signaling domain is therefore intended to include any truncated portion of the intracellular signaling domain sufficient for effector function signaling.
[0138] In some embodiments, the intracellular signaling domain can comprise a primary intracellular signaling domain. Examples of primary intracellular signaling domains include those derived from molecules responsible for primary stimulation or antigen-dependent stimulation. In some embodiments, the intracellular signaling domain can comprise a costimulatory intracellular domain. Examples of costimulatory intracellular signaling domains include those derived from molecules responsible for costimulatory signals or antigen-independent stimulation. For example, in the case of CART, the primary intracellular signaling domain can comprise the cytoplasmic sequence of a T cell receptor, and the costimulatory intracellular signaling domain can comprise the cytoplasmic sequence from a co-receptor or costimulatory molecule.
[0139] The primary intracellular signaling domain can contain a signaling motif known as an immunoreceptor tyrosine-based activation motif, or ITAM. Examples of ITAM-containing primary cytoplasmic signaling sequences include, but are not limited to, those derived from CD3 zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, CD278 ("ICOS"), FcεRI, and CD66d, CD32, DAP10, and DAP12.
[0140] The term "zeta" or alternatively "zeta chain," "CD3 zeta," or "TCR zeta" is defined as the protein provided as GenBank Acc. No. BAG36664.1 or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc., and a "zeta stimulatory domain" or alternatively "CD3 zeta stimulatory domain" or "TCR zeta stimulatory domain" is defined as the amino acid residues from the cytoplasmic domain of the zeta chain sufficient for functional transmission of an early signal required for T cell activation. In one aspect, the cytoplasmic domain of zeta comprises residues 52-164 of GenBank Acc. No. BAG36664.1 or the equivalent residues from a non-human species that is a functional ortholog, e.g., mouse, rodent, monkey, ape, etc. In one aspect, a "zeta stimulatory domain" or "CD3 zeta stimulatory domain" is the sequence provided as SEQ ID NO:9. In one aspect, the "zeta stimulatory domain" or "CD3 zeta stimulatory domain" is the sequence provided as SEQ ID NO: 10.
[0141] The term "costimulatory molecule" refers to a cognate binding partner on a T cell that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are necessary for an efficient immune response. Costimulatory molecules include MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, Toll ligand receptors, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a / CD18), 4-1BB (CD137), B7-H3, and the like. , CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8 alpha, CD8 beta, IL-2R beta, IL-2R gamma, IL-7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA- 1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, C Ligands that specifically bind to RTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, and CD83 are included, but are not limited to these.
[0142] A costimulatory intracellular signaling domain refers to the intracellular portion of a costimulatory molecule. The intracellular signaling domain can include the entire intracellular portion of the molecule from which it is derived, or the entire native intracellular signaling domain, or a functional fragment thereof.
[0143] The intracellular signaling domain can comprise the entire intracellular portion of the molecule from which it is derived or the entire native intracellular signaling domain or a functional fragment thereof.
[0144] The term "4-1BB" refers to a member of the TNFR superfamily having the amino acid sequence provided as GenBank Acc. No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc., and the "4-1BB costimulatory domain" is defined as amino acid residues 214-255 of GenBank Acc. No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc. In one aspect, the "4-1BB costimulatory domain" is the sequence provided as SEQ ID NO:7, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc.
[0145] As used herein, "immune effector cells" refers to cells that are involved in an immune response, e.g., promoting an immune effector response. Examples of immune effector cells include T cells, e.g., alpha / beta T cells and gamma / delta T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and bone marrow-derived phagocytes.
[0146] As used herein, the term "immune effector function or immune effector response" refers to a function or response, e.g., of an immune effector cell, that enhances or promotes an immune attack of a target cell. For example, an immune effector function or response refers to a property of a T or NK cell that promotes the killing or inhibition of growth or proliferation of a target cell. In the case of T cells, primary stimulation and costimulation are examples of immune effector functions or responses.
[0147] The term "effector function" refers to a specialized function of a cell. Effector functions of T cells can be, for example, cytolytic activity or helper activity, including cytokine secretion.
[0148] The term "encoding" refers to the inherent property of a specific sequence of nucleotides in a polynucleotide, such as a gene, cDNA, or mRNA, to serve as a template for the synthesis of other polymers and macromolecules in biological processes, having a defined sequence of nucleotides (e.g., rRNA, tRNA, and mRNA) or a defined sequence of amino acids. Thus, a gene, cDNA, or RNA encodes a protein if transcription and translation of the mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, whose nucleotide sequence is identical to the mRNA sequence and is usually provided in a sequence listing, and the non-coding strand, which is used as a template for transcription of the gene or cDNA, can be said to encode the protein or other product of that gene or cDNA.
[0149] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The term nucleotide sequence encoding a protein or RNA can also include introns if the nucleotide sequence encoding the protein contains introns in some versions.
[0150] The term "endogenous" refers to any substance that is derived from or produced within an organism, cell, tissue, or system.
[0151] The term "exogenous" refers to any substance introduced into or produced exogenously in an organism, cell, tissue, or system.
[0152] The term "expression" refers to the transcription and / or translation of a particular nucleotide sequence driven by a promoter.
[0153] The term "transfer vector" refers to a composition that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid to the interior of a cell. Numerous vectors are known in the art, including, but not limited to, linear polynucleotides, polynucleotides bound to ionic or amphipathic compounds, plasmids, and viruses. Thus, the term "transfer vector" includes self-replicating plasmids or viruses. The term should also be construed to include non-plasmid and non-viral compounds that facilitate the introduction of nucleic acids into cells, such as, for example, polylysine compounds, liposomes, etc. Examples of viral transfer vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, lentiviral vectors, etc.
[0154] The term "expression vector" refers to a vector containing a recombinant polynucleotide comprising expression control sequences operably linked to a nucleotide sequence to be expressed. An expression vector contains sufficient cis-acting elements for expression; other elements for expression can be provided by the host cell or can be in an in vitro expression system. Expression vectors include all known vectors, including cosmids, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.
[0155] The term "lentivirus" refers to a genus belonging to the Retroviridae family. Lentiviruses are unique among retroviruses in that they can infect non-dividing cells and transfer significant amounts of genetic information into the DNA of host cells, making them one of the most efficient gene delivery vectors. HIV, SIV, and FIV are all examples of lentiviruses.
[0156] The term "lentiviral vector" refers to a vector derived from at least a portion of a lentiviral genome, including, in particular, the self-inactivating lentiviral vector provided by Milone et al., Mol. Ther. 17(8): 1453-1464 (2009). Other examples of lentiviral vectors that may be used clinically include, for example, LENTIVECTOR® Gene Delivery Technology from Oxford BioMedica and LENTIMAX® from Lentigen. TM Vector systems include, but are not limited to, non-clinical lentiviral vectors, etc. Non-clinical types of lentiviral vectors are also available and known to those skilled in the art.
[0157] The term "homology" or "identity" refers to the subunit sequence identity between two polymeric molecules, e.g., between two nucleic acid molecules, such as two DNA molecules or two RNA molecules, or between two polypeptide molecules. Two molecules are homologous or identical at a subunit position in both molecules when that position is occupied by the same monomeric subunit, e.g., if a position in two DNA molecules is occupied by adenine, then they are homologous or identical at that position. The homology between two sequences is a direct function of the number of matching or homologous positions; for example, if half of the positions in two sequences (e.g., 5 positions in a 10-subunit long polymer) are homologous, then the two sequences are 50% homologous; if 90% of the positions (e.g., 9 out of 10) are matched or homologous, then the two sequences are 90% homologous.
[0158] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies and antibody fragments are human immunoglobulins (recipient antibody or antibody fragment) in which residues from a complementarity-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies / antibody fragments can comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications can be further refined to optimize antibody or antibody fragment performance. Typically, a humanized antibody or antibody fragment thereof will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin, and all or a substantial portion of the FR regions are those of a human immunoglobulin sequence. The humanized antibody or antibody fragment may also comprise at least a portion of an immunoglobulin constant region (Fc), typically a human immunoglobulin. For further details, see Jones et al., Nature, 321: 522-525, 1986; Reichmann et al., Nature, 332: 323-329, 1988; Presta, Curr. Op. Struct. Biol., 2: 593-596, 1992.
[0159] "Fully human" refers to an immunoglobulin, such as an antibody or antibody fragment, where the entire molecule is of human origin or consists of an amino acid sequence identical to a human form of the antibody or immunoglobulin.
[0160] The term "isolated" means changed or removed from the natural state. For example, a nucleic acid or peptide that is naturally present in a living animal is not "isolated," but the same nucleic acid or peptide that is partially or completely separated from the coexisting materials in its natural state is "isolated." An isolated nucleic acid or protein can exist in substantially purified form, or it can exist in a non-native environment, such as, for example, a host cell.
[0161] In the context of the present invention, the following abbreviations are used for commonly occurring nucleobases: "A" refers to adenosine, "C" refers to cytosine, "G" refers to guanosine, "T" refers to thymidine, and "U" refers to uridine.
[0162] The term "operably linked" or "transcriptional control" refers to a functional association of a regulatory sequence and a heterologous nucleic acid sequence that results in expression of the latter. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences can be contiguous with each other and, for example, in the same reading frame, as necessary to join two protein-coding regions.
[0163] The term "parenteral" administration of an immunogenic composition refers, for example, to subcutaneous (sc), intravenous (iv), intramuscular (im), intrasternal, or intratumoral injection or infusion techniques.
[0164] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), or a polymeric combination of DNA or RNA, in single- or double-stranded form. The term "nucleic acid" includes a gene, cDNA, or mRNA. In certain embodiments, a nucleic acid molecule is synthetic (e.g., chemically synthesized) or recombinant. Unless otherwise specified, the term encompasses nucleic acids containing analogs or derivatives of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specified, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. In particular, degenerate codon substitution can be achieved by producing sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0165] The terms "peptide," "polypeptide," and "protein" are used interchangeably and refer to compounds consisting of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit on the maximum number of amino acids that a protein or peptide sequence may contain. Polypeptide includes any peptide or protein containing two or more amino acids linked to each other by peptide bonds. As used herein, the term encompasses both short chains, commonly referred to in the art as peptides, oligopeptides, and oligomers, and longer chains, commonly referred to in the art as proteins, of which there are many types. "Polypeptide" includes, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, and fusion proteins, among others. Polypeptides include natural peptides, recombinant peptides, or combinations thereof.
[0166] The term "promoter" refers to a DNA sequence recognized by the synthetic machinery of a cell or introduced synthetic machinery necessary for the specific initiation of transcription of a polynucleotide sequence.
[0167] The term "promoter / regulatory sequence" refers to a nucleic acid sequence required for expression of a gene product operably linked to the promoter / regulatory sequence. In some instances, this sequence may be the core promoter sequence, and in other instances, this sequence may also include an enhancer sequence and other regulatory elements required for expression of the gene product. A promoter / regulatory sequence is one that, for example, causes the gene product to be expressed in a tissue-specific manner.
[0168] The term "constitutive" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell.
[0169] The term "inducible" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes a cell to produce the gene product only when an inducer corresponding to the promoter is present in the cell.
[0170] The term "tissue-specific" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes a cell to produce the gene product substantially only if the cell is a cell of the tissue type corresponding to the promoter.
[0171] The terms "cancer-associated antigen" or "tumor antigen" refer interchangeably to a molecule (generally a protein, carbohydrate, or lipid) that is preferentially expressed on the surface of cancer cells, either in whole or as fragments (e.g., MHC / peptides), relative to normal cells, and that is useful for preferential targeting of substances to cancer cells. In some embodiments, a tumor antigen is a marker expressed by both normal and cancer cells, e.g., a cell lineage marker, e.g., CD19 on B cells. In some aspects, the tumor antigens of the present invention are derived from cancers including, but not limited to, primary or metastatic melanoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia, uterine cancer, cervical cancer, bladder cancer, kidney cancer, and adenocarcinomas such as breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, and the like. In some embodiments, a cancer-associated antigen is a cell surface molecule that is overexpressed on cancer cells relative to normal cells, e.g., by 1-fold overexpression, 2-fold overexpression, 3-fold or more overexpression relative to normal cells. In some embodiments, cancer-associated antigens are cell surface molecules that are inappropriately synthesized in cancer cells, e.g., molecules that contain deletions, additions, or mutations compared to molecules expressed on normal cells. In some embodiments, cancer-associated antigens are expressed exclusively on the cell surface of cancer cells, either in their entirety or as fragments (e.g., MHC / peptide), and are not synthesized or expressed on the surface of normal cells. In some embodiments, the CARs of the present invention include CARs that contain an antigen-binding domain (e.g., an antibody or antibody fragment) that binds to an MHC-presented peptide. Typically, peptides derived from endogenous proteins fill the pocket of major histocompatibility complex (MHC) class I molecules and are recognized by the T cell receptor (TCR) of CD8+ T lymphocytes. MHC class I complexes are constitutively expressed by all nucleated cells. In cancer, virus-specific and / or tumor-specific peptide / MHC complexes represent a unique class of cell surface targets for immunotherapy.TCR-like antibodies that target viral or tumor antigen-derived peptides in the context of human leukocyte antigen (HLA)-A1 or HLA-A2 have been described (see, e.g., Sastry et al., J Virol. 2011 85(5):1935-1942; Sergeeva et al., Blood, 2011 117(16):4262-4272; Verma et al., J Immunol 2010 184(4):2156-2165; Willemsen et al., Gene Ther 2001 8(21):1601-1608; Dao et al., Sci Transl Med 2013 5(176):176ra33; Tassev et al., Cancer Gene Ther 2012 19(2):84-100). For example, TCR-like antibodies can be identified from screening libraries such as human cFv phage display libraries.
[0172] The term "flexible polypeptide linker" or "linker" as used in the context of scFvs refers to a peptide linker composed of amino acids, such as glycine and / or serine residues, used alone or in combination to link the variable heavy and variable light chain regions. In some embodiments, the flexible polypeptide linker is a Gly / Ser linker and comprises the amino acid sequence (Gly-Gly-Gly-Ser)n (SEQ ID NO: 15), where n is a positive integer greater than or equal to 1. For example, n=1, n=2, n=3, n=4, n=5, n=6, n=7, n=8, n=9, and n=10. In some embodiments, the flexible polypeptide linker includes, but is not limited to, (Gly4Ser)4 (SEQ ID NO: 27) or (Gly4Ser)3 (SEQ ID NO: 28). In other embodiments, the linker comprises multiple repeats of (Gly2Ser), (GlySer), or (Gly3Ser) (SEQ ID NO: 29). Also included within the scope of the present invention are the linkers described in WO2012 / 138475, which is incorporated herein by reference.
[0173] The 5' cap used here (RNA cap, RNA 7-methylguanosine cap or RNA m 7 A 5' cap (also called a G-cap) is a modified guanine nucleotide added to the "front" or 5' end of eukaryotic messenger RNA immediately after transcription initiation. The 5' cap consists of a terminal group attached to the first transcribed nucleotide. Its presence is important for ribosome recognition and protection from RNases. Capping is coupled to transcription and occurs co-transcriptionally, with each step affecting the other. Shortly after transcription initiation, the 5' end of the synthesizing mRNA is attached by a cap-synthesizing complex associated with RNA polymerase. This enzyme complex catalyzes the chemical reactions required for mRNA capping. Synthesis proceeds as a multi-step biochemical reaction. The capping moiety can be modified to modulate mRNA functionality, such as stability or translation efficiency.
[0174] As used herein, "in vitro transcribed RNA" refers to RNA, e.g., mRNA, that has been synthesized in vitro. Generally, in vitro transcribed RNA is produced from an in vitro transcription vector. The in vitro transcription vector contains a template that is used to produce the in vitro transcribed RNA.
[0175] As used herein, "poly(A)" refers to a series of adenosines attached to an mRNA by polyadenylation. In some embodiments of constructs for transient expression, the poly(A) is between 50 and 5000 (SEQ ID NO: 30), e.g., greater than 64, e.g., greater than 100, e.g., greater than 300 or 400 poly(A) sequences can be chemically or enzymatically modified to modulate mRNA functionality such as localization, stability, or translation efficiency.
[0176] As used herein, "polyadenylation" refers to the covalent attachment of polyadenylyl groups or modified variants thereof to messenger RNA molecules. In eukaryotes, most messenger RNA (mRNA) molecules are polyadenylated at their 3' ends. The 3' poly(A) tail is a long sequence (often several hundred) of adenine nucleotides added to pre-mRNA by the action of the enzyme polyadenylate polymerase. In higher eukaryotes, the poly(A) tail is added to transcripts containing a specific sequence, the polyadenylation signal. The poly(A) tail and its associated proteins help protect mRNA from exonucleolytic degradation. Polyadenylation is also important for transcription termination, nuclear export of mRNA, and translation. Polyadenylation occurs in the nucleus immediately after transcription of DNA into RNA, but can also occur later in the cytoplasm. After transcription is terminated, the mRNA strand is cleaved by the action of an endonuclease complex associated with RNA polymerase. The cleavage site is usually characterized by the presence of the base sequence AAUAAA near the cleavage site. Once the mRNA is cleaved, an adenosine residue is added to the free 3' end of the cleavage site.
[0177] As used herein, "transient" refers to expression of a non-integrated transgene for a period of hours, days, or weeks, where the period of expression is shorter than the period of expression of the gene when integrated into the genome or contained within a stable plasmid replicon in the host cell.
[0178] Apheresis is a process in which whole blood is removed from an individual, separated into selected components, and the remainder returned to the circulation. Generally, there are centrifugal and non-centrifugal methods for separating blood components. Leukapheresis involves the active selection and removal of a patient's white blood cells.
[0179] As used herein, the terms "treatment" and "treating" refer to a reduction or amelioration of the progression, severity, and / or duration of a proliferative disorder or an amelioration of one or more symptoms (e.g., one or more discernible symptoms) of a proliferative disorder resulting from the administration of one or more therapies (e.g., one or more therapeutic agents, such as a CAR of the invention). In specific embodiments, the terms "treatment" and "treating" refer to an improvement in at least one measurable physical parameter of a proliferative disorder, such as tumor growth, which may not necessarily be discernible by the patient. In other embodiments, the terms "treatment" and "treating" refer to arresting the progression of a proliferative disorder physically, e.g., by stabilization of discernible symptoms, physiologically, e.g., by stabilization of physical parameters, or both. In other embodiments, the terms "treatment" and "treating" refer to a reduction or stabilization of tumor size or cancerous cell number.
[0180] The term "signal transduction pathway" refers to the biochemical relationships between various signaling molecules that are responsible for transmitting a signal from one part of a cell to another part of the cell. The term "cell surface receptor" refers to molecules and complexes of molecules that can receive and transmit signals across the membrane of a cell.
[0181] The term "subject" is intended to include living organisms in which an immune response can be elicited (eg, mammals, humans).
[0182] The term "substantially purified" cells refers to cells that are essentially free of other cell types. Substantially purified cells also refer to cells that have been separated from other cell types with which they are normally associated in their naturally occurring state. In some instances, a population of substantially purified cells refers to a homogenous population of cells. In other instances, the term simply refers to cells that have been separated from the cells with which they are naturally associated in their native state. In some aspects, the cells are cultured in vitro. In other aspects, the cells are not cultured in vitro.
[0183] In the context of this invention, a "tumor antigen" or "hyperproliferative disorder antigen" or "antigen associated with a hyperproliferative disorder" refers to an antigen that is common to a particular hyperproliferative disorder. In some embodiments, the tumor antigen is derived from a cancer, including, but not limited to, primary or metastatic melanoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia, uterine cancer, cervical cancer, bladder cancer, kidney cancer, and adenocarcinomas such as breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, and the like.
[0184] The terms "transfection" or "transformation" or "transduction" refer to the process by which exogenous nucleic acid is transferred or introduced into a host cell. A "transgenic" or "transformed" or "transduced" cell is one that has been transfected, transformed or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.
[0185] The term "specifically binds" refers to an antibody or ligand that is recognized and bound by its cognate binding partner protein present in a sample, but which does not substantially recognize or bind other molecules in the sample.
[0186] Ranges: Throughout this specification, various aspects of the invention may be presented in range form. It should be understood that the description in range form is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be construed as specifically disclosing all the possible subranges and individual numerical values within that range. For example, description of a range such as 1 to 6 should be construed as a specific disclosure of subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as individual numbers within that range, e.g., 1, 2, 2.7, 3, 4, 5, 5.3, and 6. As another example, a range such as 95-99% identity includes those with 95%, 96%, 97%, 98% or 99% identity, and subranges such as 96-99%, 96-98%, 96-97%, 97-99%, 97-98% and 98-99% identity. This applies regardless of the breadth of the scope.
[0187] description Provided herein are methods for producing immune effector cells (e.g., T cells, NK cells) that can be engineered with a CAR, e.g., a CAR described herein, and reaction mixtures and compositions comprising such cells.
[0188] In one aspect, the present invention relates to immune effector cells (e.g., T cells, NK cells) engineered to express a CAR, wherein the engineered immune effector cells exhibit anti-tumor properties. Exemplary antigens are cancer-associated antigens (i.e., tumor antigens) described herein. In one aspect, cells are transformed with a CAR, and the CAR is expressed on the cell surface. In some embodiments, cells (e.g., T cells, NK cells) are transduced with a viral vector encoding a CAR. In some embodiments, the viral vector is a retroviral vector. In some embodiments, the viral vector is a lentiviral vector. In some such embodiments, the cells may stably express the CAR. In other embodiments, cells (e.g., T cells, NK cells) are transduced with a nucleic acid, e.g., mRNA, cDNA, DNA, encoding a CAR. In some such embodiments, the cells may transiently express the CAR.
[0189] Additionally, the present invention provides CAR-expressing cells, e.g., CART compositions and their use in medicines or methods for treating, among other diseases, cancer or any malignancy or autoimmune disease involving cells or tissues that express the tumor antigens described herein.
[0190] In one aspect, the CARs of the invention can be used to eradicate normal cells that express the tumor antigens described herein, thereby making them applicable for use as cell conditioning therapy prior to cell transplantation.
[0191] Source of immune effector cells In some embodiments, before expansion and genetic or other modification, the source of cells, such as T cells or natural killer (NK) cells, can be obtained from a subject. Examples of subjects include humans, monkeys, chimpanzees, dogs, cats, mice, rats, and transgenic species thereof. T cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from an infected site, ascites, pleural effusion, spleen tissue, and tumors.
[0192] In one aspect of the invention, immune effector cells, e.g., T cells, are cultured using Ficoll TM Cells can be obtained from blood collected from a subject using any number of techniques known to those of skill in the art, such as cell separation. In one aspect, cells from an individual's circulating blood are obtained by apheresis. The apheresis product generally contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one aspect, cells collected by apheresis can be washed to remove the plasma fraction, and optionally, the cells are added to an appropriate buffer or medium for subsequent processing steps. In one embodiment, the cells are washed with phosphate-buffered saline (PBS). In another embodiment, the wash solution lacks calcium, may lack magnesium, or may lack most, if not all, divalent cations.
[0193] An initial activation step in the absence of calcium may result in enhanced activation. As those skilled in the art will readily recognize, the washing step can be accomplished by methods known in the art, such as by using a semi-automated "flow-through" centrifuge (e.g., a Cobe 2991 cell processor, a Baxter CytoMate, or a Haemonetics Cell Saver 5) according to the manufacturer's instructions. After washing, the cells can be resuspended in a variety of biocompatible buffers, such as, for example, Ca-free, Mg-free PBS, PlasmaLyte A, or other saline solutions with or without buffering agents. Alternatively, undesirable components of the apheresis sample can be removed and the cells resuspended directly in culture medium.
[0194] In one aspect, T cells are lysed by lysing red blood cells and monocytes, e.g., by PERCOLL TM It is isolated from peripheral blood lymphocytes by depletion through gradients or counterflow centrifugal elutriation.
[0195] The methods described herein can include selection of a subpopulation of specific immune effector cells, e.g., T cells, that is a T regulatory cell-depleted population, CD25+ depleted cells, e.g., using, e.g., negative selection techniques, e.g., as described herein. In some embodiments, the population of T regulatory depleted cells comprises fewer than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1% CD25+ cells.
[0196] In some embodiments, T regulatory cells, e.g., CD25+ T cells, are removed from the population using an anti-CD25 antibody or fragment thereof, or a CD25-binding ligand, e.g., IL-2. In some embodiments, the anti-CD25 antibody or fragment thereof, or CD25-binding ligand, is conjugated to or otherwise coated on a substrate, e.g., a bead. In some embodiments, the anti-CD25 antibody or fragment thereof is conjugated to a substrate described herein.
[0197] In one embodiment, T regulatory cells, e.g., CD25+ T cells, are expressed in the Miltenyi TM The population is depleted using a CD25 depletion agent from 1000,000,000 cells / ml. In one embodiment, the cell to CD25 depletion agent ratio is 1e7 cells to 20 μL, or 1e7 cells to 15 μL, or 1e7 cells to 10 μL, or 1e7 cells to 5 μL, or 1e7 cells to 2.5 μL, or 1e7 cells to 1.25 μL. In one embodiment, for example, for T regulatory cells, e.g., CD25+ depletion, greater than 500 million cells / ml are used. In a further aspect, a cell concentration of 600,000,000,000,000, or 900 million cells / ml is used.
[0198] In one embodiment, the population of immune effector cells to be depleted is about 6 x 10 9 In another aspect, the population of immune effector cells to be depleted comprises about 1 x 109 ~1×10 10 In one embodiment, the resulting population of T regulatory depleted cells comprises 2 x 10 CD25+ T cells and any integer value therebetween. 9 T regulatory cells, such as CD25+ cells (e.g., 1 x 10 9 , 5×10 8 , 1×10 8 , 5×10 7 , 1×10 7 have CD25+ cells below
[0199] In one embodiment, T regulatory cells, e.g., CD25+ cells, are removed from the population using a CliniMAC system equipped with a depletion tubing set, e.g., tubing 162-01. In one embodiment, the CliniMAC system is operated in a depletion setting, e.g., DEPLETION2.1.
[0200] Without wishing to be bound by a particular theory, it is believed that reducing the levels of negative regulators of immune cells (e.g., unwanted immune cells, e.g., T) in a subject prior to apheresis or during the manufacture of a CAR-expressing cell product may contribute to the production of CAR-expressing cells. REG The reduction in the number of T cells significantly reduces the risk of recurrence. REG Methods for depleting cells are known in the art. REG Methods for reducing cells include, but are not limited to, cyclophosphamide, anti-GITR antibodies (such as the anti-GITR antibodies described herein), CD25 depletion, mTOR inhibitors, and combinations thereof.
[0201] In one embodiment, the manufacturing method comprises the step of: REG For example, a manufacturing method can include contacting a sample, e.g., an apheresis sample, with an anti-GITR antibody and / or an anti-CD25 antibody (or a fragment thereof or a CD25-binding ligand), e.g., to reduce the number of cells prior to CAR-expressing cell (e.g., T cells, NK cells) product manufacturing. REG This involves depleting the cells.
[0202] Without wishing to be bound by a particular theory, it is believed that reducing the levels of negative regulators of immune cells (e.g., unwanted immune cells, e.g., T) in a subject prior to apheresis or during the manufacture of the CAR-expressing cell product may contribute to the production of CAR-expressing cells. REG In some embodiments, the subject is treated with T cell count reduction prior to cell harvest for CAR-expressing cell product manufacturing. REG In one embodiment, the subject is pre-treated with one or more therapies to reduce the T REG Methods for reducing T cells include, but are not limited to, administering to the subject one or more of cyclophosphamide, anti-GITR antibodies, CD25 depletion, or a combination thereof. REG Methods for reducing cells include, but are not limited to, administering one or more of cyclophosphamide, anti-GITR antibody, CD25 depletion, mTOR inhibitor, or a combination thereof to a subject. Administration of one or more of cyclophosphamide, anti-GITR antibody, CD25 depletion, or a combination thereof may be performed before, during, or after infusion of a CAR-expressing cell product. Administration of one or more of cyclophosphamide, anti-GITR antibody, CD25 depletion, mTOR inhibitor, or a combination thereof may be performed before, during, or after infusion of a CAR-expressing cell product.
[0203] In one embodiment, the manufacturing method comprises the step of: REG For example, a manufacturing method can involve contacting a sample, e.g., an apheresis sample, with an anti-GITR antibody and / or an anti-CD25 antibody (or a fragment thereof or a CD25-binding ligand), e.g., to reduce (e.g., deplete) the number of cells prior to manufacturing of a CAR-expressing cell (e.g., T cell, NK cell) product. REG This involves depleting the cells.
[0204] In some embodiments, subjects are pretreated with cyclophosphamide prior to collection of cells for CAR-expressing cell product manufacturing, thereby reducing the risk of subject relapse to CAR-expressing cell treatment (e.g., CTL019 treatment). In some embodiments, subjects are pretreated with an anti-GITR antibody prior to collection of cells for CAR-expressing cell (e.g., T cell or NK cell) product manufacturing, thereby reducing the risk of subject relapse to CAR-expressing cell treatment.
[0205] In some embodiments, the CAR-expressing cell (e.g., T cell, NK cell) manufacturing method comprises transfecting a CAR-expressing cell (e.g., T cell, NK cell) with a T cell prior to manufacturing the CAR-expressing cell (e.g., T cell, NK cell) product (e.g., CTL019 product). REG In some embodiments, CD25 depletion is used to deplete T cells prior to manufacturing of a CAR-expressing cell (e.g., T cell, NK cell) product (e.g., CTL019 product). REG Deplete the cells.
[0206] In some embodiments, the population of cells to be removed are cells that are not regulatory T cells or tumor cells, but that otherwise negatively affect the growth and / or function of CART cells, e.g., cells that express CD14, CD11b, CD33, CD15, or other markers expressed by potentially immunosuppressive cells. In some embodiments, it is contemplated that such cells are removed simultaneously with the regulatory T cells and / or tumor cells, or after their depletion, or in other sequences.
[0207] The methods described herein can include more than one selection step, e.g., more than one depletion step. Enrichment of a T cell population by negative selection can be achieved, for example, in combination with antibodies directed against surface markers unique to the cells being negatively selected. One method is cell sorting and / or selection by negative magnetic immunoadhesion or flow cytometry using a cocktail of monoclonal antibodies directed against cell surface markers present on the cells being negatively selected. For example, to enrich CD4+ cells by negative selection, the monoclonal antibody cocktail can include antibodies against CD14, CD20, CD11b, CD16, HLA-DR, and CD8.
[0208] The methods described herein can further include removing cells from the population that express a tumor antigen, e.g., a tumor antigen that does not contain CD25, e.g., CD19, CD30, CD38, CD123, CD20, CD14, or CD11b, thereby providing a population of T regulatory-depleted, e.g., CD25+-depleted and tumor antigen-depleted cells suitable for expression of a CAR, e.g., a CAR described herein. In some embodiments, tumor antigen-expressing cells are removed simultaneously with T regulatory, e.g., CD25+ cells. For example, an anti-CD25 antibody or fragment thereof and an anti-tumor antigen antibody or fragment thereof can be bound to the same substrate, e.g., beads, that can be used to remove cells or the anti-CD25 antibody or fragment thereof, or the anti-tumor antigen antibody or fragment thereof can be bound to separate beads, the mixture of which can be used to remove cells. In other embodiments, removal of T regulatory cells, e.g., CD25+ cells, and removal of tumor antigen-expressing cells are sequential, e.g., can occur in either order.
[0209] Also provided are methods of removing cells from a population, e.g., one or more of PD1+ cells, LAG3+ cells, and TIM3+ cells, that express a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein, thereby providing a population of T regulatory-depleted, e.g., CD25+-depleted cells, and checkpoint inhibitor-depleted cells, e.g., PD1+, LAG3+ and / or TIM3+-depleted cells. Exemplary checkpoint inhibitors include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3, and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFR beta), e.g., as described herein. In some embodiments, checkpoint inhibitor-expressing cells are removed simultaneously with T regulatory, e.g., CD25+, cells. For example, the anti-CD25 antibody or fragment thereof and the anti-checkpoint inhibitor antibody or fragment thereof can be attached to the same bead that can be used to remove cells, or the anti-CD25 antibody or fragment thereof and the anti-checkpoint inhibitor antibody or fragment thereof can be attached to separate beads that can be used to remove cells in combination. In other embodiments, the removal of T regulatory cells, e.g., CD25+ cells, and the removal of checkpoint inhibitor-expressing cells are sequential, e.g., can occur in either order.
[0210] The methods described herein may include a positive selection step. For example, T cells can be isolated by incubation with anti-CD3 / anti-CD28 (e.g., 3x28) conjugated beads, such as DYNABEADS® M-450 CD3 / CD28 T, for a time sufficient for positive selection of the desired T cells. In one embodiment, the time is approximately 30 minutes. In a further embodiment, the time ranges from 30 minutes to 36 hours or longer, and all integer values therebetween. In further embodiments, the time is at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, or 6 hours. In yet other embodiments, the time is 10 to 24 hours, e.g., 24 hours. Longer incubation times may be used to isolate T cells in any situation where T cells are scarce compared to other cell types, such as the isolation of tumor-infiltrating lymphocytes (TILs) from tumor tissue or immunocompromised individuals. Furthermore, the use of longer incubation times may increase the efficiency of CD8+ T cell capture. Therefore, subpopulations of T cells can be preferentially selected for at the beginning or at other times during the process by simply increasing or decreasing the time that the T cells are bound to the CD3 / CD28 beads and / or increasing or decreasing the bead to T cell ratio (as further described herein). Additionally, by increasing or decreasing the ratio of anti-CD3 and / or anti-CD28 antibodies on the beads or other surface, subpopulations of T cells can be preferentially selected for at the beginning of the culture or at other desired time points.
[0211] In some embodiments, a T cell population can be selected that expresses one or more of IFN-γ, TNFα, IL-17A, IL-2, IL-3, IL-4, GM-CSF, IL-10, IL-13, granzyme B, and perforin, or other suitable molecules, e.g., other cytokines. Methods for screening for cell expression can be determined, for example, by methods described in PCT Publication WO2013 / 126712.
[0212] For isolation of a desired population of cells by positive or negative selection, the concentration of cells and surfaces (e.g., particles such as beads) can be varied. In certain aspects, it may be desirable to significantly reduce the volume in which the beads and cells are mixed together (e.g., increasing the concentration of cells) to ensure maximum contact between the cells and beads. For example, in some aspects, concentrations of 10 billion cells / ml, 9 billion / ml, 8 billion / ml, 7 billion / ml, 6 billion / ml, or 5 billion / ml are used. In some aspects, a concentration of 1 billion cells / ml is used. In yet some aspects, concentrations of 75 million, 80 million, 85 million, 90 million, 95 million, or 100 million cells / ml are used. In further aspects, concentrations of 125 million or 150 million cells / ml can be used.
[0213] The use of high concentrations can increase cell yield, cell activation, and cell expansion. Furthermore, the use of high cell concentrations allows for more efficient capture of cells that may only weakly express a target antigen of interest, such as CD28-negative T cells, or from samples containing many tumor cells (e.g., leukemia blood, tumor tissue, etc.). Such cell populations may have therapeutic value and are desirable to obtain. For example, the use of high cell concentrations allows for more efficient selection of CD8+ T cells, which normally have weak CD28 expression.
[0214] In a related aspect, it may be desirable to use a low concentration of cells. By significantly diluting the mixture of T cells and surface (e.g., particles such as beads), particle-cell interactions are minimized. This selects for cells that express high amounts of the desired antigen that binds to the particles. For example, CD4+ T cells express high levels of CD28 and are captured more efficiently than CD8+ T cells at dilute concentrations. In one aspect, the concentration of cells used is 5×10 6 In another aspect, the concentration used is about 1 x 10 5 / ml ~ 1 × 10 6 / ml and any integer value therebetween.
[0215] In other aspects, the cells may be incubated on a rotary shaker at various speeds for various lengths of time at 2-10° C. or at room temperature.
[0216] In some embodiments, the population of immune effector cells does not express diglycerol kinase (DGK), e.g., is DGK-deficient. In some embodiments, the population of immune effector cells does not express Ikaros, e.g., is Ikaros-deficient. In some embodiments, the population of immune effector cells does not express DGK and Ikaros, e.g., is both DGK- and Ikaros-deficient.
[0217] T cells for stimulation can also be frozen after a washing step. Without wishing to be bound by theory, the freezing and subsequent thawing step provides a more uniform product by removing granulocytes and, to some extent, monocytes in the cell population. After a washing step to remove plasma and platelets, the cells can be suspended in a freezing solution. While many freezing solutions and parameters are known in the art and useful for this purpose, one method involves using PBS containing 20% DMSO and 8% human serum albumin, or culture medium containing 10% dextran 40 and 5% dextrose, 20% human serum albumin and 7.5% DMSO, or 31.25% PlasmaLyte A, 31.25% dextrose 5%, 0.45% NaCl, 10% dextran 40 and 5% dextrose, 20% human serum albumin and 7.5% DMSO, or other suitable cell freezing medium, such as Hespan and PlasmaLyte A, which is cooled and frozen at a rate of 1° / min to -80°C and stored in the vapor phase of a liquid nitrogen storage tank. Other methods of controlled freezing, as well as immediate uncontrolled freezing at -20°C or in liquid nitrogen, can also be used.
[0218] In one aspect, cryopreserved cells are thawed and washed as described herein and allowed to rest at room temperature for 1 hour before activation using the methods of the invention.
[0219] Also contemplated in the context of the present invention is the collection of a blood sample or apheresis product from a subject at a time prior to when the expanded cells described herein are needed. To that end, a source of cells to be expanded can be collected at any time needed, and desired cells, such as T cells, isolated and frozen for later use in immune effector cell therapy for any number of diseases or conditions that would benefit from immune effector cell therapy, such as those described herein. In one aspect, the blood sample or apheresis product is taken from a generally healthy subject. In one aspect, the blood sample or apheresis product is taken from a generally healthy subject who is at risk for developing a disease but has not yet developed the disease, and the cells of interest are isolated and frozen for later use. In one aspect, the T cells can be expanded, frozen, and used at a later time. In one aspect, a sample is taken from a patient shortly after diagnosis of a particular disease described herein but prior to treatment. In a further aspect, the cells are isolated from a blood sample or apheresis product from the subject prior to any number of appropriate treatment modalities, including, but not limited to, treatment with agents such as natalizumab, efalizumab, antivirals, chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as campath, anti-CD3 antibodies, cytoxan, fludarabine, cyclosporine, FK506, rapamycin, mycophenolic acid, steroids, FR901228, and radiation.
[0220] In a further aspect of the invention, T cells are obtained from a patient directly after a treatment that leaves the subject with functional T cells. In this regard, it has been observed that following certain cancer treatments, particularly treatment with drugs that damage the immune system, the quality of the T cells obtained may be optimal or their ability to be expanded ex vivo may be improved immediately after treatment, during the period when the patient would normally recover from the treatment. Similarly, after ex vivo manipulation using the methods described herein, these cells may be in a state favorable for enhanced engraftment and in vivo expansion. Therefore, in the context of the present invention, it is contemplated to harvest blood cells, including T cells, dendritic cells, or other cells of the hematopoietic lineage, during this recovery period. Furthermore, in certain aspects, mobilization (e.g., mobilization with GM-CSF) and conditioning regimens can be used to create a state in a subject in which repopulation, recirculation, regeneration, and / or expansion of specific cell types is favorable, particularly within a certain time frame after treatment. Examples of cell types include T cells, B cells, dendritic cells, and other cells of the immune system.
[0221] In some embodiments, immune effector cells expressing a CAR molecule, e.g., a CAR molecule described herein, are obtained from a subject receiving a low, immune-enhancing dose of an mTOR inhibitor. In some embodiments, a population of immune effector cells, e.g., T cells, engineered to express a CAR are harvested after administration of a sufficient time or sufficient dose of the low, immune-enhancing dose of an mTOR inhibitor such that the level of PD1-negative immune effector cells, e.g., T cells, or the ratio of PD1-negative immune effector cells, e.g., T cells / PD1-positive immune effector cells, e.g., T cells, in or harvested from the subject is at least transiently increased.
[0222] In other embodiments, a population of immune effector cells, e.g., T cells, that have been or will be engineered to express a CAR can be treated ex vivo by contact with an amount of an mTOR inhibitor that increases the number of PD1 negative immune effector cells, e.g., T cells, or increases the ratio of PD1 negative immune effector cells, e.g., T cells / PD1 positive immune effector cells, e.g., T cells.
[0223] It is recognized that the methods of the present invention utilize culture media conditions comprising 5% or less, e.g., 2%, human AB serum, and that known culture media conditions and compositions can be used, such as those described in Smith et al., "Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement" Clinical & Translational Immunology (2015) 4, e31; doi:10.1038 / cti.2014.31.
[0224] In some embodiments, the methods of the present invention utilize culture medium conditions that include serum-free medium. In some embodiments, the serum-free medium is OpTmizer CTS (LifeTech), Immunocult XF (Stemcell technologies), CellGro (CellGenix), TexMacs (Miltenyi), Stemline (Sigma), Xvivo15 (Lonza), PrimeXV (Irvine Scientific), or StemXVivo (RandD systems). The serum-free medium may be supplemented with a serum replacement, such as ICSR (Immune Cell Serum Replacement) from LifeTech. The level of serum replacement (e.g., ICSR) may be, for example, up to 5%, e.g., about 1%, 2%, 3%, 4%, or 5%.
[0225] In some embodiments, the T cell population is deficient in diglycerol kinase (DGK). DGK-deficient cells include cells that do not express DGK RNA or protein, or cells in which DGK activity is reduced or inhibited. DGK-deficient cells can be generated by genetic approaches to reduce or inhibit DGK expression, for example, by administering RNA interference agents, such as siRNA, shRNA, miRNA. Alternatively, DGK-deficient cells can be generated by treatment with DGK inhibitors described herein.
[0226] In some embodiments, the T cell population is Ikaros-deficient. Ikaros-deficient cells include cells that do not express Ikaros RNA or protein or have reduced or inhibited Ikaros activity, and Ikaros-deficient cells can be generated by genetic approaches to reduce or inhibit Ikaros expression, such as administering RNA interference agents, e.g., siRNA, shRNA, miRNA. Alternatively, Ikaros-deficient cells can be generated by treatment with an Ikaros inhibitor, e.g., lenalidomide.
[0227] In some embodiments, the T cell population is DGK-deficient and Ikaros-deficient, e.g., does not express DGK and Ikaros or has reduced or absent DGK and Ikaros activity. Such DGK- and Ikaros-deficient cells can be produced by any method described herein.
[0228] In some embodiments, the NK cells are obtained from a subject. In other embodiments, the NK cells are an NK cell line, e.g., the NK-92 cell line (Conkwest).
[0229] Allogeneic CAR In embodiments described herein, the immune effector cells can be allogeneic immune effector cells, e.g., T cells or NK cells. For example, the cells can be allogeneic T cells, e.g., allogeneic T cells that lack expression of a functional T cell receptor (TCR) and / or human leukocyte antigen (HLA), e.g., HLA class I and / or HLA class II.
[0230] T cells lacking a functional TCR can be, for example, engineered not to express any functional TCR on their surface, engineered not to express one or more subunits that comprise a functional TCR (e.g., engineered to not express (or have reduced expression of) TCR alpha, TCR beta, TCR gamma, TCR delta, TCR epsilon, and / or TCR zeta), or engineered to produce only a minimal functional TCR on their surface. Alternatively, the T cell can express a substantially impaired TCR, for example, by expression of mutated or truncated forms of one or more of the subunits of the TCR. The term "substantially impaired TCR" means that the TCR does not elicit a deleterious immune response in the host.
[0231] The T cells described herein can be engineered, for example, to not express functional HLA on their surface. For example, the T cells described herein can be engineered to downregulate cell surface expression of HLA, e.g., HLA class 1 and / or HLA class II. In some embodiments, downregulation of HLA can be achieved by reducing or eliminating beta-2 microglobulin (B2M) expression.
[0232] In some embodiments, the T cells can lack a functional TCR and a functional HLA, e.g., HLA class I and / or HLA class II.
[0233] Modified T cells lacking expression of a functional TCR and / or HLA can be obtained by any suitable means, including knockout or knockdown of one or more subunits of the TCR or HLA. For example, T cells can include knockdown of the TCR and / or HLA using siRNA, shRNA, clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nuclease (TALEN), or zinc finger endonuclease (ZFN).
[0234] In some embodiments, the allogeneic cells can be cells that do not express or express only low levels of an inhibitory molecule, e.g., by any of the methods described herein. For example, the cells can be cells that do not express or express only low levels of an inhibitory molecule, e.g., that can reduce the ability of a CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3, and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFR beta). Inhibition of inhibitory molecules, e.g., by inhibition at the DNA, RNA, or protein level, can optimize CAR-expressing cell performance. In some embodiments, inhibitory nucleic acids, e.g., inhibitory nucleic acids, e.g., dsRNA, e.g., siRNA or shRNA, clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nucleases (TALENs), or zinc finger endonucleases (ZFNs), e.g., as described herein, can be used.
[0235] siRNA and shRNA for inhibiting TCR or HLA In some embodiments, TCR expression and / or HLA expression can be inhibited in a cell, e.g., a T cell, using an siRNA or shRNA targeting a nucleic acid encoding a TCR and / or HLA and / or an inhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta).
[0236] Expression systems for siRNAs and shRNAs and exemplary shRNAs are described, for example, in paragraphs 649 and 650 of International Application WO2015 / 142675, filed March 13, 2015, which is incorporated herein by reference in its entirety.
[0237] CRISPR to inhibit TCR or HLA As used herein, "CRISPR" or "CRISPR for TCR and / or HLA" or "CRISPR for inhibiting TCR and / or HLA" refers to a system comprising a series of clustered regularly interspaced short palindromic repeats or a series of such repeats. As used herein, "Cas" refers to a CRISPR-associated protein. "CRISPR / Cas" systems refer to systems derived from CRISPR and Cas that can be used to silence or mutate TCR and / or HL genes and / or inhibitory molecules described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta) in cells, e.g., T cells.
[0238] CRISPR / Cas systems and their uses are described, for example, in paragraphs 651-658 of International Application WO2015 / 142675, filed March 13, 2015, which is incorporated herein by reference in its entirety.
[0239] TALENs to inhibit TCR and / or HLA "TALEN" or "TALEN to HLA and / or TCR" or "TALEN to inhibit HLA and / or TCR" refers to a transcription activator-like effector nuclease, an artificial nuclease that can be used to edit HLA and / or TCR genes and / or inhibitory molecules described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta) in a cell, e.g., a T cell.
[0240] TALENs and their uses are described, for example, in paragraphs 659-665 of International Application WO2015 / 142675, filed March 13, 2015, the entire contents of which are incorporated herein by reference.
[0241] Zinc finger nucleases for inhibiting HLA and / or TCR "ZFN" or "zinc finger nuclease" or "ZFN against HLA and / or TCR" or "ZFN for inhibiting HLA and / or TCR" refers to a nuclease that inhibits the expression of HLA and / or TCR genes and / or inhibitory molecules described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and / or TCR) in a cell, e.g., a T cell). Zinc finger nuclease refers to an artificial nuclease that can be used to edit genes encoding chromatin-dependent proteins (e.g., chromatin-dependent protein kinase C (C-C), chromatin-dependent protein kinase C (C-C), chromatin-dependent protein kinase D (C), chromatin-dependent protein kinase A (C), chromatin-dependent protein kinase C (C), chromatin-dependent protein kinase D (C), chromatin-dependent protein kinase E (C), chromatin-dependent protein kinase C (C), chromatin-dependent protein kinase C (C), chromatin-dependent protein kinase E (C), chromatin-dependent protein kinase C (C), chromatin-dependent protein kinase C (C), chromatin-dependent protein kinase C (C), chromatin-dependent protein kinase D (C), chromatin-dependent protein kinase E (C), chromatin-dependent protein kinase C ...
[0242] ZFNs and their uses are described, for example, in paragraphs 666-671 of International Application WO2015 / 142675, filed March 13, 2015, which is incorporated herein by reference in its entirety.
[0243] Telomerase expression Telomeres play an important role in somatic cell persistence, and their length is maintained by telomerase (TERT). Telomere length in CLL cells can be extremely short (Roth et al., "Significantly shorter telomeres in T-cells of patients with ZAP-70+ / CD38 chronic lymphocytic leukaemia," British Journal of Haematology, 143, 383-386., August 28, 2008), and may be even shorter in engineered CAR-expressing cells, such as CART19 cells, limiting their potential for expansion in patients after adoptive transfer. Telomerase expression can rescue CAR-expressing cells from replicative exhaustion.
[0244] While not wishing to be bound by any particular theory, in certain embodiments, therapeutic T cells have short-term persistence in patients due to short telomeres of the T cells; therefore, gene transfer with a telomerase gene can lengthen the telomeres of the T cells and improve T cell persistence in the patient. See Carl June, "Adoptive T cell therapy for cancer in the clinic," Journal of Clinical Investigation, 117:1466-1476 (2007). Thus, in certain embodiments, immune effector cells, e.g., T cells, ectopically express a telomerase subunit, e.g., the catalytic subunit of telomerase, e.g., TERT, e.g., hTERT. In one aspect, the invention provides a method of producing a CAR-expressing cell, comprising contacting a cell with a nucleic acid encoding a telomerase subunit, e.g., the catalytic subunit of telomerase, e.g., TERT, e.g., hTERT. The cell can be contacted with the nucleic acid before, simultaneously with, or after contact with a construct encoding a CAR.
[0245] Telomerase expression can be stable (e.g., the nucleic acid can be integrated into the cell's genome) or transient (e.g., the nucleic acid is not integrated and expression wanes after a period of time, e.g., several days). Stable expression can be achieved by transfecting or transducing cells with DNA encoding the telomerase subunits and a selectable marker and selecting for stable integrants. Alternatively or in combination, stable expression can be achieved by site-specific recombination, e.g., using the Cre / Lox or FLP / FRT systems.
[0246] Transient expression can include gene transfer or transduction with nucleic acids, e.g., DNA or RNA, such as mRNA. In some embodiments, transient mRNA gene transfer avoids the genetic instability sometimes associated with stable gene transfer with TERT. Transient expression of exogenous telomerase activity is described, for example, in International Application WO2014 / 130909, the entire contents of which are incorporated herein by reference. In some embodiments, mRNA-based gene transfer of telomerase subunits is achieved using messenger RNA Therapeutics, a commercial product of Moderna Therapeutics. TM For example, the method may be the method described in U.S. Patent Nos. 8,710,200, 8,822,663, 8,680,069, 8,754,062, 8,664,194, or 8,680,069.
[0247] In one embodiment, hTERT has the amino acid sequence of GenBank Protein ID AAC51724.1 (Meyerson et al., "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization" Cell Volume 90, Issue 4, 22 August 1997, Pages 785-795): [ka] (SEQ ID NO: 108)
[0248] In some embodiments, the hTERT has a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 108. In some embodiments, the hTERT has the sequence of SEQ ID NO: 108. In some embodiments, the hTERT comprises a deletion (e.g., not more than 5, 10, 15, 20, or 30 amino acids) at the N-terminus, C-terminus, or both ends. In some embodiments, the hTERT comprises a transgenic amino acid sequence (e.g., not more than 5, 10, 15, 20, or 30 amino acids) at the N-terminus, C-terminus, or both ends.
[0249] In one embodiment, hTERT is encoded by the nucleic acid sequence of GenBank Accession No. AF018167 (Meyerson et al., "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization" Cell Volume 90, Issue 4, 22 August 1997, Pages 785-795): [ka] (SEQ ID NO: 23)
[0250] In some embodiments, hTERT is encoded by a nucleic acid having a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 23. In some embodiments, hTERT is encoded by the sequence of SEQ ID NO: 23.
[0251] Chimeric antigen receptor (CAR) The present invention provides immune effector cells (e.g., T cells, NK cells) engineered to contain one or more CARs that direct the immune effector cells to cancer. This is achieved via an antigen-binding domain on the CAR that is specific for a cancer-associated antigen. There are two classes of cancer-associated antigens (tumor antigens) that can be targeted by the CARs described herein: (1) cancer-associated antigens that are expressed on the surface of cancer cells; and (2) cancer-associated antigens that are themselves intracellular, but whose fragments (peptides) are presented on the surface of cancer cells by MHC (major histocompatibility complex).
[0252] Thus, for example, immune effector cells obtained by the methods described herein can be engineered to include a CAR that targets one of the following cancer-associated antigens (tumor antigens): CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, Kit, IL-13Ra2, mesothelin, IL-11Ra, PSCA, VEGFR2, Lewis Y, CD24, PDGFR-beta, PRSS21, SSEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1, EGFR, NCAM, Prostase, PAP, ELF2M, ephrin B2, IGF-I receptor, CAIX, LMP2, gp100, bcr- abl, tyrosinase, EphA2, fucosyl-GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, TSHR, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, legumain, HPV E6, E7, MAGE-A1, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin and telomerase, PCTA-1 / galectin 8, MelanA / MART1, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxylesterase, and mutated hsp70-2.
[0253] Bispecific CAR In some embodiments, a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence having binding specificity for a first epitope and a second immunoglobulin variable domain sequence having binding specificity for a second epitope. In some embodiments, the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein). In some embodiments, the first and second epitopes overlap. In some embodiments, the first and second epitopes do not overlap. In some embodiments, the first and second epitopes are on different antigens, e.g., different proteins (or different subunits of a multimeric protein). In some embodiments, a bispecific antibody molecule comprises heavy and light chain variable domain sequences having binding specificity for a first epitope and heavy and light chain variable domain sequences having binding specificity for a second epitope. In some embodiments, a bispecific antibody molecule comprises a half antibody having binding specificity for a first epitope and a half antibody having binding specificity for a second epitope. In some embodiments, a bispecific antibody molecule comprises a half antibody, or fragment thereof, having binding specificity for a first epitope and a half antibody, or fragment thereof, having binding specificity for a second epitope. In some embodiments, a bispecific antibody molecule comprises an scFv, or fragment thereof, having binding specificity for a first epitope and an scFv, or fragment thereof, having binding specificity for a second epitope.
[0254] In some embodiments, the antibody molecule is a multispecific (e.g., bispecific or trispecific) antibody molecule. Protocols for the preparation of bispecific or heterodimeric antibody molecules and various configurations of bispecific antibody molecules are described, for example, in paragraphs 455-458 of WO 2015 / 142675, filed March 13, 2015, the entire contents of which are incorporated herein by reference.
[0255] In one aspect, the bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence, e.g., an scFv described herein, or comprising light chain CDRs and / or heavy chain CDRs from an scFv described herein, that has binding specificity for CD19, and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope on a different antigen.
[0256] Chimeric TCR In certain aspects, antibodies and antibody fragments of the invention (e.g., CD19 antibodies and fragments) can be grafted onto one or more constant domains of a T cell receptor ("TCR") chain, e.g., a TCR alpha or TCR beta chain, to create a chimeric TCR. Without being bound by theory, it is believed that the chimeric TCR signals through the TCR complex upon antigen binding. For example, an scFv disclosed herein can be grafted onto the constant domains of a TCR chain, e.g., a TCR alpha chain and / or a TCR beta chain, e.g., at least a portion of the extracellular constant domain, transmembrane domain, and cytoplasmic domain. As another example, an antibody fragment, e.g., a VL domain described herein, can be grafted onto the constant domain of a TCR alpha chain, and an antibody fragment, e.g., a VH domain described herein, can be grafted onto the constant domain of a TCR beta chain (or alternatively, the VL domain can be grafted onto the constant domain of a TCR beta chain, and the VH domain can be grafted onto the TCR alpha chain). In another example, the CDRs of an antibody or antibody fragment can be grafted onto the TCR alpha and / or beta chains to create a chimeric TCR. For example, the LCDRs disclosed herein can be grafted onto the variable domain of the TCR alpha chain, and the HCDRs disclosed herein can be grafted onto the variable domain of the TCR beta chain, or vice versa. Such chimeric TCRs can be produced, for example, by methods known in the art (e.g., Willemsen RA et al., Gene Therapy 2000;7:1369-1377; Zhang T et al., Cancer Gene Ther 2004;11:487-496; Aggen et al., Gene Ther. 2012 Apr;19(4):365-74).
[0257] Non-antibody scaffolds In some embodiments, the antigen-binding domain comprises a non-antibody scaffold, such as fibronectin, ankyrin, domain antibody, lipocalin, small modular immunopharmaceutical, maxibody, protein A, or affilin. The non-antibody scaffold has the ability to bind to a target antigen on a cell. In some embodiments, the antigen-binding domain is a polypeptide or fragment thereof of a naturally occurring protein expressed in a cell. In some embodiments, the antigen-binding domain comprises a non-antibody scaffold. A wide variety of non-antibody scaffolds can be used, as long as the resulting polypeptide comprises at least one binding region that specifically binds to a target antigen on a target cell.
[0258] Non-antibody scaffolds include fibronectin (Novartis, MA), ankyrin (Molecular Partners AG, Zurich, Switzerland), domain antibodies (Domantis, Ltd., Cambridge, MA and Ablynx nv, Zwijnaarde, Belgium), lipocalin (Pieris Proteolab AG, Freising, Germany), small modular immunopharmaceuticals (Trubion Pharmaceuticals Inc., Seattle, WA), maxybodies (Avidia, Inc., Mountain View, CA), protein A (Affibody AG, Sweden), and affilin (gamma-crystallin or ubiquitin) (Scil Proteins GmbH, Halle, Germany).
[0259] In some embodiments, the antigen binding domain comprises the extracellular domain of a molecule that binds to a counterligand on the surface of a target cell, or a counterligand-binding fragment thereof.
[0260] The immune effector cells can comprise a recombinant DNA construct comprising a sequence encoding a CAR, where the CAR comprises an antigen binding domain (e.g., an antibody or antibody fragment, a TCR or TCR fragment) that specifically binds to a tumor antigen, e.g., a tumor antigen described herein, and an intracellular signaling domain. The intracellular signaling domain can comprise a costimulatory signaling domain and / or a primary signaling domain, e.g., a zeta chain. As described elsewhere, the methods described herein can include transducing cells, e.g., from a population of T regulatory-depleted cells, with a nucleic acid encoding a CAR, e.g., a CAR described herein.
[0261] In a specific aspect, the CAR comprises an scFv domain, where the scFv can be preceded by an optional leader sequence such as provided in SEQ ID NO: 1, followed by an optional hinge sequence such as provided in SEQ ID NO: 2 or SEQ ID NO: 36 or SEQ ID NO: 38, a transmembrane region such as provided in SEQ ID NO: 6, an intracellular signaling domain comprising SEQ ID NO: 7 or SEQ ID NO: 16, and a CD3 zeta sequence comprising SEQ ID NO: 9 or SEQ ID NO: 10, e.g., where the domains are contiguous and in the same reading frame to form a single fusion protein.
[0262] In one aspect, an exemplary CAR construct comprises an optional leader sequence (e.g., a leader sequence described herein), an extracellular antigen binding domain (e.g., an antigen binding domain described herein), a hinge (e.g., a hinge region described herein), a transmembrane domain (e.g., a transmembrane domain described herein), and an intracellular stimulatory domain (e.g., an intracellular stimulatory domain described herein). In one aspect, an exemplary CAR construct comprises an optional leader sequence (e.g., a leader sequence described herein), an extracellular antigen binding domain (e.g., an antigen binding domain described herein), a hinge (e.g., a hinge region described herein), a transmembrane domain (e.g., a transmembrane domain described herein), an intracellular costimulatory signaling domain (e.g., a costimulatory signaling domain described herein), and / or an intracellular primary signaling domain (e.g., a primary signaling domain described herein).
[0263] An exemplary leader sequence is provided as SEQ ID NO: 1. An exemplary hinge / spacer sequence is provided as SEQ ID NO: 2 or SEQ ID NO: 36 or SEQ ID NO: 38. An exemplary transmembrane domain sequence is provided as SEQ ID NO: 6. An exemplary 4-1BB protein intracellular signaling domain sequence is provided as SEQ ID NO: 7. An exemplary CD27 intracellular signaling domain sequence is provided as SEQ ID NO: 16. An exemplary CD3 zeta domain sequence is provided as SEQ ID NO: 9 or SEQ ID NO: 10.
[0264] In one aspect, the immune effector cell comprises a recombinant nucleic acid construct comprising a nucleic acid molecule encoding a CAR, wherein the nucleic acid molecule comprises a nucleic acid sequence encoding an antigen-binding domain, wherein the sequence is contiguous with and in the same reading frame as a nucleic acid sequence encoding an intracellular signaling domain. Examples of intracellular signaling domains that can be used in a CAR include, but are not limited to, one or more intracellular signaling domains, such as CD3 zeta, CD28, CD27, 4-1BB, etc. In some examples, a CAR can comprise any combination of CD3 zeta, CD28, 4-1BB, etc.
[0265] Nucleic acid sequences encoding the desired molecules can be obtained using recombinant methods known in the art, such as by screening libraries of cells which express the nucleic acid molecule, by deriving the nucleic acid molecule from a vector known to contain it, or by isolating it directly from cells and tissues which contain it, using standard techniques. Alternatively, the nucleic acid of interest is produced synthetically, rather than cloned.
[0266] Nucleic acids encoding CARs can be introduced into immune effector cells, for example, using retroviral or lentiviral vector constructs.
[0267] Nucleic acids encoding CARs can also be introduced into immune effector cells, e.g., using RNA constructs that can be directly transfected into cells. Methods for producing mRNA for use in transfection include in vitro transcription (IVT) of a template with specifically engineered primers, followed by poly(A) addition, to produce a construct containing 3' and 5' untranslated sequences ("UTRs") (e.g., 3' and / or 5' UTRs described herein), a 5' cap (e.g., a 5' cap described herein) and / or an internal ribosome entry site (IRES) (e.g., an IRES described herein), the nucleic acid to be expressed, and a poly(A) tail, typically 50-2000 bases in length (e.g., as described in the Examples, e.g., SEQ ID NO: 35). The RNA thus produced can be efficiently transfected into cells of different species. In some embodiments, the template contains the sequence of the CAR. In some embodiments, the RNA CAR vector is transduced into cells, e.g., T cells, by electroporation.
[0268] antigen-binding domain In one aspect, a population of immune effector cells, e.g., T regulatory depleted cells, comprises a nucleic acid encoding a CAR, which comprises a target-specific binding moiety, also referred to as an antigen binding domain. The selection of the binding moiety depends on the type and number of ligands that define the surface of the target cell. For example, the antigen binding domain can be selected to recognize a ligand that acts as a cell surface marker on target cells associated with a particular disease state. Thus, examples of cell surface markers that can act as ligands for the antigen binding domain in the CAR described herein include those associated with viral, bacterial, and parasitic infections, autoimmune diseases, and cancer cells.
[0269] In one aspect, the portion of the CAR comprising the antigen binding domain comprises an antigen binding domain that targets a tumor antigen, e.g., a tumor antigen described herein.
[0270] The antigen-binding domain may be any domain that binds to an antigen, including, but not limited to, monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, and functional fragments thereof, including single-domain antibodies such as heavy chain variable domains (VH), light chain variable domains (VL), and variable domains of camelid-derived nanobodies (VHH), as well as alternative scaffolds known in the art to function as antigen-binding domains, such as recombinant fibronectin domains, T cell receptors (TCR) or fragments thereof, e.g., single-chain TCRs, etc. In some instances, it is beneficial for the antigen-binding domain to be derived from the same species as the CAR will ultimately be used in. For example, for human use, it is beneficial for the antigen-binding domain of the CAR to comprise human or humanized residues for the antigen-binding domain of an antibody or antibody fragment.
[0271] In some embodiments, the antigen-binding domain comprises an anti-CD19 antibody or fragment thereof, e.g., an scFv. For example, the antigen-binding domain comprises a variable heavy chain and a variable light chain listed in Table 1. The linker sequence connecting the variable heavy chain and the variable light chain can be, for example, any of the linker sequences described herein, or GSTSGSGKPGSGEGSTKG (SEQ ID NO: 104).
[0272] [Table 1] [Table 2]
[0273] [Table 3]
[0274] Any CD19 CAR, for example, the CD19 antigen binding domain of any known CD19 CAR, can be used in accordance with the present invention. For example, LG-740; U.S. Patent No. 8,399,645; U.S. Patent No. 7,446,190; Xu et al., Leuk Lymphoma. 2013 54(2):255-260(2012); Cruz et al., Blood 122(17):2965-2973 (2013); Brentjens et al., Blood, 118(18):4817-4828 (2011); Kochenderfer et al., Blood 116(20):4099-102 (2010); Kochenderfer et al., Blood 122 (25):4129-39(2013); and the CD19 CAR described in 16th Annu Meet Am Soc Gen Cell Ther (ASGCT) (May 15-18, Salt Lake City) 2013, Abst 10.
[0275] Exemplary target antigens that can be targeted using CAR-expressing cells include, but are not limited to, CD19, CD123, EGFRvIII, mesothelin, among others, as described, for example, in WO2014 / 130635, WO2014 / 130657, and WO2015 / 090230 (each of which is incorporated herein by reference in its entirety).
[0276] In one embodiment, the CAR T cells that specifically bind to CD19 have the USAN designation TISAGENLECLEUCEL-T. CTL019 is produced by stable insertion-mediated genetic modification of T cells by transduction with a self-inactivating, replication-deficient lentiviral (LV) vector containing the CTL019 transgene under the control of the EF-1 alpha promoter. CTL019 can be a mixture of transgene-positive and -negative T cells delivered to a subject based on the percentage of transgene-positive T cells.
[0277] In other embodiments, the CAR-expressing cells can specifically bind to human CD19 and can comprise a CAR molecule or antigen-binding domain (e.g., a humanized antigen-binding domain) according to, for example, Table 3 of WO2014 / 153270, which is incorporated herein by reference.
[0278] In other embodiments, the CAR-expressing cells can specifically bind to CD123 and can comprise, for example, a CAR molecule (e.g., any of CAR1-CAR8) or antigen-binding domain according to Tables 1-2 of WO2014 / 13063 No. 5, which is incorporated herein by reference.
[0279] In other embodiments, the CAR-expressing cells can specifically bind to EGFRvIII and can comprise a CAR molecule or antigen-binding domain according to, for example, Table 2 or SEQ ID NO: 11 of WO2014 / 130657, which are incorporated herein by reference.
[0280] In other embodiments, the CAR-expressing cells can specifically bind mesothelin and can comprise a CAR molecule or antigen-binding domain according to, for example, Tables 2-3 of WO2015 / 090230, which is incorporated herein by reference.
[0281] In some embodiments, the antigen binding domain comprises one, two, three (e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2, and HC CDR3, from an antibody listed above and / or one, two, three (e.g., all three) light chain CDRs, LC CDR1, LC CDR2, and LC CDR3, from an antibody listed above. In some embodiments, the antigen binding domain comprises a heavy chain variable region and / or a variable light chain region of an antibody listed or described above.
[0282] In some embodiments, the tumor antigen is a tumor antigen described in International Application WO2015 / 142675, filed March 13, 2015, which is incorporated herein by reference in its entirety. In some embodiments, the tumor antigen is CD19; CD123; CD22; CD30; CD171; CS-1 (also known as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); TNF receptor family member B-cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAcα-Ser / Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-like tyrosine kinase 3 (FLT3); tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; carcinoembryonic antigen (CEA); epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); Kit (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); mesothelin; interleukin-11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); protease serine 21 (Testisin or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis (Y) antibody Gen; CD24; platelet-derived growth factor receptor beta (PDGFR-beta); stage-specific embryonic antigen-4 (SSEA-4); CD20; folate receptor alpha; receptor tyrosine-protein kinase ERBB2 (Her2 / neu); mucin 1, cell surface associated (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); prostase; prostatic acid phosphatase (PAP); elongation factor 2 mutated (ELF2M); ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX); proteasome (prosome, macropain) subunit, beta, 9 (LMP2); glycoprotein 100 (gp100);Oncogene fusion protein (bcr-abl) consisting of breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (Abl); tyrosinase; ephrin type A receptor 2 (EphA2); fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); transglutaminase 5 (TGS5); high molecular weight melanoma-associated antigen ( HMWMAA; o-acetyl-GD2 ganglioside (OAcGD2); folate receptor beta; tumor endothelial marker 1 (TEM1 / CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid-stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); hexasaccharide moiety of globoH glycoceramide (GloboH); mammary differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); hepatitis A virus cellular receptor 1 (HAVCR1); adrenergic receptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K9 (LY6K); olfactory receptor 51E2 (OR5 1E2); TCR gamma alternate reading frame protein (TARP); Wilms tumor protein (WT1); cancer / testis antigen 1 (NY-ESO-1); cancer / testis antigen 2 (LAGE-1a); melanoma-associated antigen 1 (MAGE-A1); ETS translocation variant gene 6, located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer-testis antigen-1 (MAD-CT-1); melanoma cancer-testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutant; prostein; surviving; telomerase; prostate cancer tumor antigen-1 (PCTA-1 or galectin-8), melanoma antigen recognized by T cells 1 (MelanA or MART1); rat sarcoma (Ras) mutant;human telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-acetylglucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); androgen receptor; cyclin B1; v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN); Ras homolog family member C (RhoC); tyrosinase-related protein 2 (TRP-2); cytochrome P4501B1 (CYP1B1); CCCTC-binding factor (zinc finger protein)-like (BORIS or Brother of the regulator of imprinted sites), squamous cell carcinoma antigen 3 recognized by T cells (SART3); paired box protein Pax-5 (PAX5); proacrosin-binding protein p32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A-kinase anchor protein 4 (AKAP-4); synovial sarcoma, X-breakpoint 2 (SSX2); receptor for advanced glycation end products (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papillomavirus E6 (HPVE6); human papillomavirus E7 (HPV E7); intestinal carboxylesterase; heat shock protein 70-2 mutant (mut) hsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1);
[0283] In some embodiments, the antigen binding domain comprises one, two, three (e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2, and HC CDR3, from an antibody listed above and / or one, two, three (e.g., all three) light chain CDRs, LC CDR1, LC CDR2, and LC CDR3, from an antibody listed above. In some embodiments, the antigen binding domain comprises a heavy chain variable region and / or a variable light chain region of an antibody listed or described above.
[0284] In one aspect, the anti-tumor antigen binding domain is a fragment, e.g., a single-chain variable fragment (scFv). In one aspect, the anti-cancer associated antigen binding domain described herein is an Fv, Fab, (Fab')2, or a bifunctional (e.g., bispecific) hybrid antibody (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)). In one aspect, the antibodies and fragments thereof of the present invention bind to a cancer associated antigen protein described herein with wild-type or enhanced affinity.
[0285] In some instances, scFvs can be produced by methods known in the art (see, e.g., Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). ScFv molecules can be produced by linking the VH and VL domains together using a flexible polypeptide linker. The scFv molecule contains a linker (e.g., a Ser-Gly linker) of optimized length and / or amino acid composition. The linker length affects how the variable regions of the scFv fold and interact. In fact, if a short polypeptide linker (e.g., 5-10 amino acids) is used, intrachain folding is prevented. Intrachain folding is also required to bring the two variable regions together to form a functional epitope-binding site. For examples of linker orientations and sizes, see, e.g., Hollinger et al. 1993 Proc Natl Acad. Sci. USA 90:6444-6448, U.S. Patent Application Publication Nos. 2005 / 0100543, 2005 / 0175606, 2007 / 0014794, and PCT Publication Nos. WO2006 / 020258 and WO2007 / 024715, which are incorporated herein by reference.
[0286] The scFv may comprise a linker of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 or more amino acid residues between the VL and VH regions. The linker sequence may comprise any naturally occurring amino acid. In some embodiments, the linker sequence comprises the amino acids glycine and serine. In other embodiments, the linker sequence comprises a series of glycine and serine repeats, such as (Gly4Ser)n, where n is a positive integer greater than or equal to 1 (SEQ ID NO: 25). In some embodiments, the linker may be (Gly4Ser)4 (SEQ ID NO: 27) or (Gly4Ser)3 (SEQ ID NO: 28). Varying the linker length may maintain or enhance activity, resulting in superior efficacy in activity tests.
[0287] In another aspect, the antigen binding domain is a T cell receptor ("TCR") or a fragment thereof, e.g., a single-chain TCR (scTCR). Methods for producing such TCRs are known in the art. See, e.g., Willemsen RA et al, Gene Therapy 7: 1369-1377 (2000); Zhang T et al, Cancer Gene Ther 11: 487-496 (2004); Aggen et al, Gene Ther. 19(4):365-74 (2012) (references hereby incorporated by reference in their entireties). For example, a scTCR can be engineered to contain Vα and Vβ genes from a T cell clone linked by a linker (e.g., a flexible peptide). This approach is extremely useful for cancer-associated targets that are themselves intracellular, but where fragments of such antigens (peptides) are presented on the cancer cell surface by MHC.
[0288] Transmembrane domain With regard to the transmembrane domain, in various embodiments, a CAR can be engineered that comprises a transmembrane domain linked to the extracellular domain of the CAR. The transmembrane domain can include one or more additional amino acids adjacent to the transmembrane region, e.g., one or more amino acids associated with the extracellular region of the protein from which the transmembrane domain is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the extracellular region) and / or one or more additional amino acids associated with the intracellular region of the protein from which the transmembrane protein is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the intracellular region). In one aspect, the transmembrane domain is associated with one of the other domains of the CAR. In certain instances, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domain of the same or a different surface membrane protein, e.g., to minimize interaction with other members of the receptor complex. In one aspect, the transmembrane domain can homodimerize with other CARs on the cell surface of a CAR-expressing cell. In a different aspect, the amino acid sequence of the transmembrane domain may be modified or altered to minimize interaction with the binding domain of a natural binding partner present in the same CART.
[0289] The transmembrane domain can be naturally derived or recombinantly derived. When the origin is natural, the domain can be derived from any membrane-bound or transmembrane protein. In one aspect, the transmembrane domain can transmit signals to the intracellular domain when the CAR is bound to the target. Particularly useful transmembrane domains in the present invention can include at least the transmembrane region of, for example, the alpha, beta, or zeta chain of the T cell receptor, CD28, CD27, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154. In some embodiments, the transmembrane domain is selected from the group consisting of, for example, KIR2DS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL-2R beta, IL-2R gamma, IL-7R alpha, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM , CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKG2D, NKG2C, or CD19.
[0290] In some examples, the transmembrane domain can be attached to the extracellular region of the CAR, e.g., the antigen-binding domain of the CAR, via a hinge, e.g., a hinge from a human protein. For example, in some embodiments, the hinge can be a human Ig (immunoglobulin) hinge, e.g., an IgG4 hinge or a CD8a hinge. In some embodiments, the hinge or spacer comprises (e.g., consists of) the amino acid sequence of SEQ ID NO:2. In one aspect, the transmembrane domain comprises (e.g., consists of) the transmembrane domain of SEQ ID NO:6.
[0291] In one aspect, the hinge or spacer comprises an IgG4 hinge. For example, in one embodiment, the hinge or spacer comprises a hinge of the amino acid sequence ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKM (SEQ ID NO: 36).In one embodiment, the hinge or spacer comprises a hinge encoded by the nucleotide sequence of (SEQ ID NO: 37).
[0292]
[0033] In one aspect, the hinge or spacer comprises an IgD hinge. For example, in one embodiment, the hinge or spacer comprises a hinge of the amino acid sequence RWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTGGVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMALREPAAQAPVKLSLNLLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPPQPGSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYVTDH (SEQ ID NO: 38).In one aspect, the hinge or spacer comprises a hinge encoded by the nucleotide sequence of AGGTGGCCCGAAAGTCCCAAGGCCCAGGCATCTAGTGTTCCTACTGCACAGCCCCAGGCAGAAGGCAGCCTAGCCAAAGCTACTACTGCACCTGCCACTACGCGCAATACTGGCCGTGGCGGGGAGGAGAAGAAAAAGGAGAAAGAGAAAGAAGAACAGGAAGAGAGGGAGACCAAGACCCCTGAATGTCCATCCCATACCCAGCCGCTGGGCGTCTATCTCTTGACTCCCGCAGTACAGGACTTGTGGCTTAGAGATAAGGCCACCTTTACATGTTTCGTCGTGGGCTCTGACCTGAAGGATGCCCATTTGACTTGGGAGGTTGCCGGAAAGGTACCCACAGGGGGGGTTGAGGAAGGGTTGCTGGAGCGCCATTCCAATGGCTCTCAGAGCCAGCACTCAAGACTCACCCTTCCGAGATCCCTGTGGAACGCCGGGACCTCTGTCACATGTACTCTAAATCATCCTAGCCTGCCCCCACAGCGTCTGATGGCCCTTAGAGAGCCAGCCGCCCAGGCACCAGTTAAGCTTAGCCTGAATCTGCTCGCCAGTAGTGATCCCCCAGAGGCCGCCAGCTGGCTCTTATGCGAAGTGTCCGGCTTTAGCCCGCCCAACATCTTGCTCATGTGGCTGGAGGACCAGCGAGAAGTGAACACCAGCGGCTTCGCTCCAGCCCGGCCCCCACCCCAGCCGGGTTCTACCACATTCTGGGCCTGGAGTGTCTTAAGGGTCCCAGCACCACCTAGCCCCCAGCCAGCCACATACACCTGTGTTGTGTCCCATGAAGATAGCAGGACCCTGCTAAATGCTTCTAGGAGTCTGGAGGTTTCCTACGTGACTGACCATT (SEQ ID NO: 103).
[0293] In one aspect, the transmembrane domain may be recombinant, in which case it comprises predominantly hydrophobic residues such as leucine and valine, hi one aspect, triplets of phenylalanine, tryptophan and valine can be found at each end of the recombinant transmembrane domain.
[0294] Optionally, a short oligo- or polypeptide linker, 2-10 amino acids in length, can form the linkage between the transmembrane domain and the cytoplasmic region of the CAR. A glycine-serine doublet provides a particularly suitable linker. For example, in one aspect, the linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 5). In one embodiment, the linker is encoded by the nucleotide sequence GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC (SEQ ID NO: 8).
[0295] In one aspect, the hinge or spacer comprises a KIR2DS2 hinge.
[0296] Cytoplasmic domain The cytoplasmic domain or region of the CAR comprises an intracellular signaling domain, which is generally responsible for activating at least one of the normal effector functions of the immune cell into which the CAR is introduced.
[0297] Examples of intracellular signaling domains for use in the CARs described herein include the cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to signal following antigen receptor binding, as well as any derivative or variant and any recombinant sequence of these sequences that have the same functional capability.
[0298] It is known that signals generated by the TCR alone are insufficient for full activation of T cells; secondary and / or costimulatory signals are also required. Therefore, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation by the TCR (primary intracellular signaling domains) and those that act in an antigen-independent manner to provide secondary or costimulatory signals (secondary cytoplasmic domains, e.g., costimulatory domains).
[0299] Primary signaling domains control the primary activation of the TCR complex in either a stimulatory or inhibitory manner. Primary intracellular signaling domains that act in a stimulatory manner may contain signaling motifs known as immunoreceptor tyrosine-based activation motifs, or ITAMs.
[0300] Examples of ITAM-containing primary intracellular signaling domains that are particularly useful in the present invention include those of TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, CD278 (also known as "ICOS"), FcεRI, DAP10, DAP12, and CD66d. In some embodiments, a CAR of the invention comprises an intracellular signaling domain, e.g., a primary signaling domain of CD3 zeta, e.g., a CD3 zeta sequence described herein.
[0301] In some embodiments, the primary signaling domain comprises a modified ITAM domain, e.g., a mutated ITAM domain that has altered (e.g., increased or decreased) activity compared to the native ITAM domain. In some embodiments, the primary signaling domain comprises a modified ITAM-containing primary intracellular signaling domain, e.g., an optimized and / or truncated ITAM-containing primary intracellular signaling domain. In some embodiments, the primary signaling domain comprises one, two, three, four, or more ITAM motifs.
[0302] Costimulatory signaling domains The intracellular signaling domain of the CAR may comprise a CD3 zeta signaling domain alone, or may be combined with any other desired intracellular signaling domain useful in the context of the CAR of the present invention. For example, the intracellular signaling domain of the CAR may comprise a CD3 zeta chain portion and a costimulatory signaling domain. The costimulatory signaling domain refers to the portion of the CAR that comprises the intracellular domain of a costimulatory molecule. In one embodiment, the intracellular domain is engineered to comprise the signaling domain of CD3 zeta and the signaling domain of CD28. In one aspect, the intracellular domain is engineered to comprise the signaling domain of CD3 zeta and the signaling domain of ICOS.
[0303] Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are necessary for lymphocytes to efficiently respond to antigens. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83. For example, CD27 costimulation has been shown to enhance the expansion, effector function, and survival of human CART cells in vitro and enhance human T cell persistence and antitumor activity in vivo (Song et al. Blood. 2012; 119(3):696-706). Further examples of such costimulatory molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp30, NKp44, NKp46, CD160, CD19, CD4, CD8 alpha, CD8 beta, IL-2R beta, IL-2R gamma, IL-7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD 29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, Including CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, NKG2D, NKG2C and PAG / Cbp.
[0304] The intracellular signaling sequences within the cytoplasmic portion of the CAR can be linked to each other in a random or specific order. Optionally, a short oligo- or polypeptide linker, e.g., 2 to 10 amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids) in length, can form the linkage between the intracellular signaling sequences. In some embodiments, a glycine-serine doublet can be used as a suitable linker. In some embodiments, a single amino acid, e.g., alanine, glycine, can be used as a suitable linker.
[0305] In one aspect, the intracellular signaling domain is engineered to comprise two or more, e.g., two, three, four, five, or more, costimulatory signaling domains. In some embodiments, the two or more, e.g., two, three, four, five, or more, costimulatory signaling domains are separated by a linker molecule, e.g., a linker molecule described herein. In some embodiments, the intracellular signaling domain comprises two costimulatory signaling domains. In some embodiments, the linker molecule is a glycine residue. In some embodiments, the linker is an alanine residue.
[0306] In one aspect, the intracellular signaling domain is engineered to comprise the signaling domain of CD3 zeta and the signaling domain of CD28. In one aspect, the intracellular signaling domain is engineered to comprise the signaling domain of CD3 zeta and the signaling domain of 4-1BB. In one aspect, the signaling domain of 4-1BB is the signaling domain of SEQ ID NO: 7. In one aspect, the signaling domain of CD3 zeta is the signaling domain of SEQ ID NO: 9.
[0307] In one aspect, the intracellular signaling domain is engineered to comprise the signaling domain of CD3 zeta and the signaling domain of CD27. In one aspect, the signaling domain of CD27 comprises the amino acid sequence of QRRKYRSNKGESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP (SEQ ID NO: 16). In one aspect, the signaling domain of CD27 is encoded by the nucleic acid sequence of AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCC (SEQ ID NO: 14).
[0308] In one aspect, a CAR-expressing cell described herein can further comprise a second CAR, e.g., a second CAR that comprises a different antigen binding domain to the same target or a different target (e.g., a target other than a cancer-associated antigen described herein or another cancer-associated antigen described herein, e.g., CD19, CD33, CLL-1, CD34, FLT3, or folate receptor beta). In one embodiment, the second CAR comprises an antigen binding domain to a target expressed on the same cancer cell type as the cancer-associated antigen. In one embodiment, the CAR-expressing cell comprises a first CAR that targets a first antigen and comprises an intracellular signaling domain with a costimulatory signaling domain but without a primary signaling domain, and a second CAR that targets a second, different antigen and comprises an intracellular signaling domain with a primary signaling domain but without a costimulatory signaling domain. Without wishing to be bound by theory, placement of a costimulatory signaling domain, e.g., 4-1BB, CD28, ICOS, CD27, or OX-40, on a first CAR and a primary signaling domain, e.g., CD3 zeta, on a second CAR can restrict CAR activity to cells in which both targets are expressed. In one embodiment, a CAR-expressing cell comprises a first cancer-associated antigen CAR comprising an antigen-binding domain that binds to a target antigen described herein, a transmembrane domain, and a costimulatory domain, and a second CAR that targets a different target antigen (e.g., an antigen expressed on the same cancer cell type as the first target antigen) and comprises an antigen-binding domain, a transmembrane domain, and a primary signaling domain. In another embodiment, a CAR-expressing cell comprises a first CAR comprising an antigen-binding domain that binds to a target antigen described herein, a transmembrane domain, and a primary signaling domain, and a second CAR that targets an antigen other than the first target antigen (e.g., an antigen expressed on the same cancer cell type as the first target antigen) and comprises an antigen-binding domain to the antigen, a transmembrane domain, and a costimulatory signaling domain.
[0309] In another aspect, the invention pertains to a population of CAR-expressing cells, e.g., CART cells. In some embodiments, the population of CAR-expressing cells comprises a mixture of cells expressing different CARs.
[0310] For example, in one embodiment, a population of CART cells can include a first cell expressing a CAR having an antigen binding domain to a cancer-associated antigen described herein and a second cell expressing a CAR having a different antigen binding domain, e.g., an antigen binding domain to a different cancer-associated antigen described herein, e.g., an antigen binding domain to a cancer-associated antigen described herein that is different from the cancer-associated antigen bound by the antigen binding domain of the CAR expressed by the first cell.
[0311] As another example, a population of CAR-expressing cells can include a first cell expressing a CAR that includes an antigen binding domain to a cancer-associated antigen described herein and a second cell that expresses a CAR that includes an antigen binding domain to a target other than a cancer-associated antigen described herein. In some embodiments, a population of CAR-expressing cells can include, for example, a first cell that expresses a CAR that includes a primary intracellular signaling domain and a second cell that expresses a CAR that includes a secondary signaling domain.
[0312] In another aspect, the invention pertains to a population of cells, wherein at least one cell in the population expresses a CAR having an antigen binding domain to a cancer-associated antigen as described herein, and a second cell expresses another substance, e.g., a substance that enhances the activity of the CAR-expressing cell. For example, in some embodiments, the substance can be a substance that inhibits an inhibitory molecule. An inhibitory molecule, e.g., PD-1, can, in some embodiments, reduce the ability of a CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD-1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (CEACAM-1, CEACAM-3, and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFR beta). In some embodiments, the substance that inhibits an inhibitory molecule is a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to a cell, e.g., an intracellular signaling domain described herein. In some embodiments, the agent comprises a first polypeptide of an inhibitory molecule such as, e.g., PD-1, PD-L1, CTLA4, TIM3, CEACAM (CEACAM-1, CEACAM-3, and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and TGFR beta, or a fragment of any of these, and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27, OX40, or CD28, e.g., as described herein) and / or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein)). In some embodiments, the agent comprises a first polypeptide of PD-1 or a fragment thereof, and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28 signaling domain described herein and / or a CD3 zeta signaling domain described herein).
[0313] The sequences of anti-CD19 binding domains are provided herein in Table 1. Complete CAR constructs can be produced by using any of the antigen binding domains listed in Table 1 and one or more additional CAR components provided below.
[0314] Leader (amino acid sequence) (SEQ ID NO: 1) MALPVTALLLPLALLLHAARP Leader (nucleic acid sequence) (SEQ ID NO: 12) ATGGCCCTGCCTGTGACAGCCCTGCTGCTGCCTCTGGCTCTGCTGCTGCATGCCGCTAGACCC
[0315] CD8 hinge (amino acid sequence) (SEQ ID NO: 2) TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD CD8 hinge (nucleic acid sequence) (SEQ ID NO: 13) ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGAT
[0316] CD8 transmembrane (amino acid sequence) (SEQ ID NO: 6) IYIWAPLAGTCGVLLLSLVITLYC Transmembrane (nucleic acid sequence) (SEQ ID NO: 17) ATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGC
[0317] 4-1BB intracellular domain (amino acid sequence) (SEQ ID NO: 7) KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL 4-1BB intracellular domain (nucleic acid sequence) (SEQ ID NO: 18) AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG
[0318] CD3 zeta domain (amino acid sequence) (SEQ ID NO: 9) RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR CD3 zeta (nucleic acid sequence) (SEQ ID NO: 20) AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAA GGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC
[0319] CD3 zeta domain (amino acid sequence; NCBI Reference Sequence NM_000734.3) (SEQ ID NO: 10) RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR CD3 zeta (nucleic acid sequence; NCBI Reference Sequence NM_000734.3); (SEQ ID NO: 21) agagtgaagttcagcaggagcgcagacgcccccgcgtaccagcagggccagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttggacaagagacgtggccgggaccctgagatggggggaaagccgagaaggaagaaccctcaggaa ggcctgtacaatgaactgcagaaagataagatggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggcaaggggcacgatggcctttaccagggtctcagtacagccaccaaggacacctacgacgcccttcacatgcaggccctgccccctcgc
[0320] IgG4 hinge (amino acid sequence) (SEQ ID NO: 36) ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE KTISKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKM IgG4 hinge (nucleotide sequence) (SEQ ID NO: 37) GAGAGCAAGTACGGCCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCTGATCAGCCGGACCCCCGAGGTGACCTGTGTGGTGGTGGACGTGTCCCAGGAGGACCCCGAGGTCCAGTTCA ACTGGTACGTGGACGGCGTGGAGGTGCACAAGCCAAGACCAAGCCCCGGGAGGAGCAGTTCAATAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGACCAGGACTGGCTGAACGGCAAGGAATACAAGTGTAAGGTGTCCAACAAGGGCCTGCCAGCAGCATCGAG AAAACCATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCTGCCCCCTAGCCAAGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACT ACAAGACCACCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAGGGCAACGTCTTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAGAGCCTGAGCCTGTCCCTGGGCAAGAT
[0321] EF1 カルファプロット
[0322] Gly / Ser (SEQ ID NO: 25) GGGGS Gly / Ser (SEQ ID NO: 26): This sequence may contain 1 to 6 "Gly Gly Gly Gly Ser" repeat units. GGGGSGGGGS GGGGSGGGGS GGGGSGGGGS Gly / Ser (SEQ ID NO: 27) GGGGSGGGGS GGGGSGGGGS Gly / Ser (SEQ ID NO: 28) GGGGSGGGGS GGGGS Gly / Ser (SEQ ID NO: 29) GGGS
[0323] PolyA (SEQ ID NO: 30): A5000 PolyA (SEQ ID NO: 31): A100 PolyT (SEQ ID NO: 32): T5000 PolyA (SEQ ID NO: 33): A5000 PolyA (SEQ ID NO: 34): A400 PolyA (SEQ ID NO: 35): A2000
[0324] Gly / Ser (SEQ ID NO: 15): This sequence may contain 1 to 10 "Gly Gly Gly Ser" repeat units. GGGSGGGSGG GSGGGSGGGS GGGSGGGSGG GSGGGSGGGS
[0325] Exemplary CD19 CAR constructs that can be used in the methods described herein are shown in Table 3. [Table 4] [Table 5]
[0326] [Table 6]
Table 7
[0327]
Table 8
Table 9
[0328]
Table 10
Table 11
[0329]
Table 12
Table 13
[0330]
Table 14
Table 15
[0331] Table 16 Table 17
[0332] Table 18 Table 19
[0333] [Table 20] [Table 21]
[0334] [Table 22] [Table 23]
[0335] [Table 24] [Table 25]
[0336] Co-expression of CAR with other molecules or substances Co-expression of a second CAR In some aspects, a CAR-expressing cell described herein can further comprise a second CAR, e.g., a second CAR comprising a different antigen binding domain to the same target (e.g., CD19) or a different target (e.g., a target different from CD19, e.g., a target described herein). In one embodiment, the CAR-expressing cell comprises a first CAR that targets a first antigen and comprises an intracellular signaling domain with a costimulatory signaling domain but without a primary signaling domain, and a second CAR that targets a second, different antigen and comprises an intracellular signaling domain with a primary signaling domain but without a costimulatory signaling domain. Placement of a costimulatory signaling domain, e.g., 4-1BB, CD28, CD27, OX-40, or ICOS, on the first CAR and a primary signaling domain, e.g., CD3 zeta, on the second CAR can restrict CAR activity to cells in which both targets are expressed. In one embodiment, the CAR-expressing cell comprises a first CAR comprising an antigen binding domain, a transmembrane domain, and a costimulatory domain, and a second CAR that targets another antigen and comprises an antigen binding domain, a transmembrane domain, and a primary signaling domain. In other embodiments, the CAR-expressing cells comprise a first CAR comprising an antigen binding domain, a transmembrane domain, and a primary signaling domain, and a second CAR that targets another antigen and comprises an antigen binding domain to the antigen, a transmembrane domain, and a costimulatory signaling domain.
[0337] In some embodiments, the CAR-expressing cells comprise an XCAR and an inhibitory CAR described herein. In some embodiments, the inhibitory CAR comprises an antigen-binding domain that binds to an antigen found in normal cells but not found in cancer cells, e.g., that also expresses X. In some embodiments, the inhibitory CAR comprises the antigen-binding domain, transmembrane domain, and intracellular domain of the inhibitory molecule. For example, the intracellular domain of the inhibitory CAR can be the intracellular domain of PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (CEACAM-1, CEACAM-3 and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFR beta).
[0338] In some embodiments, when a CAR-expressing cell comprises two or more different CARs, the antigen-binding domains of the different CARs are such that these antigen-binding domains do not interact with each other. For example, a cell expressing a first and a second CAR can have the antigen-binding domain of the first CAR, e.g., as a fragment, e.g., an scFv, which does not bind to the antigen-binding domain of the second CAR, e.g., the antigen-binding domain of the second CAR is a VHH.
[0339] In some embodiments, the antigen-binding domain comprises a single-domain antigen-binding (SDAB) molecule, which includes molecules in which the complementary determining region is part of a single-domain polypeptide. Examples include, but are not limited to, heavy chain variable domains, binding molecules that naturally lack light chains, conventional four-chain antibodies derived from single domains, engineered domains, and single-domain scaffolds other than those derived from antibodies. The SDAB molecule can be any single-domain molecule known in the art or that will become known in the future. The SDAB molecule can be derived from any species, including, but not limited to, mouse, human, camel, llama, lamprey, fish, shark, goat, rabbit, and cow. The term also includes naturally occurring single-domain antibody molecules from species other than camelids and sharks.
[0340] In one aspect, SDAB molecules can be derived from the variable regions of immunoglobulins found in fish, such as those derived from an immunoglobulin isotype known as the novel antigen receptor (NAR), discovered in shark serum. Methods for producing NAR variable region-derived single domain molecules ("IgNAR") are described in WO 03 / 014161 and Streltsov (2005) Protein Sci. 14:2901-2909.
[0341] In another aspect, the SDAB molecule is a naturally occurring single domain antigen binding molecule known as a heavy chain devoid of light chains.Such single domain molecules are disclosed, for example, in WO9404678 and Hamers-Casterman, C. et al. (1993) Nature 363:446-448.For clarity, this variable domain derived from a heavy chain molecule naturally devoid of light chains is known in the art as a VHH or nanobody, to distinguish it from the conventional VH of four-chain immunoglobulins.Such VHH molecules can be derived from Camelidae species, such as camel, llama, dromedary, alpaca and guanaco.Species other than Camelidae can naturally produce heavy chain molecules devoid of light chains, and such VHHs are within the scope of the present invention.
[0342] SDAB molecules can be recombinant, CDR-grafted, humanized, camelized, deimmunized and / or produced in vitro (eg, selected by phage display).
[0343] It has also been found that in cells having multiple chimeric membrane-embedded receptors containing antigen-binding domains, interactions between the antigen-binding domains of the receptors can be undesirable, for example, because they inhibit the ability of one or more antigen-binding domains to bind to their cognate antigen. Accordingly, disclosed herein are cells having first and second non-naturally occurring chimeric membrane-embedded receptors containing antigen-binding domains in which such interactions have been minimized. Also disclosed herein are nucleic acids encoding first and second non-naturally occurring chimeric membrane-embedded receptors containing antigen-binding domains in which such interactions have been minimized, as well as methods for making and using such cells and nucleic acids. In some embodiments, one of the antigen-binding domains of the first and second non-naturally occurring chimeric membrane-embedded receptors comprises an scFv, and the other comprises a single VH domain, e.g., a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence.
[0344] In some embodiments, the composition herein comprises a first and a second CAR, wherein the antigen-binding domain of one of the first and second CARs does not comprise a variable light domain and a variable heavy domain. In some embodiments, the antigen-binding domain of one of the first and second CARs is an scFv, and the other is not an scFv. In some embodiments, the antigen-binding domain of one of the first and second CARs comprises a single VH domain, e.g., a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence. In some embodiments, the antigen-binding domain of one of the first and second CARs comprises a nanobody. In some embodiments, the antigen-binding domain of one of the first and second CARs comprises a camelid VHH domain.
[0345] In some embodiments, the antigen-binding domain of one of the first and second CARs comprises an scFv, and the other comprises a single VH domain, e.g., a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence. In some embodiments, the antigen-binding domain of one of the first and second CARs comprises an scFv, and the other comprises a nanobody. In some embodiments, the antigen-binding domain of one of the first and second CARs comprises an scFv, and the other comprises a camelid VHH domain.
[0346] In some embodiments, when present on the surface of a cell, binding of the antigen binding domain of the first CAR to its cognate antigen is not substantially diminished by the presence of the second CAR, hi some embodiments, binding of the antigen binding domain of the first CAR to its cognate antigen in the presence of the second CAR is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99%, e.g., 85%, 90%, 95%, 96%, 97%, 98%, or 99%, of the binding of the antigen binding domain of the first CAR to its cognate antigen in the absence of the second CAR.
[0347] In some embodiments, when present on the surface of a cell, the antigen binding domains of the first and second CARs bind to each other less than when both are in scFv antigen binding domains, hi some embodiments, the antigen binding domains of the first and second CARs bind to each other at least 85%, 90%, 95%, 96%, 97%, 98% or 99% less than when both are in scFv antigen binding domains, e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99% less.
[0348] Co-expression of substances that enhance CAR activity In other aspects, the CAR-expressing cells described herein can further express other substances, e.g., substances that enhance the activity or compatibility of the CAR-expressing cells.
[0349] For example, in some embodiments, the substance can be a substance that inhibits a molecule that regulates or controls, e.g., inhibits, T cell function. In some embodiments, the molecule that regulates or controls T cell function is an inhibitory molecule. In some embodiments, an inhibitory molecule, e.g., PD1, can reduce the ability of a CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD1, PD-L1, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, or TGFR beta.
[0350] In some embodiments, a substance, e.g., an inhibitory nucleic acid, e.g., a dsRNA, e.g., an siRNA or shRNA; or, e.g., an inhibitory protein or system, e.g., a clustered regularly interspaced short palindromic repeats (CRISPR), a transcription activator-like effector nuclease (TALEN), or a zinc finger endonuclease (ZFN), e.g., as described herein, can be used to inhibit the expression of a molecule that regulates or controls, e.g., inhibits, T cell function in a CAR-expressing cell. In some embodiments, the substance is an shRNA, e.g., an shRNA described herein. In some embodiments, a factor that regulates or controls, e.g., inhibits, T cell function is inhibited in a CAR-expressing cell. For example, a dsRNA molecule that inhibits the expression of a molecule that regulates or controls, e.g., inhibits, T cell function is linked to a nucleic acid encoding a component of a CAR, e.g., all of the components.
[0351] In some embodiments, the substance that inhibits an inhibitory molecule comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In some embodiments, the agent comprises a first polypeptide, e.g., an inhibitory molecule such as PD1, PD-L1, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, or TGFR beta, or a fragment of any of these (e.g., at least an extracellular domain portion of any of these), and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27, or CD28, e.g., as described herein) and / or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein)). In some embodiments, the agent comprises a first polypeptide of PD1 or a fragment thereof (e.g., at least a portion of the extracellular domain of PD1) and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28 signaling domain described herein and / or a CD3 zeta signaling domain described herein). PD1 is an inhibitory member of the CD28 family of receptors, which also includes CD28, CTLA-4, ICOS, and BTLA. PD-1 is expressed on activated B cells, T cells, and myeloid cells (Agata et al. 1996 Int. Immunol 8:765-75).Two ligands for PD1, PD-L1 and PD-L2, have been shown to downregulate T cell activation by binding to PD1 (Freeman et al. 2000 J Exp Med 192:1027-34; Latchman et al. 2001 Nat Immunol 2:261-8; Carter et al. 2002 Eur J Immunol 32:634-43). PD-L1 is abundant in human cancers (Dong et al. 2003 J Mol Med 81:281-7; Blank et al. 2005 Cancer Immunol. Immunother 54:307-314; Konishi et al. 2004 Clin Cancer Res 10:5094). Local inhibition of PD1 and PD-L1 can reverse immune suppression.
[0352] In some embodiments, an inhibitory molecule, for example, a substance comprising the extracellular domain (ECD) of programmed death 1 (PD1), can be fused to a transmembrane domain and an intracellular signaling domain, such as 41BB and CD3 zeta (also referred to herein as a PD1 CAR). In some embodiments, the PD1 CAR improves T cell persistence when used in combination with an XCAR described herein. In some embodiments, the CAR is a PD1 CAR comprising the extracellular domain of PD1 underlined in SEQ ID NO: 105. In some embodiments, the PD1 CAR comprises the amino acid sequence of SEQ ID NO: 105. [ka]
[0353] In one embodiment, the PD1 CAR comprises the amino acid sequence shown below (SEQ ID NO: 106). [ka]
[0354] In some embodiments, the agent comprises a nucleic acid sequence encoding a PD1 CAR, e.g., a PD1 CAR described herein. In some embodiments, the nucleic acid sequence of a PD1 CAR is shown below, with the PD1 ECD underlined in SEQ ID NO: 107. [ka]
[0355] In another example, in some embodiments, the substance that enhances the activity of a CAR-expressing cell can be a costimulatory molecule or costimulatory molecule ligand. Examples of costimulatory molecules include MHC class I molecules, BTLA and Toll ligand receptors, as well as OX40, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), and 4-1BB (CD137). Further examples of such costimulatory molecules include, e.g., CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8 alpha, CD8 beta, IL-2R beta, IL-2R gamma, IL-7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, IT These include ligands that specifically bind to GB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, and CD83. Examples of costimulatory molecule ligands include CD80, CD86, CD40L, ICOSL, CD70, OX40L, 4-1BBL, GITRL, and LIGHT. In some embodiments, the costimulatory molecule ligand is a ligand of a costimulatory molecule that is different from the costimulatory molecule domain of the CAR. In some embodiments, the costimulatory molecule ligand is a ligand of the same costimulatory molecule as the costimulatory molecule domain of the CAR. In some embodiments, the costimulatory molecule ligand is 4-1BBL.In some embodiments, the costimulatory ligand is CD80 or CD86. In some embodiments, the costimulatory molecule ligand is CD70. In some embodiments, the CAR-expressing immune effector cells described herein can be further engineered to express one or more additional costimulatory molecules or costimulatory molecule ligands.
[0356] Co-expression of CAR and chemokine receptors In some embodiments, the CAR-expressing cells described herein, e.g., CD19 CAR-expressing cells, further comprise a chemokine receptor molecule. Transgenic expression of the chemokine receptors CCR2b or CXCR2 in T cells enhances trafficking to CCL2- or CXCL1-secreting solid tumors, including melanoma and neuroblastoma (Craddock et al., J Immunother. 2010 Oct; 33(8):780-8 and Kershaw et al., Hum Gene Ther. 2002 Nov 1; 13(16):1971-80). Therefore, without wishing to be bound by theory, it is believed that a chemokine receptor expressed in a CAR-expressing cell that recognizes a chemokine secreted by a tumor, e.g., a solid tumor, improves homing of the CAR-expressing cell to the tumor, promotes tumor infiltration of the CAR-expressing cell, and enhances the anti-tumor efficacy of the CAR-expressing cell. The chemokine receptor molecule can comprise a naturally occurring or recombinant chemokine receptor or a chemokine-binding fragment thereof. Chemokine receptor molecules suitable for expression in a CAR-expressing cell (e.g., a CAR-Tx) described herein include a C-X-C chemokine receptor (e.g., CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, or CXCR7), a C-C chemokine receptor (e.g., CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, or CCR11), a C-C chemokine receptor (e.g., CX3CR1), an X-C chemokine receptor (e.g., XCR1), or a chemokine-binding fragment thereof. In some embodiments, the chemokine receptor molecule to be expressed with a CAR described herein is selected based on a chemokine expressed by the tumor. In some embodiments, a CAR-expressing cell described herein further comprises, e.g., expresses, a CCR2b receptor or a CXCR2 receptor. In some embodiments, the CAR and chemokine receptor molecules described herein are on the same vector or on two different vectors. In embodiments where the CAR and chemokine receptor molecules described herein are on the same vector, the CAR and chemokine receptor molecules are each under the control of two different promoters or under the control of the same promoter.
[0357] Nucleic acid construct encoding a CAR The present invention also provides immune effector cells comprising a nucleic acid molecule encoding one or more CAR constructs described herein, e.g., produced by a method described herein. In some aspects, the nucleic acid molecule is provided as a messenger RNA transcript. In some aspects, the nucleic acid molecule is provided as a DNA construct.
[0358] The nucleic acid molecules described herein can be DNA molecules, RNA molecules, or a combination thereof. In some embodiments, the nucleic acid molecule is an mRNA encoding a CAR polypeptide described herein. In other embodiments, the nucleic acid molecule is a vector comprising any of the aforementioned nucleic acid molecules.
[0359] In one aspect, the antigen binding domain (e.g., scFv) of a CAR of the invention is encoded by a nucleic acid molecule whose sequence has been codon-optimized for expression in mammalian cells. In one aspect, the entire CAR construct of the invention is encoded by a nucleic acid molecule whose entire sequence has been codon-optimized for expression in mammalian cells. Codon optimization refers to the discovery that the frequency of occurrence of synonymous codons (i.e., codons that encode the same amino acid) in coding DNA is biased from species to species. Such codon degeneracy allows the same polypeptide to be encoded by a variety of nucleotide sequences. Various codon optimization methods are known in the art, including, for example, the methods disclosed in at least U.S. Patent Nos. 5,786,464 and 6,114,148.
[0360] Thus, in one aspect, an immune effector cell, e.g., produced by the methods described herein, comprises a nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain that binds to a tumor antigen described herein, a transmembrane domain (e.g., a transmembrane domain described herein), and an intracellular signaling domain (e.g., an intracellular signaling domain described herein) that includes a stimulatory domain, e.g., a costimulatory signaling domain (e.g., a costimulatory signaling domain described herein) and / or a primary signaling domain (e.g., a primary signaling domain described herein, e.g., a zeta chain described herein).
[0361] The present invention also provides a vector into which a nucleic acid molecule encoding a CAR, such as a nucleic acid molecule described herein, has been inserted. Vectors derived from retroviruses, such as lentiviruses, are suitable tools for achieving long-term gene transfer because they allow long-term, stable integration of transgenes and their inheritance in daughter cells. Lentiviral vectors have the advantage over vectors derived from oncoretroviruses, such as murine leukemia viruses, because they can transduce non-proliferating cells, such as hepatocytes. They also have the additional advantage of being less immunogenic. The retroviral vector can also be, for example, a gammaretroviral vector. A gammaretroviral vector can include, for example, a promoter, a packaging signal (ψ), a primer binding site (PBS), one or more (e.g., two) long terminal repeats (LTRs), and a transgene of interest, such as a gene encoding a CAR. A gammaretroviral vector can lack viral structural genes, such as gag, pol, and env. Exemplary gammaretroviral vectors include murine leukemia virus (MLV), spleen focus-forming virus (SFFV), and myeloproliferative sarcoma virus (MPSV) and vectors derived therefrom. Other gammaretroviral vectors are described, for example, in Tobias Maetzig et al., "Gammaretroviral Vectors: Biology, Technology and Application" Viruses. 2011 Jun; 3(6): 677-713.
[0362] In other embodiments, the vector containing the nucleic acid encoding the desired CAR is an adenoviral vector (A5 / 35). In other embodiments, expression of the nucleic acid encoding the CAR can be achieved by using transposons such as sleeping beauty, crisper, CAS9, and zinc finger nucleases. See June et al. 2009 Nature Reviews Immunology 9.10: 704-716, incorporated herein by reference.
[0363] Briefly, the expression of natural or synthetic nucleic acid encoding CAR is generally achieved by operably linking the nucleic acid encoding CAR polypeptide or its part with a promoter, and incorporating this construct into an expression vector.The vector can be suitable for replication and integration in eukaryotes.Typical cloning vectors include transcription and translation terminators, initiation sequences and promoters that are useful for controlling the expression of desired nucleic acid sequences.
[0364] Nucleic acids can be cloned into many types of vectors. For example, nucleic acids can be cloned into vectors including, but not limited to, plasmids, phagemids, phage derivatives, animal viruses, and cosmids. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors, and sequencing vectors.
[0365] Furthermore, expression vectors can be provided to cells in the form of viral vectors.Viral vector technology is well known in the art and is described, for example, in Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1-4, Cold Spring Harbor Press, NY, and other virology and molecular biology manuals.Viruses useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, and lentiviruses.Generally, suitable vectors include a replication origin functional in at least one organism, a promoter sequence, a convenient restriction endonuclease site, and one or more selectable markers (e.g., WO01 / 96584; WO01 / 29058; and U.S. Patent No. 6,326,193).
[0366] Many virus-based systems have been developed for gene transfer into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. Using techniques known in the art, a selected gene can be inserted into a vector and packaged into retroviral particles. The recombinant virus can then be isolated in vivo or ex vivo and delivered to target cells. Many retroviral systems are known in the art. In some embodiments, adenoviral vectors are used. Many adenoviral vectors are known in the art. In some embodiments, lentiviral vectors are used.
[0367] Additional promoter elements, such as enhancers, control the frequency of transcription initiation. Generally, these are located in the region 30–110 bp upstream of the start site, although many promoters have been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements is often flexible, such that promoter function is maintained when these elements are inverted or moved relative to one another. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decrease. Depending on the promoter, individual elements appear to be able to function cooperatively or individually to activate transcription. Exemplary promoters include the CMV IE gene, EF-1α, ubiquitin C, or phosphoglycerokinase (PGK) promoters.
[0368] An example of a promoter that can express a CAR-encoding nucleic acid molecule in mammalian T cells is the EF1 promoter. The native EF1 promoter drives the expression of the alpha subunit of the elongation factor 1 complex, which is responsible for the enzymatic delivery of aminoacyl-tRNA to ribosomes. The EF1 promoter is widely used in mammalian expression plasmids and has been shown to be effective in driving CAR expression from nucleic acid molecules cloned into lentiviral vectors. See, for example, Milone et al., Mol. Ther. 17(8): 1453-1464 (2009). In one aspect, the EF1 promoter comprises the sequence provided in the Examples.
[0369] Another example of a promoter is the immediate-early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operably linked to it. However, other constitutive promoters, including but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukosis virus promoter, Epstein-Barr virus immediate-early promoter, and Rous sarcoma virus promoter, as well as human gene promoter sequences, such as but not limited to the actin promoter, myosin promoter, elongation factor 1α promoter, hemoglobin promoter, and creatine kinase promoter, may also be used. Furthermore, the present invention should not be limited to the use of constitutive promoters. Inducible promoters are also contemplated as part of the present invention. The use of an inducible promoter can provide a molecular switch that can turn on expression of an operably linked polynucleotide sequence when such expression is desired or turn off expression when expression is undesirable. Examples of inducible promoters include, but are not limited to, a metallothionein promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter.
[0370] Another example of a promoter is the phosphoglycerate kinase (PGK) promoter. In some embodiments, a truncated PGK promoter (e.g., a PGK promoter having one or more, e.g., 1, 2, 5, 10, 100, 200, 300, or 400 nucleotide deletions when compared to the wild-type PGK promoter sequence) may be desired.
[0371] The nucleotide sequence of an exemplary PGK promoter is provided below. WT PGK promoter: ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTACGCCTTGTGGCGCGCCCGTCCTTGTCCCGGGTGTGATGGCGGGGTGTGGGGCGGAGGGCG TGGCGGGGAAGGGCCGGCGACGAGAGCCGCGCGGGACGACTCGTCGGCGATAACCGGTGTCGGGTAGCGCCAGCCGCGCGACGGTAACGAGGGACCGCGACAGGCAGACGCTCCCATGATCACTCTGCACGCC GAAGGCAAATAGTGCAGGCCGTGCGGCGCTTGGCGTTCCTTGGAAGGGCTGAATCCCCGCCTCGTCCTTCGCAGCGGCCCCCCGGGTGTTCCCATCGCCGCTTCTAGGCCCACTGCGACGCTTGCCTGCACT TCTTACACGCTCTGGGTCCCAGCCGCGGCGACGCAAAGGGCCTTGGTGCGGGTCTCGTCGGCGCAGGGACGCGTTTGGGTCCCGACGGAACCTTTTCCGCGTTGGGGTTGGGGCACCATAAGCT (SEQ ID NO: 109)
[0372] Exemplary truncated PGK promoters: PGK100: ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTACGCCTTGTGGCGCCCGTCCTGTGCCCGGGTGTGATGGCGGGGTG (sequence number 110)
[0373] PGK200: ACCCCTCTCTCCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTACGCCTTGTGGCGCGCCCGTCCTTGTCCCGGGTGTGATGCGGGTGTGGGCGGAGGGCGTGGCGGGGAAGGCCCGGCGAGAGACCGCGGGACGACTCGTCGGCGATAACCGGTGTCGGGTAGCGCCAGCCGCGCGACGGTAACG (sequence number 111)
[0374] PGK300: ACCCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCTCGGCTGACGGCTGCACGCGGAGGCCTCCCGAACGTCTTACGCCTTGTGGCGCGCCCGTCCTTGTCCCGGGTGTGATGCGGGTGTGGGCGGAGGCGTGGCGGGAAGGGCCGGCGACGAGAGCCGCGGGACACTCGTCGGCGATAACCGGTGCGGTAGCGCCGCGCGACGTAACGAGGGACCGCGACAGGCAGACGCTCCCATGATCACTCTGCACGCCGAAGGCAAATAGTGCAGGCCGTGGCGGCGCTTGGCGTTCCTTGGAAGGGCTGAAACCCCCG(sequence number 112)
[0375] PGK400: ACCCCCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTACGCCTTGTGGCGCGCCCGTCCTTGTCCCGGGTGTGATGGCGGGTTGGGGCGGAGGGCGTGGCGGGGAAGGGCCGGCGACGAGAGCCGCGCGGGACGACTCGTCGGCGATAACCGGTGTCGGGTAGCGCCAGCCGCGCGACG GTAACGAGGGACCGCGACAGGCAGACGCTCCCATGATCACTCTGCACGCCGAAGGCAAATAGTGCAGGCCGTGCGGCGCTTGGCGTTCCTTGGAAGGGCTGAATCCCCGCCTCGTCCTTCGCAGCGGCCCCCGGTGTTCCCATCGCCGCTTCTAGGCCCACTGCGACGCTTGCCTGCACTTCTTACACGCTCTGGGTCCCAGCCG (SEQ ID NO: 113)
[0376] Vectors may also include, for example, a signal sequence to facilitate secretion, a polyadenylation signal and a transcription terminator (e.g., from the bovine growth hormone (BGH) gene), elements allowing episomal replication and replication in prokaryotes (e.g., SV40 origin and ColE1 or others known in the art), and / or elements allowing selection (e.g., an ampicillin resistance gene and / or a Zeocin marker).
[0377] To assess the expression of a CAR polypeptide or a portion thereof, the expression vector introduced into the cell may also contain a selectable marker gene or a reporter gene, or both, to facilitate the identification and selection of expressing cells from a cell population examined for transfection or infection via a viral vector. In another aspect, the selectable marker may be carried by a separate piece of DNA and used in a co-transfection method. Both the selectable marker and the reporter gene may be flanked by appropriate regulatory sequences to enable expression in the host cell. Useful selectable markers include, for example, antibiotic resistance genes, such as neo.
[0378] Reporter genes are used to identify potential transgenic cells and evaluate the functionality of regulatory sequences. Generally, reporter genes are genes that encode polypeptides that are not present in or expressed by recipient organisms or tissues and whose expression is manifested by an easily detectable property, such as enzymatic activity. Expression of the reporter gene is assayed at an appropriate time after DNA is introduced into recipient cells. Suitable reporter genes include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyltransferase, secreted alkaline phosphatase, or green fluorescent protein (e.g., Ui-Tei et al., 2000 FEBS Letters 479: 79-82). Suitable expression systems are well known and can be prepared by known techniques or obtained commercially. Generally, the construct with the minimal 5' flanking region that exhibits the highest level of reporter gene expression is identified as the promoter. Such promoter regions can be linked to reporter genes and used to evaluate substances for their ability to modulate promoter-driven transcription.
[0379] In some embodiments, the vector can include sequences encoding two or more nucleic acid CARs, such as a CAR described herein, e.g., a CD19 CAR, and a second CAR, e.g., an inhibitory CAR or a CAR that specifically binds to an antigen other than CD19. In such embodiments, two or more nucleic acid sequences encoding CARs are encoded in the same frame by a single nucleic molecule as a single polypeptide chain. In this aspect, the two or more CARs can be separated, for example, by one or more peptide cleavage sites (e.g., autocleavage sites or substrates for intracellular proteases). Examples of peptide cleavage sites include T2A, P2A, E2A, or F2A sites.
[0380] Methods for introducing and expressing genes in cells are known in the art. In the context of expression vectors, the vectors can be easily introduced into host cells, such as mammalian, bacterial, yeast, or insect cells, by any method, e.g., methods known in the art. For example, expression vectors can be introduced into host cells by physical, chemical, or biological means.
[0381] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, etc. Methods for producing cells containing vectors and / or foreign nucleic acids are well known in the art. See, for example, Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1-4, Cold Spring Harbor Press, NY. A suitable method for introducing polynucleotides into host cells is calcium phosphate gene transfer.
[0382] Biological methods for introducing a target polynucleotide into host cells include the use of DNA and RNA vectors.Viral vectors, especially retroviral vectors, have become the most widely used method for inserting genes into mammalian, for example, human cells.Other viral vectors can be derived from lentivirus, poxvirus, herpes simplex virus I, adenovirus and adeno-associated virus, etc.See, for example, U.S. Patent Nos. 5,350,674 and 5,585,362.
[0383] Chemical means for introducing polynucleotides into host cells include colloidal dispersion systems such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system used as a delivery vehicle in vitro and in vivo is a liposome (e.g., artificial membrane vesicle). Other cutting-edge nucleic acid targeted delivery methods are available, such as delivery of polynucleotides in targeted nanoparticles or other suitable submicron-sized delivery systems.
[0384] When a non-viral delivery system is utilized, an exemplary delivery vehicle is a liposome. The use of lipid formulations is contemplated for the introduction of nucleic acids into host cells (in vitro, ex vivo, or in vivo). In another aspect, the nucleic acid can be associated with a lipid. The lipid-associated nucleic acid can be encapsulated in the aqueous interior of a liposome, dispersed within the lipid bilayer of a liposome, bound to a liposome via a linking molecule that binds both the liposome and the oligonucleotide, encapsulated in a liposome, complexed with a liposome, dispersed in a lipid-containing solution, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed in a micelle, or otherwise associated with a lipid. Lipid, lipid / DNA, or lipid / expression vector-associated compositions are not limited to any particular structure in solution. For example, they can exist in a bilayer structure, micelles, or "collapsed" structure. They may simply be dispersed in solution, possibly forming aggregates that are not uniform in size or shape. Lipids are fatty substances that can be naturally occurring or synthetic lipids. For example, lipids include the lipid droplets that occur naturally in the cytoplasm as well as a group of compounds that contain long-chain aliphatic hydrocarbons and their derivatives such as fatty acids, alcohols, amines, aminoalcohols, and aldehydes.
[0385] Lipids suitable for use can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine ("DMPC") can be obtained from Sigma, St. Louis, MO; dicetyl phosphate ("DCP") can be obtained from K & K Laboratories (Plainview, NY); cholesterol ("Choi") can be obtained from Calbiochem-Behring; and dimyristyl phosphatidylglycerol ("DMPG") and other lipids can be obtained from Avanti Polar Lipids, Inc. (Birmingham, AL). Stock solutions of lipids in chloroform or chloroform / methanol can be stored at approximately -20°C. Chloroform is used as the sole solvent because it evaporates more readily than methanol. "Liposome" is a general term that encompasses a variety of unilamellar and multilamellar lipid vesicles formed by the formation of enclosed lipid bilayers or aggregates. Liposomes can be characterized as having a vesicular structure with a phospholipid bilayer and an internal aqueous medium. Multilamellar liposomes contain multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components self-rearrange, subsequently forming a closed structure, encapsulating water and dissolved solutes within the lipid bilayer (Ghosh et al., 1991 Glycobiology 5: 505-10). However, compositions with structures different from the normal vesicular structure in solution are also encompassed. For example, the lipids may be in a micellar structure or simply be considered as heterogeneous aggregates of lipid molecules. Lipofectamine-nucleic acid complexes are also contemplated.
[0386] Regardless of the method by which exogenous nucleic acid is introduced into a host cell or otherwise exposed to an inhibitor of the invention, a variety of assays can be performed to confirm the presence of the recombinant nucleic acid sequence in the host cell. Such assays include "molecular biological" assays well known to those skilled in the art, such as Southern and Northern blotting, RT-PCR, and PCR; "biochemical" assays, such as by immunological means (ELISA and Western blot), to detect the presence or absence of specific peptides, or by assays described herein to identify substances within the scope of the invention.
[0387] Natural killer cell receptor (NKR) CAR In some embodiments, the CAR molecules described herein comprise one or more components of a natural killer cell receptor (NKR), thereby forming an NKR-CAR. The NKR component can be a transmembrane domain, hinge domain, or cytoplasmic domain from any of the following natural killer cell receptors: killer cell immunoglobulin-like receptors (KIR), such as KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, DIR2DS5, KIR3DL1 / S1, KIR3DL2, KIR3DL 3, KIR2DP1 and KIR3DP1; natural cytotoxicity receptors (NCRs), such as NKp30, NKp44, NKp46; signaling lymphocyte activation molecule (SLAM) family of immune cell receptors, such as CD48, CD229, 2B4, CD84, NTB-A, CRACC, BLAME and CD2F-10; Fc receptors (FcRs), such as CD16 and CD64; and Ly49 receptors, such as LY49A and LY49C. The NKR-CAR molecules described herein can interact with adaptor molecules or intracellular signaling domains, such as DAP12. Exemplary configurations and sequences of CAR molecules containing NKR components are described in International Publication WO2014 / 145252, the contents of which are incorporated herein by reference.
[0388] Split CAR In some embodiments, CAR-expressing cells use split CAR. Split CAR approach is described in more detail in publications WO2014 / 055442 and WO2014 / 055657. Briefly, split CAR system comprises a cell that expresses a first CAR with a first antigen binding domain and a costimulatory domain (e.g., 41BB), and the cell also expresses a second CAR with a second antigen binding domain and an intracellular signaling domain (e.g., CD3 zeta). When the cell encounters the first antigen, the costimulatory domain is activated, causing the cell to proliferate. When the cell encounters the second antigen, the intracellular signaling domain is activated, causing cell-killing activity. Therefore, CAR-expressing cells are only fully activated in the presence of both antigens.
[0389] Strategies for controlling chimeric antigen receptors In some embodiments, a controllable CAR (RCAR), whose CAR activity can be controlled, is desirable to optimize the safety and efficacy of CAR therapy. There are many ways in which CAR activity can be controlled. For example, inducible apoptosis, using a caspase fused to a dimerization domain (see, e.g., Di Stasa et al., N Engl. J. Med. 2011 Nov. 3; 365(18):1673-1683), can be used as a safety switch in the CAR therapy of the present invention. In some embodiments, cells (e.g., T cells or NK cells) expressing the CAR of the present invention further comprise an inducible apoptosis switch, in which a human caspase (e.g., caspase 9) or a modified version is fused to a modification of the human FKB protein that allows conditional dimerization. In the presence of a small molecule such as a rapalog (e.g., AP1903, AP20187), the inducible caspase (e.g., caspase 9) is activated, resulting in rapid apoptosis and death of the cells (e.g., T cells or NK cells) expressing the CAR of the present invention. Examples of caspase-based inducible apoptosis switches (or one or more aspects of such switches) are described, e.g., in US2004040047; US20110286980; US20140255360; WO1997031899; WO2014151960; WO2014164348; WO2014197638; WO2014197638; all of which are incorporated herein by reference.
[0390] In other examples, CAR-expressing cells can also express an inducible caspase-9 (iCaspase-9) molecule, which, upon administration of a dimerizing agent (e.g., rimiducid (also known as AP1903 (Bellicum Pharmaceuticals) or AP20187 (Ariad)), leads to activation of caspase-9 and apoptosis of the cell. The iCaspase-9 molecule contains a chemical inducer of dimerization (CID) binding domain that mediates dimerization in the presence of a CID. This results in the inducible and selective depletion of CAR-expressing cells. In some cases, the iCaspase-9 molecule is encoded by a nucleic acid molecule separate from the CAR-encoding vector. In some cases, the iCaspase-9 molecule is encoded by the same nucleic acid molecule as the CAR-encoding vector. iCaspase-9 can provide a safety switch to avoid any toxicity of CAR-expressing cells. See, e.g., Song et al. Cancer Gene Ther. 2008; 15(10):667-75; Clinical Trial Id. No. NCT02107963; and Di Stasi et al. N. Engl. J. Med. 2011; 365:1673-83.
[0391] Alternative strategies for controlling the CAR therapy of the present invention include small molecules or antibodies that inactivate or turn off CAR activity, for example, by triggering antibody-dependent cell-mediated cytotoxicity (ADCC), e.g., by deleting CAR-expressing cells. For example, the CAR-expressing cells described herein can also express antigens recognized by molecules that can trigger cell death, e.g., ADCC or complement-induced cell death. For example, the CAR-expressing cells described herein can also express receptors that can be targeted by antibodies or antibody fragments. Examples of such receptors include EpCAM, VEGFR, integrins (e.g., integrins ανβ3, α4, αΙ3 / 4β3, α4β7, α5β1, ανβ3, αν), members of the TNF receptor superfamily (e.g., TRAIL-R1, TRAIL-R2), PDGF receptors, interferon receptors, folate receptors, GPNMB, ICAM-1, HLA-DR, CEA, CA-125, MUC1, TAG-72, IL-6 receptor, 5T4, GD2, GD3, CD2, CD3, CD4, CD5, CD11, CD11a / LFA-1, CD 15, CD18 / ITGB2, CD19, CD20, CD22, CD23 / IgE receptor, CD25, CD28, CD30, CD33, CD38, CD40, CD41, CD44, CD51, CD52, CD62L, CD74, CD80, CD125, CD147 / basigin, CD152 / CTLA-4, CD154 / CD40L, CD195 / CCR5, CD319 / SLAMF7 and EGFR and truncated versions thereof (e.g., versions that retain one or more extracellular epitopes but lack one or more regions within the cytoplasmic domain).
[0392] For example, the CAR-expressing cells described herein can also express a truncated epidermal growth factor receptor (EGFR) that lacks signaling capability but retains the epitope recognized by cetuximab (Erbitux®), such that cetuximab administration also induces ADCC and subsequent depletion of the CAR-expressing cells (see, e.g., WO 2011 / 056894 and Jonnalagadda et al., Gene Ther. 2013; 20(8)853-860). Other strategies include expression of a highly compact marker / suicide gene that combines target epitopes from both the CD32 and CD20 antigens in the CAR-expressing cells described herein that binds rituximab, resulting in selective depletion of CAR-expressing cells, e.g., by ADCC (see, e.g., Philip et al., Blood. 2014; 124(8)1277-1287). Other methods of depleting CAR-expressing cells described herein include the administration of Campath, a monoclonal anti-CD52 antibody that selectively binds to and targets mature lymphocytes, e.g., CAR-expressing cells, for destruction, e.g., by ADCC. In other embodiments, CAR-expressing cells can be selectively targeted using a CAR ligand, e.g., an anti-idiotypic antibody. In some embodiments, the anti-idiotypic antibody can trigger effector cell activity, e.g., ADCC or ADC activity, thereby reducing the number of CAR-expressing cells. In other embodiments, the CAR ligand, e.g., an anti-idiotypic antibody, can be linked to a substance that induces cell death, e.g., a toxin, thereby reducing the number of CAR-expressing cells. Alternatively, the CAR molecule itself can be engineered so that its activity can be controlled, e.g., turned on and off, as described below.
[0393] In other embodiments, the CAR-expressing cells described herein may also express a target protein recognized by a T cell depletion agent. In some embodiments, the target protein is CD20, and the T cell depletion agent is an anti-CD20 antibody, e.g., rituximab. In such embodiments, the T cell depletion agent is administered when it is desirable to reduce or eliminate CAR-expressing cells, e.g., to reduce CAR-induced toxicity. In other embodiments, the T cell depletion agent is an anti-CD52 antibody, e.g., alemtuzumab, as described in the Examples herein.
[0394] In other embodiments, an RCAR comprises a set of polypeptides, generally two in the simplest embodiment, in which components of a standard CAR described herein, e.g., an antigen-binding domain and an intracellular signaling domain, are split into separate polypeptides or members. In some embodiments, the set of polypeptides comprises a dimerization switch that can link one polypeptide to another in the presence of a dimerization molecule, e.g., linking an antigen-binding domain to an intracellular signaling domain. In some embodiments, the CAR of the invention utilizes a dimerization switch, such as those described in WO2014127261, which is incorporated herein by reference. Further description and exemplary configurations of such controllable CARs are provided herein and in, e.g., paragraphs 527-551 of International Publication WO2015 / 090229, filed March 13, 2015, which is incorporated herein by reference in its entirety. In some embodiments, an RCAR comprises a switch domain, e.g., an FKBP switch domain set forth in SEQ ID NO: 114, or a fragment of FKBP capable of binding to FRB, e.g., as set forth in SEQ ID NO: 115. In one embodiment, the RCAR comprises a switch domain comprising, for example, the FRB sequence set forth in SEQ ID NO: 116, or a mutant FRB sequence set forth in, for example, SEQ ID NOs: 117-122.
[0395] DVPDYASLGGPSSPKKKRKVSRGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLETSY (SEQ ID NO: 114) VQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLETS (SEQ ID NO: 115) ILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISK (SEQ ID NO: 116)
[0396] [Table 26]
[0397] RNA gene transfer Disclosed herein is a method for producing in vitro transcribed RNA CARs. RNA CARs and methods for using them are described, for example, in paragraphs 553-570 of International Application WO2015 / 142675, filed March 13, 2015, the entire contents of which are incorporated herein by reference.
[0398] Immune effector cells can comprise a CAR encoded by messenger RNA (mRNA). In one aspect, mRNA encoding a CAR described herein can be introduced into immune effector cells, e.g., produced by the methods described herein, to produce a CAR-expressing cell.
[0399] In some embodiments, in vitro transcribed RNA CARs can be introduced into cells in the form of transient gene transfer. RNA is produced using in vitro transcription using a polymerase chain reaction (PCR)-generated template. DNA of interest from any source can be directly converted into a template for in vitro mRNA synthesis using appropriate primers and RNA polymerase by PCR. The source of DNA can be, for example, genomic DNA, plasmid DNA, phage DNA, cDNA, synthetic DNA sequence, or any other suitable source of DNA. The desired template for in vitro transcription is a CAR described herein. For example, the template for an RNA CAR includes an extracellular region comprising a single-chain variable domain of an antibody against a tumor-associated antigen described herein; a hinge region (e.g., a hinge region described herein), a transmembrane domain (e.g., a transmembrane domain described herein, such as the transmembrane domain of CD8a); and a cytoplasmic region comprising an intracellular signaling domain, for example, an intracellular signaling domain described herein, for example, the signaling domain of CD3 zeta and the signaling domain of 4-1BB.
[0400] In some embodiments, the DNA used in PCR comprises an open reading frame. The DNA can be derived from a naturally occurring DNA sequence from the genome of an organism. In some embodiments, the nucleic acid can comprise some or all of the 5' and / or 3' untranslated region (UTR). The nucleic acid can comprise exons and introns. In some embodiments, the DNA used in PCR is a human nucleic acid sequence. In other embodiments, the DNA used in PCR is a human nucleic acid sequence comprising the 5' and 3' UTR. The DNA can alternatively be an artificial DNA sequence that is not normally expressed in naturally occurring organisms. An exemplary artificial DNA sequence is one that comprises portions of genes ligated together to form an open reading frame encoding a fusion protein. The portions of DNA ligated together can be from a single organism or from more than one organism.
[0401] PCR is used to generate templates for in vitro transcription of mRNA for use in gene transfer. Methods for performing PCR are well known in the art. Primers used in PCR are engineered to contain regions that are substantially complementary to a region of DNA used as a PCR template. As used herein, "substantially complementary" refers to a sequence of nucleotides in which most or all of the bases in the primer sequence are complementary, or in which one or more bases are non-complementary or mismatched. A substantially complementary sequence is capable of annealing or hybridizing with the intended DNA target under the annealing conditions used for PCR. Primers can be designed to be substantially complementary to any portion of the DNA template. For example, primers can be engineered to amplify a nucleic acid portion normally transcribed in cells (open reading frame), including the 5' and 3' UTRs. Primers can also be engineered to amplify a portion of a nucleic acid encoding a specific domain of interest. In some embodiments, primers can be engineered to amplify the coding region of a human cDNA, including all or part of the 5' and 3' UTRs. Primers useful for PCR can be produced by synthetic methods well known in the art. A "forward primer" is a primer that contains a region of nucleotides that are substantially complementary to nucleotides on a DNA template that are upstream of the DNA sequence to be amplified. "Upstream" is used herein to refer to a position 5' of the DNA sequence to be amplified, relative to the coding strand. A "reverse primer" is a primer that contains a region of nucleotides that are substantially complementary to a double-stranded DNA template that is downstream of the DNA sequence to be amplified. "Downstream" is used herein to refer to a position 3' of the DNA sequence to be amplified, relative to the coding strand.
[0402] Any DNA polymerase useful in PCR can be used in the methods disclosed herein. Reagents and polymerases are commercially available from a number of sources.
[0403] Chemical structures capable of promoting stability and / or translation efficiency may also be used. In some embodiments, the RNA has 5' and 3' UTRs. In some embodiments, the 5' UTR is 1 to 3,000 nucleotides in length. The length of the 5' and 3' UTR sequences added to the coding region can be modified by various methods, including, but not limited to, engineering PCR primers that anneal to different regions of the UTR. Using this approach, one skilled in the art can modify the 5' and 3' UTR lengths necessary to achieve optimal translation efficiency after transfection of the transcribed RNA.
[0404] The 5' and 3' UTRs can be naturally occurring, endogenous 5' and 3' UTRs for the nucleic acid of interest. Alternatively, UTR sequences that are not endogenous to the nucleic acid of interest can be added by incorporating UTR sequences into forward and reverse primers or by some other modification of the template. The use of UTR sequences that are not endogenous to the nucleic acid of interest can be useful for modifying RNA stability and / or translation efficiency. For example, it is known that AU-rich components in 3' UTR sequences can reduce mRNA stability. Therefore, 3' UTRs can be selected or engineered to increase the stability of transcribed RNA based on the properties of UTRs, which are well known in the art.
[0405] In some embodiments, the 5'UTR can contain the Kozak sequence of the endogenous nucleic acid. Alternatively, when a 5'UTR that is not endogenous to the nucleic acid of interest is added by PCR as described above, a consensus Kozak sequence can be re-engineered by adding the 5'UTR sequence. While the Kozak sequence can increase the translation efficiency of some RNA transcripts, it does not appear to be necessary for all RNAs to enable efficient translation. The necessity of the Kozak sequence for many mRNAs is known in the art. In other embodiments, the 5'UTR is the 5'UTR of an RNA virus whose RNA genome is stable in cells. In other embodiments, various nucleotide analogs can be used in the 3' or 5'UTR to prevent exonuclease degradation of the mRNA.
[0406] To enable RNA synthesis from a DNA template without the need for gene cloning, a transcription promoter should be attached to the DNA template upstream of the sequence to be transcribed. When a sequence that functions as a promoter for RNA polymerase is added to the 5' end of the forward primer, the RNA polymerase promoter is incorporated into the PCR product upstream of the open reading frame to be transcribed. In some embodiments, the promoter is a T7 polymerase promoter, as described elsewhere herein. Other useful promoters include, but are not limited to, T3 and SP6 RNA polymerase promoters. Consensus nucleotide sequences for T7, T3, and SP6 promoters are known in the art.
[0407] In some embodiments, mRNAs have caps on both the 5' end and a 3' poly(A) tail, which determine ribosome binding, translation initiation, and mRNA stability in cells. On circular DNA templates, such as plasmid DNA, RNA polymerase produces long concatemeric products that are not suitable for expression in eukaryotic cells. Transcription of linearized plasmid DNA at the end of the 3' UTR, even with post-transcriptional polyadenylation, results in normal-sized mRNAs that are not effective for eukaryotic gene transfer.
[0408] On a linear DNA template, phage T7 RNA polymerase can extend the 3' end of the transcript beyond the last base of the template (Schenborn and Mierendorf, Nuc Acids Res., 13:6223-36 (1985); Nacheva and Berzal-Herranz, Eur. J. Biochem., 270:1485-65 (2003)).
[0409] The conventional method for incorporating a polyA / T stretch into a DNA template is molecular cloning. However, polyA / T sequences integrated into plasmid DNA can cause plasmid instability, which is why plasmid DNA templates obtained from bacterial cells are often highly contaminated with deletions and other abnormalities. This makes cloning methods not only laborious and time-consuming, but also often unreliable. This is why the construction of DNA templates with polyA / T 3' stretches without cloning is highly desirable.
[0410] The poly(A) / T segment of the transcription DNA template can be generated during or after PCR by using a reverse primer containing a poly(T) tail (size can be 50-5000T (SEQ ID NO: 32)), such as a 100T tail (SEQ ID NO: 31), or by other methods, including, but not limited to, DNA ligation or in vitro recombination. The poly(A) tail also provides stability to the RNA, reducing its degradation. Generally, the length of the po...
Claims
1. 1. A method for producing a population of immune effector cells (e.g., T cells, NK cells) that are depleted of T regulatory cells and can be engineered to express a CAR, comprising: providing a population of immune effector cells (e.g., T cells); T regulatory cells, e.g., CD25+ T cells, are removed from the population, thereby providing a population of T regulatory depleted cells, e.g., CD25+ depleted cells, suitable for CAR expression. The method includes:
2. 2. The method of claim 1, wherein the population of T regulatory depleted cells comprises less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells.
3. 2. The method of claim 1, wherein the population of immune effector cells are cells of a subject having cancer, e.g., a subject having a CD25-expressing cancer, such as chronic lymphocytic leukemia (CLL).
4. 4. The method of claim 3, wherein the population of T regulatory depleted cells comprises less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% tumor cells.
5. 2. The method of claim 1, wherein T regulatory cells, e.g., CD25+ T cells, have been depleted from the population using an anti-CD25 antibody or fragment thereof.
6. The method of claim 5, wherein the anti-CD25 antibody or fragment thereof is conjugated to a substrate, e.g., a bead.
7. 4. The method of claim 3, wherein the population of immune effector cells is obtained from a subject having a hematological cancer, e.g., a leukemia, e.g., chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), or a lymphoma, e.g., mantle cell lymphoma (MCL).
8. 8. The method of claim 7, wherein the population of T regulatory depleted cells comprises less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of leukemia cells, e.g., CLL cells, ALL cells or lymphoma cells, e.g., MCL cells, HL cells, e.g., wherein the population of T regulatory depleted cells comprises less than 15%, 10%, 5%, 4%, 3%, 2%, 1% of CD25+ cells and less than 15%, 10%, 5%, 4%, 3%, 2%, 1% of tumor cells, e.g., CLL cells, e.g., wherein the population of T regulatory depleted cells comprises less than 10%, 5%, 4%, 3%, 2%, 1% of CD25+ cells and less than 10%, 5%, 4%, 3%, 2%, 1% of tumor cells, e.g., CLL cells.
9. 2. The method of claim 1, further comprising removing cells from the population that express a tumor antigen, e.g., CD25, e.g., CD19, CD30, CD38, CD123, CD20, CD14 or CD11b, thereby providing a population of T regulatory depleted, e.g., CD25+ depleted and tumor antigen depleted cells suitable for expression of a CAR, e.g., a CAR described herein.
10. 2. The method of claim 1, further comprising removing cells from the population that express a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein, e.g., one or more of PD1+ cells, LAG3+ cells and TIM3+ cells, thereby providing a population of T regulatory depleted, e.g., CD25+ depleted cells and checkpoint inhibitor depleted cells, e.g., PD1+, LAG3+ and / or TIM3+ depleted cells.
11. 2. The method of claim 1, wherein the population of immune effector cells provided has been selected based on expression of one or more markers, e.g., CD3, CD28, CD4, CD8, CD45RA and CD45RO, e.g., the provided population of immune effector cells (e.g., T cells) are CD3+ and / or CD28+.
12. 12. The method of any of claims 1-11, further comprising activating the population of T regulatory depleted cells, e.g., CD25+ depleted cells, e.g., by a method described herein, and / or transducing cells from the population of T regulatory depleted cells, e.g., the population of CD25+ depleted cells, with a vector comprising a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein.
13. The method of claim 12, further comprising expanding the population of engineered T regulatory depleted cells, e.g., by a method described herein, to express a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein.
14. 14. The method of claim 13, wherein the population of cells is expanded for a period of 8 days or less, e.g., 7, 6, 5, 4 or 3 days, or the population of cells is expanded in culture for 5 days and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same culture conditions, e.g., the cells expanded for 5 days exhibit at least a 1-, 2-, 3- or 4-fold increase in cell doublings upon antigen stimulation compared to the same cells expanded in culture for 9 days under the same culture conditions, or the cells are expanded in culture for 5 days and the resulting cells exhibit higher pro-inflammatory cytokine production, e.g., IFN-γ and / or GM-CSF levels, compared to the same cells expanded in culture for 9 days under the same culture conditions.
15. The method of claim 13, wherein the population of cells is expanded by culturing the cells in the presence of an agent that stimulates a CD3 / TCR complex-associated signal and a ligand that stimulates a costimulatory molecule on the surface of the cells, e.g., as described herein.
16. The method of any of claims 13-15, wherein the population of cells is expanded in an appropriate medium (e.g., a medium described herein) containing one or more interleukins that result in at least a 200-fold (e.g., 200-fold, 250-fold, 300-fold, 350-fold) expansion of cells over a 14 day expansion period, as measured by a method described herein, such as flow cytometry, e.g., wherein the population of cells is expanded in the presence of IL-15 and / or IL-7 (e.g., IL-15 and IL-7).
17. The method according to any of claims 13 to 16, wherein the population of cells is cryopreserved after a suitable expansion period.
18. 18. The method of any of claims 1 to 17, further comprising contacting the population of immune effector cells with a nucleic acid encoding a telomerase subunit, e.g., hTERT, wherein the nucleic acid is, e.g., DNA or RNA.
19. A reaction mixture comprising a population of T regulatory depleted cells that comprises less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of CD25+ cells.
20. A reaction mixture comprising a population of T regulatory depleted cells comprising less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25-expressing tumor cells, e.g., CLL cells.
21. 21. The reaction mixture of claim 20, wherein the population of cells comprises less than 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 15%, 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells, or wherein the population of cells comprises less than 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells.
22. 22. The reaction mixture of claim 20 or 21, wherein the reaction mixture comprises a population of T regulatory depleted cells comprising less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% checkpoint inhibitor expressing cells, e.g., PD1+ cells, LAG3+ cells or TIM3+ cells.
23. 23. The reaction mixture of any of claims 19 to 22, wherein the reaction mixture further comprises a substance that activates and / or expands the cells of the population, e.g. a substance that stimulates a CD3 / TCR complex associated signal and / or a ligand that stimulates a costimulatory molecule on the surface of the cells, e.g. the substance is a bead conjugated with an anti-CD3 antibody or fragment thereof and / or an anti-CD28 antibody or fragment thereof.
24. 24. The reaction mixture of any of claims 19 to 23, further comprising one or more factors for proliferation and / or viability including serum (e.g. fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-γ, IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGFβ and TNF-α or any other additive for cell growth, e.g. wherein the reaction mixture further comprises IL-15 and / or IL-7.
25. 25. The reaction mixture of any of claims 19-24, wherein a plurality of population of cells in the reaction mixture comprises a nucleic acid molecule, e.g., a nucleic acid molecule described herein, comprising a CAR-encoding sequence, e.g., a CD19 CAR-encoding sequence, e.g., as described herein, e.g., a plurality of population of cells in the reaction mixture comprises a vector comprising a nucleic acid sequence encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein, e.g., wherein the vector is a vector described herein, e.g., a vector selected from the group consisting of a DNA, RNA, plasmid, lentiviral vector, adenoviral vector, or retroviral vector.
26. 25. The reaction mixture of claims 19 to 24, further comprising cryoprotectants or stabilizers such as, for example, saccharides, oligosaccharides, polysaccharides and polyols (e.g., trehalose, mannitol, sorbitol, lactose, sucrose, glucose and dextran), salts and crown ethers.
27. 1. A method for producing a population of immune effector cells (e.g., T cells, NK cells) engineered to express a CAR, comprising: providing a population of immune effector cells (e.g., T cells), where a plurality of the immune effector cells comprise a nucleic acid encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein; expanding the population of cells in the presence of one or more interleukins resulting in at least a 200-fold (e.g., 200-fold, 250-fold, 300-fold, 350-fold) expansion of the cells over a 14-day expansion period, as measured by a method described herein, such as, for example, flow cytometry; method.
28. 28. The method of claim 27, wherein the population of cells is expanded in the presence of IL-15 and / or IL-7, eg, IL-15 and IL-7.
29. 29. The method of claim 27 or 28, wherein the population of cells is expanded for a period of less than 8 days, such as 7, 6, 5, 4 or 3 days.
30. 29. The method of claim 27 or 28, wherein the cells are expanded in culture for 5 days and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same culture conditions.
31. 31. The method of claim 30, wherein the cells expanded for 5 days exhibit at least a 1-fold, 2-fold, 3-fold or 4-fold increase in cell doublings upon antigen stimulation compared to the same cells expanded in culture for 9 days under the same culture conditions, or the cells are expanded in culture for 5 days and the resulting cells exhibit increased pro-inflammatory cytokine production, e.g., IFN-γ and / or GM-CSF levels, compared to the same cells expanded in culture for 9 days under the same culture conditions.
32. 32. The method of any of claims 27-31, wherein the population of cells is expanded by culturing the cells in the presence of an agent that stimulates a CD3 / TCR complex associated signal and a ligand that stimulates a costimulatory molecule on the surface of the cells, e.g., as described herein, e.g., the agent is a bead conjugated with an anti-CD3 antibody or fragment thereof and / or an anti-CD28 antibody or fragment thereof.
33. 33. The method of any of claims 27 to 32, wherein the population of immune effector cells provided is a population of T regulatory depleted cells comprising less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells or wherein the population of immune effector cells provided is a population of T regulatory depleted cells comprising less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25 expressing tumor cells, such as CLL cells.
34. 34. The method of claim 33, wherein the population of cells provided comprises less than 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 15%, 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells, or wherein the population of cells provided comprises less than 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells and less than 10%, 5%, 4%, 3%, 2%, 1% tumor cells, e.g., CD25-expressing tumor cells, e.g., CLL cells.
35. 54. The method of any of claims 50-53, wherein the population of immune effector cells provided also comprises less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of checkpoint inhibitor expressing cells, e.g. PD1+ cells, LAG3+ cells or TIM3+ cells.
36. The method of any of claims 33-35, further comprising contacting the population of immune effector cells with a nucleic acid encoding a telomerase subunit, e.g., hTERT, wherein the nucleic acid is, e.g., DNA or RNA.
37. A reaction mixture comprising a population of immune effector cells, wherein a plurality of the population of cells therein comprises a nucleic acid molecule comprising a CAR-encoding sequence, e.g., a CD19 CAR-encoding sequence, e.g., as described herein, e.g., a nucleic acid molecule described herein, and IL-7 and / or IL-15.
38. A reaction mixture comprising a population of immune effector cells, wherein a plurality of the population of cells therein comprises a vector comprising a nucleic acid sequence encoding a CAR, e.g., a CAR described herein, e.g., a CD19 CAR described herein, and IL-7 and / or IL-15, optionally wherein the vector is a vector described herein, e.g., a vector selected from the group consisting of a DNA, RNA, plasmid, lentiviral vector, adenoviral vector, or retroviral vector.
39. 39. The reaction mixture of claim 37 or 38, further comprising an agent that activates and / or expands the cells of the population, e.g., an agent that stimulates a CD3 / TCR complex associated signal and / or a ligand that stimulates a costimulatory molecule on the surface of the cells, e.g., the agent is a bead conjugated with an anti-CD3 antibody or fragment thereof and / or an anti-CD28 antibody or fragment thereof.
40. 1. A method for producing a population of immune effector cells (e.g., T cells, NK cells), comprising: providing a population of immune effector cells (e.g., T cells); contacting a population of immune effector cells with a nucleic acid encoding a CAR and an RNA encoding a telomerase subunit, e.g., hTERT, under conditions suitable for expression of the CAR and the telomerase subunit; method.
41. 41. The method of claim 40, wherein the nucleic acid encoding the CAR and the RNA encoding the telomerase subunit are part of the same nucleic acid molecule or the nucleic acid encoding the CAR and the RNA encoding the telomerase subunit are part of separate nucleic acid molecules.
42. 41. The method of claim 40, comprising contacting the population of immune effector cells with a nucleic acid encoding a CAR and an RNA encoding a telomerase subunit substantially simultaneously, or contacting the population of immune effector cells with a nucleic acid encoding a CAR prior to contacting the population of immune effector cells with the RNA encoding a telomerase subunit, or contacting the population of immune effector cells with a nucleic acid encoding a CAR after contacting the population of immune effector cells with the RNA encoding a telomerase subunit.
43. The method of claim 40, wherein the RNA encoding the telomerase subunit is an mRNA or the RNA encoding the telomerase subunit comprises a poly(A) tail or a 5' cap structure.
44. 41. The method of claim 40, comprising genetically transferring, transducing or electroporating an immune effector cell with an RNA encoding a telomerase subunit.
45. A nucleic acid encoding a CAR, and An exogenous telomerase subunit, e.g., an RNA (e.g., an mRNA) encoding hTERT. and an immune effector cell (e.g., a T cell or an NK cell).
46. CAR and Exogenous telomerase subunits, e.g., hTERT but does not contain exogenous telomerase subunit-encoding DNA, Immune effector cells (e.g., T cells or NK cells).
Citation Information
Patent Citations
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
WO2013126712A1
Treatment of cancer using humanized Anti-CD19 chimeric antigen receptor
WO2014153270A1
